A0A2R8ZGZ1 (A0A2R8ZGZ1_PANPA) Pan paniscus (Pygmy chimpanzee) (Bonobo)
Beta-2-microglobulin UniProtKBInterProSTRINGInteractive Modelling
119 aa; Sequence (Fasta) ;
5 identical sequences: Homo sapiens: P61769; Pongo pygmaeus: P16213; Pan troglodytes: P61770, A0A2J8NTN7; Gorilla gorilla gorilla: P61771
It is possible new templates exist for this target since these models were created.
Available Structures
1230 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Structure of 5F3 TCR in complex with HLA-A2/MART-1 |
Heteromer P04439; P61769; Q6PJ56; | 50.0 | 1×NAG; | |||
| Crystal structure of HLA-B*07:02 with R140Q mutant IDH2 peptide |
Heteromer P01889; P48735; P61769; | 100 | 1×K; 2×NA; | |||
| Crystal structure of HLA-A3*01 in complex with a wild-type beta-catenin peptide |
Heteromer P04439; P35222; P61769; | 100 | 2×PG4; 3×MES; 2×IMD; 4×PEG; 7×EDO; | |||
| Crystal structure of HLA-B*07:02 with wild-type IDH2 peptide |
Heteromer P01889; P48735; P61769; | 100 | 4×PEG; 1×1PE; 2×SO4; 1×PGE; | |||
| Structure of KRAS WT(7-16)-HLA-A*03:01 |
Heteromer P01116; P04439; P61769; | 100 | 13×SO4; 1×PEG; | |||
| Structure of KRAS G12V/HLA-A*03:01 in complex with antibody fragment V2 |
Heteromer P01116; P04439; P61769; | 100 | ||||
| Crystal structure of HLA-C*1402 complexed with 8-mer HIV gag peptide |
Heteromer A0A858LG55; P04591; P61769; | 100 | 7×EDO; 1×NA; 1×ACT; | |||
| Crystal structure of HLA-C*1402 complexed with 4-mer lipopeptide |
Heteromer A0A858LG55; P61769; | 100 | 18×EDO; 1×MYR; | |||
| TCR F50 recgonizing M1-HLA-A2 |
Heteromer P03485; P04439; P61769; | 100 | ||||
| CD1c with antigen analogue 1 |
Heteromer P29016; P29017; P61769; | 100 | 1×NAG; 1×ZPD; 1×D12; 1×ZP7; 1×NHE; 2×MLA; | |||
| HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) IN COMPLEX WITH A NONAMERIC PEPTIDE FROM HTLV… |
Heteromer P04439; P61769; | 99.0 | ||||
| Crystal structure of HLA-A*2402 complexed with 4-mer lipopeptide |
Heteromer A0A5H2UYS3; P61769; | 100 | 1×TRS; 2×ACT; 2×ZN; 26×EDO; | |||
| Crystal structure of HLA-A*2402 complexed with 8-mer Influenza PB1 peptide |
Heteromer A0A5H2UYS3; P61769; Q9WLS3; | 100 | 33×EDO; 2×ZN; 2×TRS; 1×ACT; | |||
| CD1c with antigen analogue 2 |
Heteromer P29016; P29017; P61769; | 100 | 1×NAG; 1×NHE; 1×ZQ4; 1×D12; 1×ZP7; 1×MLA; | |||
| A T cell receptor in complex with HLA-A0201 restricted Hepatitis C virus NS3 peptide (KLVALGINAV) |
Heteromer P04439; P27958; P61769; | 97.0 | ||||
| Crystal structure of HLA-A*2450 complexed with 8-mer model peptide |
Heteromer A0A109QAI7; P61769; Q9WLS3; | 100 | 1×ZN; 1×TRS; 35×EDO; | |||
| CD1c with antigen analogue 3 |
Heteromer P29016; P29017; P61769; | 100 | 1×NAG; 1×ZQ7; 1×D12; 1×ZP7; 2×MLA; | |||
| CRYSTAL STRUCTURE OF HLA-A*0201/OCTAMERIC TAX PEPTIDE COMPLEX |
Heteromer P04439; P61769; | 99.0 | ||||
| Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide I5A |
Heteromer K9N5Q8; P01902; P61769; | 100 | ||||
| POOR BINDING OF A HER-2/NEU EPITOPE (GP2) TO HLA-A2.1 IS DUE TO A LACK OF INTERACTIONS IN THE CENTE… |
Heteromer P04439; P04626; P61769; | 99.0 | ||||
| Crystal structure of HLA-A3*01 in complex with a mutant beta-catenin peptide |
Heteromer P04439; P35222; P61769; | 100 | 2×MES; 10×SO4; 2×PEG; | |||
| Human leukocyte antigen F (HLA-F) presents peptides and regulates immunity through interactions wit… |
Heteromer P30511; P61769; | 99.0 | ||||
| STRUCTURE OF HUMAN A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE V7R |
Heteromer P04439; P61769; | 99.0 | ||||
| STRUCTURE OF A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE Y8A |
Heteromer P01848; P04439; P61769; | 99.0 | ||||
| Crystal structure of HLA-B*07:02 with R140Q mutant IDH2 peptide in complex with Fab |
Heteromer P01889; P48735; P61769; | 100 | 6×PEG; 1×NHE; 8×SO4; | |||
| Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25… |
Heteromer A0A0X9JHC1; P04439; P61769; | 100 | ||||
| Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25… |
Heteromer A0A0X9JHC1; P04439; P61769; | 100 | ||||
| HLA-B*2709 BOUND TO NONA-PEPTIDE M9 |
Heteromer P01889; P61769; | 100 | 2×GOL; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with EBV bmlf1-280-288 nonapeptide |
Heteromer P04439; P61769; Q3KSU1; | 100 | ||||
| Structures of HLA-B8E76C loaded with long peptides reveal novel features at the N-terminus of the g… |
Heteromer P61769; Q5SS57; | 100 | ||||
| Crystal structure of HLA B*18:01 in complex with QEIRTFSF, an 8-mer epitope from Influenza A |
Heteromer P61769; Q76MT9; S6AU73; | 100 | 3×EDO; 2×CL; 1×NA; | |||
| Crystal structure of HLA-B*5301 complex with an HIV-1 Gag-derived epitope QW9 S3T variant |
Heteromer O91080; P61769; S6BVK3; | 100 | ||||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P01889; P03407; P61769; | 100 | 26×EDO; 4×GOL; | |||
| Crystal structure of HLA-B*2709 complexed with the glucagon receptor (GR) peptide (residues 412-420) |
Heteromer P01889; P47871; P61769; | 100 | 3×GOL; | |||
| Crystal structure of HLA-B2705 complexed with the nona-peptide mA |
Heteromer A0A6B7HFJ9; P61769; | 100 | 4×GOL; 1×CL; | |||
| Crystal Structure of HLA-B*18:01 in complex with NP338 influenza peptide |
Heteromer P01889; P61769; | 100 | ||||
| Structures of HLA-B8E76C loaded with long peptides reveal novel features at the N-terminus of the g… |
Heteromer P61769; Q5SS57; | 100 | ||||
| Crystal structure of HLA-B*44:05 (T73C) with 9mer EEFGRAFSF |
Heteromer D5H3J5; P61769; Q9TQB0; | 100 | 2×GOL; 3×EDO; | |||
| Crystal structure of HLA-B2705 complexed with the nona-peptide mQ |
Heteromer A0A6B7HFJ9; P61769; | 100 | 5×GOL; | |||
| HLA-B*57:01 presenting the peptide ASLNLPAVSW |
Heteromer P35221; P61769; U6BR87; | 100 | 1×ACT; | |||
| Crystal structure of HLA-B2709 complexed with the nona-peptide mE |
Heteromer A0A2R7Z5J3; P61769; | 100 | 4×GOL; | |||
| Crystal structure of HLA-B*4103 in complex with a 16mer self-peptide derived from heterogeneous nuc… |
Heteromer P01889; P07910; P61769; | 100 | 2×ACT; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide |
Heteromer P04439; P61769; Q03463; | 100 | 1×CIT; | |||
| Crystal structure of a peptide-HLA complex |
Heteromer P01889; P03206; P61769; | 100 | 2×ACT; 1×NA; | |||
| HLA-B*57:03 presenting the peptide ASLNLPAVSW |
Heteromer I3ZN84; P35221; P61769; | 100 | 1×PEG; 1×ACT; | |||
| Crystal Structure of HLA B*3508 in complex with a HCMV 8-mer peptide from the pp65 protein |
Heteromer P01889; P18139; P61769; | 100 | ||||
| Crystal structure of peptide KAGQVVTIW in complex with HLA-B5801 |
Heteromer F4NC28; P02545; P61769; | 100 | 3×GOL; | |||
| Crystal Structure of HLA-B*37:01 in complex with NP338 influenza peptide |
Heteromer P01889; P61769; | 100 | 2×ACT; | |||
| Crystal Structure of HLA-A*0201in complex with SARS-CoV-2 N222-230 |
Heteromer P0DTC9; P61769; Q861F7; | 100 | 2×CD; 2×CA; 1×EDO; | |||
| Structures of Three HIV-1 HLA-B5703-Peptide Complexes and Identification of Related HLAs Potentiall… |
Heteromer P01889; P61769; Q8URG0; | 100 | ||||
| Crystal structure of BRLF peptide from EBV in complex with HLA-A1101. |
Heteromer P04439; P61769; | 100 | 7×GOL; | |||
| Crystal Structure of HLA-B*44:05 in complex with NP338 influenza peptide |
Heteromer P01889; P61769; | 100 | 1×ACT; | |||
| Crystal structure of HLA-B2709 complexed with the nona-peptide mQ |
Heteromer A0A2R7Z5J3; P61769; | 100 | 4×GOL; | |||
| HLA-A02 carrying YLGGPDFPTI |
Heteromer P04439; P61769; | 100 | 14×EDO; 1×SO4; | |||
| Structures of HLA-B8E76C loaded with long peptides reveal novel features at the N-terminus of the g… |
Heteromer P61769; Q5SS57; | 100 | ||||
| Crystal Structure of HLA-B*2705-W60A in complex with LRN, a self-peptide |
Heteromer P01889; P37268; P61769; | 100 | ||||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P01889; P04585; P61769; | 100 | 7×EDO; | |||
| Crystal structure of HLA-B2709 complexed with the nona-peptide mA |
Heteromer A0A2R7Z5J3; P61769; | 100 | 3×GOL; 1×CL; | |||
| HLA-A02 carrying MVWGPDPLYV |
Heteromer P04439; P61769; | 100 | 10×EDO; 4×GOL; | |||
| Structure of a nested set of N-terminally extended MHC I-peptides provides novel insights into anti… |
Heteromer P01889; P61769; | 100 | ||||
| Crystal structure of peptide KAGQVVTI in complex with HLA-B5801 |
Heteromer A0A678ZMW1; P02545; P61769; | 100 | 3×GOL; | |||
| Crystal Structure of HLA B*0801 in complex with ELN_YYM, ELNRKMIYM |
Heteromer P01889; P61769; Q9YRL8; | 100 | 1×EDO; | |||
| The structure of HLA-A*3003/NP44 |
Heteromer P04439; P61769; Q9Q0U8; | 100 | ||||
| CRYSTAL STRUCTURE OF HLA-A*0201/MAGE-A4-PEPTIDE COMPLEX |
Heteromer P04439; P43358; P61769; | 100 | 2×1PG; | |||
| Crystal structure of HLA B*18:01 in complex with YERMCNIL, an 8-mer epitope from Influenza A |
Heteromer P61769; Q91UL1; S6AU73; | 100 | 9×EDO; 1×MG; 3×K; 1×SO4; 1×NO3; | |||
| Crystal structure of the disulfide engineered HLA-A0201 molecule in complex with one GL dipeptide i… |
Heteromer F6IQS1; P61769; | 100 | 1×NA; 1×GLY; 1×LEU; 2×GOL; | |||
| Structure of HLA-A2:01 with peptide MM96 |
Heteromer A0A140T913; P01116; P61769; | 100 | 4×GOL; 1×SO4; 2×NA; | |||
| Crystal structure of hla-b*2705 complexed with the glucagon receptor (gr) peptide (residues 412-420) |
Heteromer P01889; P47871; P61769; | 100 | 6×GOL; 1×NA; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide A7H v… |
Heteromer P04439; P61769; Q6SW59; | 100 | ||||
| Crystal Structure of HLA-B8 in complex with ELR, an Influenza A virus peptide |
Heteromer P01889; P61769; | 100 | ||||
| A structural basis for immunodominant human T-cell receptor recognition. |
Heteromer P01848; P01850; P04439; P61769; | 100 | ||||
| Crystal structure of peptide VSFIEFVI in complex with HLA-B5801 |
Heteromer A0A678ZMW1; P03203; P61769; | 100 | 3×GOL; | |||
| HLA-B*1801 in complex with a self-peptide, DELEIKAY |
Heteromer P01889; P61769; | 100 | 1×ACT; | |||
| Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR |
Heteromer P01889; P32241; P61769; | 100 | 4×GOL; | |||
| Crystal Structure of HLA-B*2705 in complex with LRN, a self-peptide |
Heteromer A0A583ZBQ2; P37268; P61769; | 100 | ||||
| Crystal structure of HLA B*18:01 in complex with TEVETYVL, an 8-mer epitope from Influenza A |
Heteromer P61769; Q2PIM0; S6AU73; | 100 | 1×EDO; 4×MG; | |||
| Crystal structure of peptide VSFIEFVGW in complex with HLA-B5801 |
Heteromer F4NC28; P03203; P61769; | 100 | 1×GOL; | |||
| Crystal Structure of HLA-B*35:01 in complex with IPFAMQMAY, an 9-mer epitope from SARS-CoV-2 spike … |
Heteromer P0DTC2; P61769; Q546I9; | 100 | 2×PO4; 3×NA; | |||
| Crystal structure of HLA-A*1101 with sars nucleocapsid peptide |
Heteromer P04439; P59595; P61769; | 100 | 3×SO4; 7×GOL; | |||
| Crystal Structure of HLA-B*57:01 with a modified HIV peptide RKV-Kyn |
Heteromer P01889; P04578; P61769; | 100 | 1×ACT; | |||
| Crystal structure of HLA-B*44:05 (T73C) with 6mer EEFGRC and dipeptide GL |
Heteromer D5H3J5; P61769; | 100 | 2×EDO; 1×GOL; | |||
| Crystal Structure of HLA-B*2703-P47G in complex with LRN, a self-peptide |
Heteromer P01889; P37268; P61769; | 100 | ||||
| HLA-A02 carrying RQWGPDPAAV |
Heteromer P04439; P61769; | 100 | 18×EDO; 1×GOL; 1×MES; 4×SO4; 2×ACY; | |||
| CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (V… |
Heteromer P01889; P32241; P61769; | 100 | 5×GOL; 1×MN; | |||
| Conformational Restraints and Flexibility of 14-Meric Peptides in Complex with HLA-B*3501 |
Heteromer P01889; P61769; | 100 | ||||
| Structure of a nested set of N-terminally extended MHC I-peptides provides novel insights into anti… |
Heteromer P01889; P61769; | 100 | ||||
| Structures of HLA-B8E76C loaded with long peptides reveal novel features at the N-terminus of the g… |
Heteromer P61769; Q5SS57; | 100 | ||||
| HLA-A02 carrying YLGGPDFPTI |
Heteromer P04439; P61769; | 100 | 1×BR; 17×EDO; 4×GOL; 11×PG4; | |||
| HLA-B*18:01 in complex with Epstein-Barr virus BZLF1-derived peptide (residues 173-180) |
Heteromer P01889; P61769; Q3KSS8; | 100 | 1×ACT; | |||
| Structure of HLA-A2:01 with peptide MM92 |
Heteromer A0A140T913; P01116; P61769; | 100 | 3×GOL; 6×NA; 1×SO4; | |||
| Crystal Structure of HLA-A*11:01 in complex with NSASFSTFK, an 9-mer epitope from SARS-CoV-2 spike … |
Heteromer P0DTC2; P61769; U5YJK1; | 100 | 1×GOL; 2×SO4; 2×NA; 2×CL; 1×CA; | |||
| Structure of HLA-A2:01 with the 12-mer peptide F12K |
Heteromer B6KDY1; P04439; P61769; | 100 | 1×GOL; | |||
| Crystal structure of HLA-B*07:02 in complex with an NY-ESO-1 peptide |
Heteromer P01889; P61769; P78358; | 100 | ||||
| crystal structure of HLA B*3508LPEP151A, HLA mutant Ala151 |
Heteromer C5MK56; P03206; P61769; | 100 | ||||
| A COVID-19 T-cell response detection method based on a newly identified human CD8+ T cell epitope f… |
Heteromer A0A6M6CC39; P0DTC9; P61769; | 100 | ||||
| Crystal Structure of HLA-B5703 and HIV-1 peptide |
Heteromer P01889; P61769; Q1KW74; | 100 | ||||
| The role of T cell receptor alpha genes in directing human MHC restriction |
Heteromer O19626; P03211; P61769; | 100 | ||||
| Crystal structure of HLA-B*3508 presenting 13-mer EBV antigen LPEPLPQGQLTAY |
Heteromer P01889; P61769; | 100 | ||||
| Engineered Human HLA_A2 MHC Class I molecule in complex with NV9 peptide |
Heteromer P04439; P61769; | 100 | 2×GOL; 7×CO; | |||
| Crystal structure of HLA-B*13:01 |
Heteromer F4NBP7; P04601; P61769; | 100 | ||||
| The structure of HLA-A*3001/RT313 |
Heteromer P04439; P04585; P61769; | 100 | ||||
| Crystal Structure of HLA A*2402 in complex with YFSPIRVTF, an 9-mer influenza epitope |
Heteromer A0A5H2UYS3; C0RVT5; P61769; | 100 | 2×MG; | |||
| Crystal Structure of HLA-B*2703 in complex with KK10, an HIV peptide |
Heteromer P01889; P04585; P61769; | 100 | 1×MG; | |||
| STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH SYNTHETIC PHOSPHONO-MLL PEPTIDE ANALOG |
Heteromer P01889; P61769; Q03164; | 100 | 4×GOL; 1×NA; | |||
| Crystal Structure of HLA-B*2703 in complex with LRN, a self-peptide |
Heteromer P01889; P37268; P61769; | 100 | ||||
| HAL-A02 carrying RQFGPDFPTI |
Heteromer P04439; P61769; | 100 | 10×EDO; 4×GOL; 2×SO4; 1×CA; | |||
| HLA Class I antigen |
Heteromer P04439; P40967; P61769; | 100 | 18×EDO; 10×GOL; 8×SO4; | |||
| Crystal structure of engineered TCR (756) complexed to HLA-A*02:01 presenting MAGE-A10 9-mer peptide |
Heteromer A0A140T913; P43363; P61769; | 100 | 4×GOL; | |||
| Human Class I MHC HLA-A2 in complex with the nonameric Melan-A/MART-1(27-35) peptide having A27L su… |
Heteromer P04439; P61769; Q16655; | 100 | 3×GOL; 3×FMT; 1×NA; | |||
| HLA A02 presenting SLYNTIATL |
Heteromer P04439; P04591; P61769; | 100 | 7×EDO; 5×GOL; | |||
| CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2)OF EPSTE… |
Heteromer P01889; P13285; P61769; | 100 | 4×GOL; | |||
| Structure of HLA-A2:01 with peptide MM90 |
Heteromer A0A140T913; P01116; P61769; | 100 | 6×GOL; 5×NA; | |||
| crystal structure of HLA B*3508 LPEP-P9Ala, peptide mutant P9-ala |
Heteromer P01889; P61769; | 100 | ||||
| Crystal Structure of HLA-B*37:01 in complex with NP338-V6L influenza peptide |
Heteromer P01889; P61769; | 100 | ||||
| STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH SYNTHETIC SULFO-MLL PEPTIDE ANALOG |
Heteromer P01889; P61769; Q03164; | 100 | 3×GOL; | |||
| Porcine (Sus scrofa) Major Histocompatibility Complex, class I, with human beta2 micro globulin, pr… |
Heteromer B1PJV3; P03466; P61769; | 100 | 2×SO4; | |||
| Crystal structure of a HLA-B*35:01-NP8 epitope from 2005 H1N1 influenza strain |
Heteromer F4NBT2; P61769; | 100 | 2×ACT; | |||
| Crystal Structure of HLA-A*0201 in complex with SARS-CoV-2 N138-146 |
Heteromer P0DTC9; P61769; Q861F7; | 100 | 2×CD; 1×ACT; | |||
| Structure of HLA-A2:01 with peptide MM91 |
Heteromer A0A140T913; P01116; P61769; | 100 | 3×GOL; 4×NA; | |||
| Crystal Structure of HLA-B*57:01 with an HIV peptide RKV |
Heteromer P01889; P04578; P61771; | 100 | ||||
| Crystal Structure of HLA-B8 in complex with QIK, a CMV peptide |
Heteromer P01889; P61769; | 100 | ||||
| Phosphorylation modification of MHC I polypeptide |
Heteromer O78189; P18583; P61769; | 100 | ||||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P01889; P04585; P61769; | 100 | 11×EDO; 3×GOL; | |||
| Structure of a nested set of N-terminally extended MHC I-peptides provides novel insights into anti… |
Heteromer P01889; P61769; | 100 | ||||
| Structure of a nested set of N-terminally extended MHC I-peptides provide novel insights into antig… |
Heteromer P01889; P61769; | 100 | ||||
| Crystal structure of HLA B*18:01 in complex with EEIEITTHF, an 9-mer epitope from Influenza A |
Heteromer P61769; Q2VNC5; S6AU73; | 100 | 1×PEG; 2×EDO; | |||
| Crystal Structure of HLA-B*4403 presenting 10mer EBV antigen |
Heteromer P01889; P03204; P61769; | 100 | 4×ACT; 2×GOL; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with Human Prostaglandin Transporter dec… |
Heteromer P04439; P61769; Q92959; | 100 | ||||
| STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PHOSPHOPEPTIDE AND BOUND GLYCEROL |
Heteromer P01889; P61769; Q03164; | 100 | 7×GOL; | |||
| Crystal Structure of HLA B*0801 in complex with ELR_MYM, ELRRKMMYM |
Heteromer P01889; P03169; P61769; | 100 | 2×ACT; | |||
| HLA-B*57:01-RVAQLENVYI in complex with abacavir |
Heteromer P01889; P61769; P62318; | 100 | 1×1KX; 1×SO4; | |||
| Crystal structure of the binary complex between HLA-A2 and HCMV NLV peptide |
Heteromer P04439; P06725; P61769; | 100 | ||||
| Crystal Structure of HLA B*4402 in complex with HLA DPA*0201 peptide |
Heteromer P01889; P61769; Q95HB9; | 100 | ||||
| Crystal structure of HLA-B*5301 complex with an HIV-1 Gag-derived epitope QW9 |
Heteromer P04585; P61769; S6BVK3; | 100 | 2×GOL; | |||
| Crystal structure of B*27:04 complex bound to the pVIPR peptide |
Heteromer P01889; P32241; P61769; | 100 | 4×GOL; 1×CL; | |||
| Crystal Structure of PKD2 Phosphopeptide Bound to Human Class I MHC HLA-A2 |
Heteromer P04439; P61769; Q9BZL6; | 100 | 4×EDO; | |||
| Crystal structure of HLA-b46 at 1.6 angstrom resolution |
Heteromer P01889; P17763; P61769; | 100 | 3×NA; | |||
| Crystal Structure of HLA B2705-KK10-L6M |
Heteromer P01889; P03366; P61769; | 100 | 1×TRS; | |||
| Crystal Structure of HLA B2705-KK10 |
Heteromer P01889; P03366; P61769; | 100 | 1×GOL; | |||
| The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its V… |
Heteromer P03485; P04439; P61769; | 100 | ||||
| Crystal structure of the HLA-B8-A66-FLR, mutant A66 of the HLA B8 |
Heteromer P01889; P61769; Q3KST2; | 100 | 1×NA; | |||
| Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with Hendra virus-de… |
Heteromer A0A125R585; O55778; P61769; | 100 | ||||
| Crystal Structure of HLA-B7 in complex with TPR, a CMV peptide |
Heteromer P01889; P61769; | 97.98 | 4×IOD; 1×NA; 4×CL; 1×PEG; 1×ZN; | |||
| Crystal structure of HLA-B*3501 presenting 13-mer EBV antigen LPEPLPQGQLTAY |
Heteromer P01889; P61769; | 100 | ||||
| Human Class I MHC HLA-A2 in complex with the HuD (G2L) peptide variant |
Heteromer P04439; P61769; | 100 | 3×GOL; | |||
| Crystal Structure of HLA B*4402 in complex with EEYLKAWTF, a mimotope |
Heteromer P01889; P61769; | 100 | ||||
| HLA-A*1101 in complex with HBV peptide homologue |
Heteromer P04439; P61769; | 100 | 3×SO4; | |||
| T cell cross-reactivity and conformational changes during TCR engagement. |
Heteromer P04439; P61769; | 100 | ||||
| T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT |
Heteromer P04439; P61769; | 100 | ||||
| HLA-B*57:03 presenting the peptide LSSPVTKSF |
Heteromer I3ZN84; P61769; | 100 | 1×ACT; | |||
| The structure of HLA-A*3003/MTB |
Heteromer P04439; P61769; P9WNK3; | 100 | ||||
| Crystal structure of the disulfide engineered HLA-A0201 molecule in complex with one GM dipeptide i… |
Heteromer F6IQS1; P61769; | 100 | 5×EDO; 2×GLY; 2×MET; 1×CL; | |||
| HCMV US11 peptide binding to HLA-A*02:01 |
Heteromer P09727; P61769; Q53Z42; | 100 | 2×GOL; 1×CD; 1×PGE; | |||
| Crystal structure of HLA-B*5701 complex with an HIV-1 Gag-derived epitope QW9 S3T variant |
Heteromer O91080; P61769; U6BR87; | 98.99 | 3×GOL; | |||
| Crystal Structure of HLA-A68 presenting a C-terminally extended peptide |
Heteromer P04439; P30279; P61769; | 100 | 6×EDO; 3×NI; 2×CD; 1×CO; | |||
| Crystal Structure of HLA-B7 in complex with RPP, an EBV peptide |
Heteromer P01889; P12977; P61769; | 97.98 | ||||
| HLA-A2.1 KVAEIVHFL |
Heteromer E0YFW1; P04439; P61769; | 100 | ||||
| SARS-CoV-2 Spike-derived peptide S417-425 K417T mutant (TIADYNYKL) presented by HLA-A*02:01 |
Heteromer P0DTC2; P61769; Q53Z42; | 100 | 1×ZN; 1×CD; 1×NA; | |||
| HLA-A02 carrying RQFGPDWIVA |
Heteromer P04439; P61769; | 100 | 11×EDO; 2×SO4; 1×CA; 1×GOL; | |||
| HLA-B*58:01 presenting LSSPVTKSW |
Heteromer P01889; P61769; | 100 | ||||
| Structures of Three HIV-1 HLA-B5703-Peptide Complexes and Identification of Related HLAs Potentiall… |
Heteromer P01889; P61769; Q70A61; | 100 | ||||
| Crystal structure of a HLA-B*35:08-HPVG-Q5 |
Heteromer C5MK56; P03211; P61769; | 100 | ||||
| Structure of HLA-A2 in complex with an altered peptide ligands based on Mart-1 variant epitope |
Heteromer P04439; P61769; Q16655; | 100 | 4×GOL; | |||
| Ca2+ release from the endoplasmic reticulum of NY-ESO-1 specific T cells is modulated by the affini… |
Heteromer P04439; P61769; P78358; | 100 | ||||
| Crystal structure of a HLA-B*35:01-HPVG-A4 |
Heteromer P01889; P61769; Q1HVF7; | 100 | 1×ACT; | |||
| Crystal Structure of RQA_M Phosphopeptide Bound to HUMAN Class I MHC HLA-A2 |
Heteromer P04439; P33241; P61769; | 100 | 2×EDO; | |||
| Crystal structure of HLA B*13:01 in complex with SVLNDIFSRL, an 10-mer epitope from SARS-CoV-2 Spik… |
Heteromer C5IYE8; P0DTC2; P61769; | 100 | 3×EDO; 2×NA; | |||
| Crystal structure of the LCMV derived peptide GP34 in complex with the murine mhc class I H-2 Kb |
Heteromer P01901; P61769; Q9QDK7; | 100 | 3×ACT; | |||
| Crystal structure of the disulfide engineered HLA-A0201 molecule in complex with one GM dipeptide i… |
Heteromer F6IQS1; P61769; | 100 | 1×GLY; 1×MET; 2×GOL; | |||
| crystal structure of HLA B*3508 LPEP-P7Ala, peptide mutant P7-ala |
Heteromer P01889; P61769; | 100 | ||||
| Human Class I MHC HLA-A2 in complex with the HuD peptide |
Heteromer P04439; P61769; | 100 | 5×GOL; | |||
| Structure of a nested set of N-terminally extended MHC I-peptides provide novel insights into antig… |
Heteromer P01889; P61769; | 100 | ||||
| HLA A02 presenting SLFNTIAVL |
Heteromer P04439; P04591; P61769; | 100 | 9×EDO; 1×GOL; 2×SO4; | |||
| HLA-A24 in complex with HIV-1 Nef126-10(8I10F) |
Heteromer P04439; P04603; P61769; | 100 | ||||
| Crystal structure of peptide in complex with HLA-A1101. |
Heteromer P04439; P61769; | 100 | 4×GOL; | |||
| Crystal structure of HLA-B*35:01-NP3 epitope from 1957 H2N2 influenza strain |
Heteromer F4NBT2; P26072; P61769; | 100 | 2×NA; | |||
| Human HLA-A*0201-ALWGPDPAAA |
Heteromer P01308; P04439; P61769; | 100 | ||||
| Structure of HLA-A*02:01-FLPTPEELGLLGPPRPQVLA complex |
Heteromer P61769; Q6UWB1; Q861F7; | 100 | 1×TRS; 1×MG; | |||
| MHC I A02 Allele presenting YLQPRTFLL |
Heteromer A0A140T913; P0DTC2; P61769; | 100 | 6×EDO; 1×ACT; 1×CA; | |||
| Human Class I MHC HLA-A2 in complex with Mart-1(27-35) nonameric peptide |
Heteromer P04439; P61769; Q16655; | 100 | 4×GOL; 1×NA; | |||
| HLA-A02 carrying AQWGPDPAAA |
Heteromer P01308; P04439; P61769; | 100 | ||||
| Crystal Structure of HLA-A*0201 in complex with ALQDA, a 15 mer self-peptide |
Heteromer P04439; P61769; | 100 | 4×CL; 3×PEG; 2×MG; | |||
| HLA-B*57:01 presenting TSTTSVASSW |
Heteromer P01889; P61769; Q14679; | 100 | 1×GOL; | |||
| HLA-A*24:02 bound to Neuroblastoma derived PHOX2B peptide |
Heteromer A0A5H2UYS3; P61769; Q99453; | 100 | 1×GOL; | |||
| Crystal Structure of Human CD1b in Complex with PS |
Heteromer P29016; P61769; | 100 | 1×NAG; 1×NAG; 1×CUY; 1×NAG; 3×EDO; 7×CL; 1×P50; 3×NA; | |||
| Crystal structure of HLA-B2705 complexed with the nona-peptide mE |
Heteromer A0A6B7HFJ9; P61769; | 100 | 6×GOL; | |||
| Crystal structure of HLA-B35 in complex with a pepetide antigen |
Heteromer P01889; P04585; P61769; | 100 | ||||
| Crystal structure of an anaplastic lymphoma kinase-derived neuroblastoma tumor antigen bound to the… |
Heteromer P01889; P61769; | 100 | ||||
| Crystal structure of the disulfide engineered HLA-A0201 molecule without peptide bound after NaCl w… |
Heteromer F6IQS1; P61769; | 100 | 4×EDO; 8×NA; 3×CL; | |||
| crystal structure of HLA B*3508 LPEP157A, HLA mutant Ala157 |
Heteromer C5MK56; P03206; P61769; | 100 | ||||
| Structural and kinetic basis for heightened immunogenicity of T cell vaccines |
Heteromer A0A0B4J279; A0A0K0K1A5; P01848; P01850; P04439; P61769; P78358; | 100 | ||||
| Crystal Structure of HLA-B0702-RFL9 |
Heteromer P01889; P12478; P61769; | 100 | ||||
| Crystal Structure of HLA A*02:06 Bound to HBV Core 18-27 |
Heteromer P0C6H2; P61769; Q5MAG5; | 100 | ||||
| A natural selected dimorphism in HLA B*44 alters self, peptide reportoire and T cell recognition. |
Heteromer P01889; P61769; Q95HB9; | 100 | 2×ACY; | |||
| Crystal Structure of RTY Phosphopeptide Bound to Human Class I MHC HLA-A2 |
Heteromer P04439; P61769; Q8WVV4; | 100 | 1×NA; 2×EDO; | |||
| Crystal Structure of HLA-A*2402 Complexed with a Newly Identified Peptide from 2009 H1N1 PB1 (498-5… |
Heteromer P04439; P61769; Q9YXL6; | 100 | ||||
| HLA-B*4405 complexed to the dominant self ligand EEFGRAYGF |
Heteromer P01889; P61769; Q9TQB0; | 100 | ||||
| Human Class I MHC HLA-A2 in complex with the nonameric Melan-A/MART-1(27-35) peptide having A28L su… |
Heteromer P04439; P61769; Q16655; | 100 | 4×GOL; 1×NA; | |||
| Structure of HLA-A2 P130 |
Heteromer P04439; P61769; Q76R61; | 100 | 1×SO4; | |||
| Crystal Structure Of HLA-B*3501 Presenting an 11-Mer EBV Antigen EPLPQGQLTAY |
Heteromer P01889; P03206; P61769; | 100 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide V6G v… |
Heteromer P04439; P06725; P61769; | 100 | ||||
| Crystal structure of HLA-B*4402 in complex with the F7A mutant of a self-peptide derived from DPA*0… |
Heteromer P01889; P61769; Q95HB9; | 100 | 4×GOL; | |||
| Crystal Structure of HLA-B7 with the HCMV pp65 peptide RPHERNGFTVL |
Heteromer P01889; P61769; Q6SW59; | 100 | 4×NI; 8×GOL; | |||
| Crystal Structure of HLA B*0801 in complex with HSKKKCDEL |
Heteromer P01889; P61769; X2G898; | 100 | ||||
| Human Class I MHC HLA-A2 in complex with the modified HTLV-1 TAX (Y5K-4-[3-Indolyl]-butyric acid) p… |
Heteromer P04439; P61769; | 100 | 2×GOL; 1×NA; 3×FMT; | |||
| Crystal structure of HLA-G presenting KLPAQFYIL peptide |
Heteromer P17693; P61769; | 100 | 1×CO; | |||
| Crystal structure of HLA-B*3508 presenting EBV peptide EPLPQGQLTAY at 1.7A |
Heteromer P01889; P61769; | 100 | ||||
| Human Class I MHC HLA-A2 in complex with the HuD (G2L,I9V) peptide variant |
Heteromer P04439; P61769; | 100 | 2×GOL; | |||
| Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-2 |
Heteromer P04439; P61769; | 100 | 3×GOL; | |||
| Crystal Structure of B*4402 presenting a 10mer EBV epitope |
Heteromer P01889; P03204; P61769; | 100 | 9×ACT; 2×GOL; | |||
| Crystal structure of AMPD2 phosphopeptide bound to HLA-A2 |
Heteromer P04439; P61769; Q01433; | 100 | 4×EDO; | |||
| Complex Structure of HLA-A*2402 with the Peptide from HCoV(CoV-229E) spike protein |
Heteromer A0A5H2UYS3; P15423; P61769; | 100 | ||||
| Human Leukocyte Antigen Class I A02 Carrying LLWNPGMAV |
Heteromer P03314; P04439; P61769; | 100 | 7×EDO; 1×EPE; 2×PEG; 5×SO4; | |||
| CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2) OF EPST… |
Heteromer P01889; P13285; P61769; | 100 | 5×GOL; | |||
| HLA-E*01:03 in complex with SARS-CoV-2 Nsp13 peptide, VMPLSAPTL |
Heteromer P0DTD1; P61769; Q59EE1; | 100 | ||||
| HLA-E*01:03 in complex with IL9 |
Heteromer P13747; P61769; P9WNK3; | 100 | 1×GOL; 3×SO4; | |||
| Crystal Structure of HLA B*3505 in complex with NPDIVIYQY, an 9-mer epitope from HIV-I |
Heteromer A0A5H2UI55; P03366; P61769; | 100 | 2×PEG; 1×TRS; 1×BTB; | |||
| HLA-C*06:02 presenting ARTELYRSL |
Heteromer P10321; P61769; Q9NY61; | 100 | ||||
| Crystal structure of HLA-B*2709 complexed with a variant of the latent membrane protein 2 peptide (… |
Heteromer P01889; P61769; | 100 | 6×GOL; 1×TRS; 1×MES; | |||
| Crystal structure of H2DB in complex with HSF2 melanoma neoantigen |
Heteromer P01899; P38533; P61769; | 100 | ||||
| Crystal Structure of HLA B*3501 in complex with NPDIVIYQY, an 9-mer epitope from HIV-I |
Heteromer P03366; P61769; Q546I9; | 100 | 1×FLC; | |||
| Insights Into Crossreactivity in Human Allorecognition: The Structure of HLA-B35011 Presenting an E… |
Heteromer O19626; P33260; P61769; | 100 | 3×GOL; | |||
| Crystal structure of the disulfide engineered HLA-A0201 molecule devoid of peptide (annealed) |
Heteromer F6IQS1; P61769; | 100 | 3×EDO; 1×NA; | |||
| Human Class I MHC HLA-A2 in complex with the decameric Melan-A/MART-1(26-35) peptide |
Heteromer P04439; P61769; Q16655; | 100 | 2×GOL; 1×NA; | |||
| Crystal Structure of HLA A*02:07 Bound to HBV Core 18-27 |
Heteromer P0C6H2; P61769; Q861F6; | 100 | ||||
| Crystal Structure of HLA B*3508 in complex with a HCMV 12-mer peptide from the pp65 protein |
Heteromer P01889; P18139; P61769; | 100 | ||||
| Crystal structure of a HLA-B*35:08-HPVG-D5 |
Heteromer C5MK56; P61769; Q3KSS4; | 100 | 1×ACT; | |||
| Crystal structure of a HLA-B*35:08-HPVG-A4 |
Heteromer C5MK56; P61769; Q1HVF7; | 100 | 1×ACT; | |||
| HLA-B*15:02 complexed with a synthetic peptide |
Heteromer F4NBQ8; P61769; | 100 | 3×EDO; 1×GOL; 1×NA; | |||
| HLA-A*02:01 bound to Neuroblastoma Derived mutant IGFBPL1 peptide |
Heteromer A0A140T913; P61769; Q8WX77; | 100 | ||||
| KIR3DL1*086 in complex with HLA-B*57:03 presenting the AW10 peptide |
Heteromer I3ZN84; I6LEK9; P35221; P61769; | 100 | 3×NAG; | |||
| Crystal structure of HLA-B*35:01-NP9 epitope from 2006 H1N1 influenza strain |
Heteromer F4NBT2; P61769; | 100 | ||||
| HLA-B*57:01 presenting TSTFEDVKILAF |
Heteromer P01889; P61769; Q6YHU6; | 100 | 3×GOL; 1×ACT; | |||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P01889; P61769; P69726; | 100 | 12×EDO; 1×SO4; 1×GOL; | |||
| Peptide-MHC complex of mouse H2-Db presenting PA224 with E4C mutation |
Heteromer O89752; P01899; P61769; | 100 | 8×NA; 2×ACT; | |||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P01889; P03407; P61769; | 100 | 12×EDO; 2×GOL; | |||
| HLA-B*27:05 presenting an HIV-1 13mer peptide |
Heteromer O78189; P04585; P61769; | 100 | 2×GOL; | |||
| Peptide length determines the outcome of T cell receptor/peptide-MHCI engagement |
Heteromer P04439; P61769; | 100 | 18×EDO; 3×GOL; 2×SO4; | |||
| Crystal structure of HLA-A*03:01 in complex with a wild-type PIK3CA peptide analogue (Trp-6 Bta) |
Heteromer P04439; P42336; P61769; | 100 | 2×GOL; | |||
| Human Leukocyte Antigen presenting ILGKFLHRL |
Heteromer O14746; P04439; P61769; | 100 | 15×EDO; 4×GOL; 2×SO4; | |||
| The structure of HLA-A/L1-1 |
Heteromer A0A0G2JPD3; P03101; P61769; | 100 | ||||
| Crystal Structures of HLA-B*1501 in Complex with Peptides from Human UbcH6 and Epstein-Barr Virus E… |
Heteromer P01889; P51965; P61769; | 100 | 2×SO4; 1×URE; 1×GOL; | |||
| HLA-A*02:01 bound to Neuroblastoma Derived IGFBPL1 peptide |
Heteromer A0A140T913; P61769; Q8WX77; | 100 | 1×GOL; | |||
| Crystal Structure of ILNAMIVKI peptide bound to HLA-A2 |
Heteromer P04439; P61769; | 100 | 3×ACT; 4×GOL; 2×MG; | |||
| HLA-B*15:02 complexed with a synthetic peptide |
Heteromer F4NBQ8; P61769; | 100 | 2×GOL; 1×EDO; 2×ACT; 1×NA; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide V6C v… |
Heteromer P04439; P06725; P61769; | 100 | ||||
| The High Resolution Crystal Structure of HLA-A1 Complexed with the MAGE-A1 Peptide |
Heteromer P04439; P43355; P61769; | 100 | 3×GOL; | |||
| human CD1b in complex with endogenous phosphatidylcholine and spacer |
Heteromer P29016; P61769; | 100 | 2×NAG; 1×6PL; 1×6UL; 1×GOL; 2×SO4; | |||
| Crystal structure of HLA-B*57:01.I80N |
Heteromer P01834; P01889; P61769; | 100 | ||||
| SARS-CoV-2 Spike-derived peptide S1185-1193 K1191N mutant (RLNEVANNL) presented by HLA-A*02:01 |
Heteromer P0DTC2; P61769; Q53Z42; | 100 | 1×CD; 1×ZN; 1×NA; 1×ACT; 1×CL; | |||
| STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PEPTIDE AND BOUND GLYCEROL |
Heteromer P01889; P61769; Q03164; | 100 | 5×GOL; | |||
| The high resolution crystal structure of HLA-B*2709 in complex with a Cathepsin A signal sequence p… |
Heteromer P01889; P10619; P61769; | 100 | 1×GOL; | |||
| CRYSTAL STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PHOSPHOPEPTIDE |
Heteromer P01889; P61769; Q03164; | 100 | 1×GLC; | |||
| Crystal Structure of hla-b*2705 Complexed with the Citrullinated Vasoactive Intestinal Peptide Type… |
Heteromer P01889; P32241; P61769; | 100 | ||||
| SARS-CoV-2 Spike-derived peptide S976-984 S982A mutant (VLNDILARL) presented by HLA-A*02:01 |
Heteromer P0DTC2; P61769; Q53Z42; | 100 | 2×ACT; 2×EDO; 2×CD; 1×PEG; | |||
| Crystal structure of 10-mer peptide from EBV in complex with HLA-A1101. |
Heteromer P04439; P13285; P61769; | 100 | 2×GOL; | |||
| Crystal structure of a HLA-B*35:01-HPVG-D5 |
Heteromer P01889; P61769; Q3KSS4; | 100 | ||||
| The Immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled by its MHC-bound Conformation |
Heteromer P01889; P03206; P61769; | 100 | 2×ACY; | |||
| Crystal structure of HLA-B*4402 in complex with the F3A mutant of a self-peptide derived from DPA*0… |
Heteromer P01889; P61769; Q95HB9; | 100 | 1×ACT; 1×GOL; | |||
| Structure of HLA-B*40:02 in complex with the endogenous peptide REFSKEPEL |
Heteromer P01889; P61769; Q9NQS7; | 100 | ||||
| Crystal structure of Melanoma Antigen gp100(209-217) Bound to Human Class I MHC HLA-A2 |
Heteromer P04439; P40967; P61769; | 100 | 9×GOL; | |||
| Crystal structure of the HLA-B8FLRGRAYVL, mutant G8V of the FLR peptide |
Heteromer P01889; P61769; Q3KST2; | 100 | ||||
| KIR3DL1 in complex with HLA-B*5701 |
Heteromer P01834; P01889; P43629; P61769; | 100 | 3×NAG; | |||
| CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-6V |
Heteromer P04439; P61769; | 100 | ||||
| Crystal Structure of a citrulline peptide variant of the minor histocompatibility peptide HA-1 in c… |
Heteromer P04439; P61769; | 100 | ||||
| Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1972 strain |
Heteromer P01889; P61769; | 100 | ||||
| Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1934 strain |
Heteromer P01889; P61769; | 100 | ||||
| Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1977 strain |
Heteromer P01889; P61769; | 100 | ||||
| Crystal structure of HLA-B*0801.N80I |
Heteromer P01889; P61769; | 100 | ||||
| Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5T peptide variant |
Heteromer P04439; P61769; | 100 | ||||
| The complex between H27-14 TCR and HLA-A24 bound to HIV-1 Nef134-10(6L) peptide |
Heteromer P04439; P61769; Q9WPU2; | 100 | ||||
| Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-1 |
Heteromer P04439; P61769; | 100 | 5×GOL; | |||
| HLA-B*57:03 presenting LTVQVARVW |
Heteromer P01889; P61769; | 100 | ||||
| 3H4-Fab HLA-E-VL9 co-complex |
Heteromer P13747; P61769; | 100 | 10×GOL; 1×CA; | |||
| Structure of HLA-A*24:02 in complex with peptide, LYLPVRVLI (ATG2A). |
Heteromer A0A5H2UYS3; P61769; Q2TAZ0; | 100 | 2×EDO; 3×SO4; | |||
| Structure of B*27:09/photoRL9 |
Heteromer A0A2R7Z5J3; P32241; P61769; | 100 | 5×GOL; 1×TRS; 1×1PE; 1×PGE; | |||
| Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 37-3 |
Heteromer K9N5Q8; P01902; P61769; | 100 | ||||
| Crystal structure of Modified Melanoma Antigen gp100(209-T2M) Bound to Human Class I MHC HLA-A2 |
Heteromer P04439; P40967; P61769; | 100 | 13×GOL; | |||
| Structure of HLA-A68 complexed with a tumor antigen derived peptide |
Heteromer P04439; P40126; P61769; | 100 | 1×GOL; | |||
| An Nt-acetylated peptide complexed with HLA-B*3901 |
Heteromer O00571; P01889; P61769; | 100 | ||||
| Crystal structure of a HLA-B*35:01-NP6 epitope from 1977 H1N1 influenza strain |
Heteromer F4NBT2; P61769; Q09159; | 100 | ||||
| Peptide phosphorylation modification of MHC class I molecules |
Heteromer O78189; P18583; P61769; | 100 | ||||
| Crystal structure of the binary complex between HLA-A2 and HCMV NLV-T8A peptide variant |
Heteromer P04439; P61769; | 100 | ||||
| Structure of S8 TCR in complex with HLA-A*03:01 bound to ELFSYLIEK peptide |
Heteromer P04439; P61769; | 100 | 1×EDO; | |||
| Crystal structure of HLA-A*11:01 in complex with KRAS G12D peptide (VVVGADGVGK) |
Heteromer A0A583ZB34; P01111; P61769; | 100 | ||||
| Crystal structure of parent TCR (728) complexed to HLA-A*02:01 presenting MAGE-A10 9-mer peptide |
Heteromer P43363; P61769; Q861F7; | 100 | 2×GOL; | |||
| Crystal Structure of HLA-B7 in complex with SPI, an influenza peptide |
Heteromer P01889; P61769; | 100 | ||||
| CRYSTAL STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PEPTIDE |
Heteromer P01889; P61769; Q03164; | 100 | 2×GOL; 1×CL; 1×NA; | |||
| Crystal structure of B*27:06 bound to the pVIPR peptide |
Heteromer P01889; P32241; P61769; | 100 | 2×GOL; | |||
| HLA-B*57:01 presenting GSFDYSGVHLW |
Heteromer P01889; P61769; | 100 | ||||
| Crystal structure of a HLA-B*35:01-NP7 epitope from 2002 H2N1 influenza strain |
Heteromer F4NBT2; P61769; | 100 | 1×ACT; | |||
| The structure of HLA-A/Pep14 |
Heteromer A0A0G2JPD3; P0DTC2; P61769; | 100 | ||||
| Structure of E8 TCR in complex in human MR1 bound to 5FSA |
Heteromer P61769; Q95460; | 100 | 1×54G; 4×EDO; | |||
| Crystal Structure of HLA B*4405 in complex with EEYLKAWTF, a mimotope |
Heteromer P01889; P61769; | 100 | ||||
| Crystal Structure of HLA-B5703 and HIV-1 peptide |
Heteromer P61769; Q70AA1; Q9MYI6; | 100 | ||||
| crystal structure of HLA B*3508LPEP-P4Ala, peptide mutant P4-ala |
Heteromer C5MK56; P03206; P61769; | 100 | ||||
| SARS-CoV-2 spike-derived peptide S1060-1068 (VVFLHVTYV) presented by HLA-A*02:01 |
Heteromer A0A140T913; P0DTC2; P61769; | 100 | 2×CD; 1×NA; | |||
| The high resolution crystal structure of HLA-B*2705 in complex with a Cathepsin A signal sequence p… |
Heteromer P01889; P10619; P61769; | 100 | 2×GOL; | |||
| Crystal structure of a HLA-B*35:01-HPVG-Q5 |
Heteromer C5MK56; P03211; P61769; | 100 | ||||
| crystal structure of HLA B*3508 LPEP158G, HLA mutant Gly158 |
Heteromer C5MK56; P03206; P61769; | 100 | 1×ACT; | |||
| Crystal Structure of HLA-B0702-RL9 |
Heteromer P01889; P12478; P61769; | 100 | ||||
| Weak TCR binding to an unstable insulin epitope drives type 1 diabetes |
Heteromer P01308; P01902; P61769; | 100 | 4×GOL; 1×15P; 7×EDO; 2×SO4; | |||
| Crystal structure of FcRn bound to UCB-84 |
Heteromer P55899; P61769; | 100 | 1×CYS; 1×ER7; 1×GOL; 1×PEG; | |||
| Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-2.1 |
Heteromer P04439; P61769; | 100 | 2×GOL; | |||
| Crystal Structure of HLA-B*15:01 in complex with spike derived peptide NQKLIANQF from SARS-CoV-2 vi… |
Heteromer P0DTC2; P61769; | 100 | 1×ACT; 1×PEG; | |||
| crystal structure of HLA B*3508LPEP-P5Ala , peptide mutant P5-ala |
Heteromer P01889; P61769; | 100 | ||||
| Structure of HLA-A2:01 with peptide G9L |
Heteromer P04439; P61769; | 100 | 3×GOL; | |||
| Crystal structure of HLA-A2*0201 in complex with a decameric altered peptide ligand from the MART-1… |
Heteromer P04439; P61769; | 100 | 1×ZN; | |||
| 6218 TCR in complex with H2-Db PA 224 |
Heteromer A0A075B6C4; A0A0G2LB96; K7N5M4; K7N5N2; O89752; P01899; P61769; | 100 | 4×NA; | |||
| Citrullination-dependent differential presentation of a self-peptide by HLA-B27 subtypes |
Heteromer P01889; P32241; P61769; | 100 | 6×GOL; | |||
| Structure of HLA-A2:01 with peptide G9V |
Heteromer P04439; P61769; | 100 | 3×GOL; | |||
| The high resolution crystal structure of HLA-B*1402 complexed with a Cathepsin A signal sequence pe… |
Heteromer P10619; P61769; Q56H30; | 100 | 4×GOL; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide V5M v… |
Heteromer P04439; P61769; Q03463; | 100 | ||||
| Crystal Structure of HLA A*1101 in complex with RVLVNGTFLK, an 10-mer epitope from Influenza B |
Heteromer P03502; P61769; U5YJK1; | 100 | 1×SO4; | |||
| Structure of HLA-A2:01 with the 11-mer peptide F11V |
Heteromer P04439; P61769; S7UWA0; | 100 | 1×GOL; | |||
| Crystal Structure of a SARS Corona Virus Derived Peptide Bound to the Human Major Histocompatibilit… |
Heteromer P01889; P61769; | 100 | 1×PG4; 1×EPE; | |||
| 6218 TCR in complex with H2Db PA with an engineered TCR-pMHC disulfide bond |
Heteromer A0A075B6C4; A0A0G2LB96; K7N5M4; K7N5N2; O89752; P01899; P61769; | 100 | 1×NA; | |||
| HLA-E*01:03 in complex with SARS-CoV-2 Omicron Nsp13 peptide, VIPLSAPTL |
Heteromer P0DTD1; P61769; Q59EE1; | 100 | ||||
| Human Leukocyte Antigen A02 presenting ILAKFLHEL |
Heteromer O14746; P04439; P61769; | 100 | 10×EDO; 1×CA; 2×MES; 3×SO4; 1×GOL; | |||
| Human Class I MHC HLA-A2 in complex with the Tel1p peptide |
Heteromer P04439; P38110; P61769; | 100 | 5×GOL; | |||
| STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH DOT1L(998-1006) PHOSPHOPEPTIDE |
Heteromer P01889; P61769; Q8TEK3; | 100 | 1×GLC; | |||
| Weak TCR binding to an unstable insulin epitope drives type 1 diabetes |
Heteromer P01308; P01902; P61769; | 100 | 5×EDO; 2×GOL; 4×SO4; | |||
| HLA-B*27:05 presenting an HIV-1 8mer peptide |
Heteromer O78189; P04585; P61769; | 100 | 3×GOL; | |||
| Crystal Structure of HLA-B*57:01-TW10-T242N complex |
Heteromer P04585; P61769; U6BR87; | 100 | 1×PEG; 2×ACT; | |||
| HLA-B*57:01 presenting TSMSFVPRPW |
Heteromer P01889; P61769; | 100 | ||||
| Human Class I MHC HLA-A2 in complex with the WT-1 (126-134) (R1Y) peptide variant. |
Heteromer P04439; P19544; P61769; | 100 | 1×GOL; | |||
| Complex Structure of HLA-A*2402 with the Peptide from HCoV(CoV-2) spike protein |
Heteromer A0A5H2UYS3; P0DTC2; P61769; | 100 | ||||
| Crystal Structures of High Affinity Human T-Cell Receptors Bound to pMHC Reveal Native Diagonal Bin… |
Heteromer P01848; P04439; P61769; P78358; | 98.99 | 8×GOL; 1×MG; 5×SO4; 1×IPA; 1×EPE; | |||
| Human Major Histocompatibility Complex A2 allele presenting LLLGIGILV |
Heteromer O78126; P61769; | 100 | 3×EDO; | |||
| TCR55 in complex with HIV(Pol448-456)/HLA-B35 |
Heteromer K7N5M4; P01889; P04585; P61769; Q6IRV4; | 100 | 3×EDO; 5×SO4; | |||
| SARS-CoV-2 Spike-derived peptide S976-984 (VLNDILSRL) presented by HLA-A*02:01 |
Heteromer P0DTC2; P61769; Q861F7; | 100 | 1×ACT; 1×CD; 1×ZN; | |||
| The role of T cell receptor alpha genes in directing human MHC restriction |
Heteromer O19626; P03211; P61769; | 100 | ||||
| HLA-B*57:01-LTTKLTNTNI in complex with abacavir |
Heteromer P00403; P01889; P61769; | 100 | 1×1KX; | |||
| Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation |
Heteromer C1K0Y1; P01111; P61769; | 100 | ||||
| Crystal structure of non-phosphorylated form of PKD2 phosphopeptide bound to HLA-A2 |
Heteromer P04439; P61769; Q9BZL6; | 100 | 3×CD; 2×GOL; | |||
| Human leukocyte antigen B*07:02 in complex with SARS-CoV2 epitope IPRRNVATL |
Heteromer P01889; P0DTD1; P61769; | 100 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1406-1415 decapeptide |
Heteromer P04439; P61769; Q9DIT6; | 100 | ||||
| Human Class I MHC HLA-A2 in complex with the native nonameric Melan-A/MART-1(27-35) peptide |
Heteromer P04439; P61769; Q16655; | 100 | 2×GOL; | |||
| HLA-B*44:03 in complex with Epstein-Barr virus BZLF1-derived peptide (residues 169-180) |
Heteromer P01889; P61769; Q3KSS8; | 100 | 1×GOL; 2×ACT; | |||
| Crystal structure of HLA-B*4104 in complex with a 11mer self-peptide derived from S-methyl-5-thioad… |
Heteromer P01889; P61769; Q13126; | 100 | ||||
| Human leukocyte antigen A*0201 in complex with SARS-CoV-2 epitope YLQPRTFLL |
Heteromer A0A140T913; P0DTC2; P61769; | 100 | 4×GOL; | |||
| Crystal structure of HLA-B*3501 presenting the human cytochrome P450 derived peptide, KPIVVLHGY |
Heteromer P01889; P33260; P61769; | 100 | ||||
| Crystal structure of human CD1b in complex with synthetic antigenic diacylsulfoglycolipid SGL12 and… |
Heteromer P29016; P61769; | 100 | 1×NAG; 1×NAG; 1×SO4; 1×ACT; 1×T8X; 1×ULI; 2×GOL; | |||
| 1.9A crystal structure of HLA-G |
Heteromer P16104; P17693; P61769; | 100 | 1×CO; 2×CL; | |||
| Human Class I MHC HLA-A2 in complex with AVGSYVYSV peptide |
Heteromer A0A140T913; P61769; Q15124; | 100 | ||||
| HLA-B*57:01 presenting SSTRGISQLW |
Heteromer P01889; P61769; Q96HA1; | 100 | 1×GOL; | |||
| Structural and kinetic basis for heightened immunogenicity of T cell vaccines |
Heteromer A0A0B4J279; A0A0K0K1A5; P01848; P01850; P04439; P61769; P78358; | 100 | ||||
| Crystal structure of an lmp2a-derived peptide bound to human class i mhc hla-a2 |
Heteromer P04439; P13285; P61769; | 100 | 5×IOD; 2×EDO; 1×CL; | |||
| Crystal Structure of HLA B*3503 in complex with NPDIVIYQY, an 9-mer epitope from HIV-I |
Heteromer A0A6B7FTL9; P03366; P61769; | 100 | 1×GOL; | |||
| HLA B8 in complex with an Epstein Barr Virus determinant |
Heteromer P01889; P12977; P61769; | 100 | 1×CD; | |||
| Crystal Structure of HLA-A*2402 Complexed with a Newly Identified Peptide from 2009H1N1 PB1 (496-50… |
Heteromer P04439; P61769; Q9YXL6; | 100 | ||||
| Structure of human MAIT TCR in complex with human MR1-RL-6-Me-7-OH |
Heteromer P01850; P61769; Q6P4G7; Q95460; | 100 | 1×1VY; 2×GOL; | |||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer P04439; P61769; | 100 | ||||
| crystal structure of HLA B*3508 LPEP155A, HLA mutant Ala155 |
Heteromer C5MK56; P61769; | 100 | ||||
| A2 HLA complex with L8A heteroclitic variant of Melanoma peptide |
Heteromer P04439; P61769; | 100 | 11×GOL; 1×MES; | |||
| Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1980 strain |
Heteromer P01889; P61769; | 100 | ||||
| Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-1.1 |
Heteromer P04439; P61769; | 100 | 6×GOL; | |||
| Crystal Structure of HLA B*4405 in complex with EEYLQAFTY a self peptide from the ABCD3 protein |
Heteromer P01889; P61769; | 100 | 2×PEG; | |||
| Crystal Structure of HLA-A*0201 in complex with M1-G4E |
Heteromer P04439; P61769; | 100 | ||||
| DIFFERENT LENGTH PEPTIDES BIND TO HLA-AW68 SIMILARLY AT THEIR ENDS BUT BULGE OUT IN THE MIDDLE |
Heteromer P04439; P61769; | 100 | 1×ALA; 1×ARG; | |||
| HLA-B*15:02 complexed with a synthetic peptide |
Heteromer F4NBQ8; P61769; | 100 | 2×GOL; | |||
| Rational development of high-affinity T-cell receptor-like antibodies |
Heteromer P04439; P61769; P78358; | 100 | ||||
| Crystal Structure of C12C TCR-HLAB2705-KK10-L6M |
Heteromer P01889; P03366; P61769; | 100 | 3×SO4; | |||
| Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5Q peptide variant |
Heteromer P04439; P61769; | 100 | ||||
| Crystal Structure of the minor histocompatibility peptide HA-1Arg in complex with HLA-A2 |
Heteromer P04439; P61769; | 100 | ||||
| HLA-B*15:01 complexed with a synthetic peptide |
Heteromer D9J307; P61769; | 100 | 2×ACT; 4×GOL; 8×EDO; 1×NA; | |||
| HLA-B*57:01 presenting LALLTGVRW |
Heteromer P01889; P61769; | 100 | ||||
| HLA-B*2709 bound to deca-peptide s10R |
Heteromer P01889; P61769; | 100 | 1×GOL; | |||
| Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide |
Heteromer P04439; P61769; | 100 | 2×MES; | |||
| Crystal Structure of HLA-A*0201 in complex with SARS-CoV-2 N226-234 |
Heteromer P0DTC9; P61769; Q861F7; | 100 | 2×CD; 1×NA; 1×ACT; | |||
| HLA-A*03:01 with WT KRAS-10mer |
Heteromer P01116; P04439; P61769; | 100 | 1×GOL; | |||
| A peptide complexed with HLA-B*3901 |
Heteromer O00571; P01889; P61769; | 100 | ||||
| Crystal Structure of ILNAMITKI peptide bound to HLA-A2 |
Heteromer P04439; P61769; Q68CZ6; | 100 | 3×GOL; 1×NA; | |||
| Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR measured at 295 K |
Heteromer P01889; P32241; P61769; | 100 | ||||
| Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR and Copper |
Heteromer P01889; P32241; P61769; | 100 | 2×CU; 2×GOL; | |||
| The structure of HLA-B*1501/BM58-66AF9 |
Heteromer D9J307; P61769; Q71UK7; | 100 | ||||
| A2 HLA complex with G4A heteroclitic variant of Melanoma peptide |
Heteromer P04439; P61769; | 100 | 5×GOL; 3×EDO; 4×SO4; | |||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P01889; P04585; P61769; | 100 | 6×EDO; 1×GOL; 1×SO4; | |||
| The structure of HLA-A/14-3-D |
Heteromer A0A0G2JL56; P0DTC2; P61769; | 100 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide M5A v… |
Heteromer P04439; P61769; Q6SW59; | 100 | ||||
| Crystal structure of dual peptide from EBV in complex with HLA-A*11:01 |
Heteromer P04439; P13285; P61769; | 100 | 4×GOL; | |||
| Crystal structure of HLA-B*2705 complexed with a peptide derived from the human voltage-dependent c… |
Heteromer P01889; P61769; Q01668; | 100 | 3×GOL; | |||
| crystal structure of HLA B*3508LPEP-P6Ala, peptide mutant P6-ala |
Heteromer P01889; P61769; | 100 | ||||
| Crystal Structure of HLA A*0301 in complex with ILRGSVAHK, a 9-mer epitope from Influenza A |
Heteromer P04439; P26079; P61769; | 100 | 2×SO4; | |||
| Ternary complex of FcRn ectodomain, FcRn binding optimised human serum albumin and the human growth… |
Heteromer P02768; P55899; P61769; | 100 | 1×MES; 2×CYS; 1×JG5; | |||
| HLA-A*02:01 bound to Neuroblastoma Derived IGFBPL1 peptide |
Heteromer A0A140T913; P61769; Q8WX77; | 100 | 3×GOL; | |||
| Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphi… |
Heteromer P01889; P61769; Q70XD7; | 100 | ||||
| Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR and Nickel |
Heteromer P01889; P32241; P61769; | 100 | 2×NI; 2×GOL; | |||
| Crystal structure of a complex between the human adenovirus type 2 E3-19K protein and MHC class I m… |
Heteromer P04439; P0C213; P61769; P68979; | 100 | ||||
| Crystal Structure of the minor histocompatibility peptide HA-1His in complex with HLA-A2 |
Heteromer P04439; P61769; Q92619; | 100 | ||||
| HLA-A24 in complex with HIV-1 Nef134-10(wt) |
Heteromer P04439; P61769; Q9YYU8; | 100 | ||||
| Crystal structure of HLA-B*2709 complexed with the double citrullinated vasoactive intestinal pepti… |
Heteromer P01889; P32241; P61769; | 100 | ||||
| Crystal structure of HTLV-1 TAX peptide Bound to Human Class I MHC HLA-A2 with the E63Q and K66A mu… |
Heteromer P04439; P14079; P61769; | 100 | 13×GOL; 1×SCN; | |||
| Crystal Structure of KS1 TCR in complex with HLA-B*57:01-TW10 |
Heteromer P04585; P61769; U6BR87; | 100 | 1×ACT; 1×NA; 2×CL; | |||
| Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5V peptide variant |
Heteromer P04439; P61769; | 100 | ||||
| Crystal Structure of HLA B*4402 in complex with EEYLQAFTY a self peptide from the ABCD3 protein |
Heteromer P01889; P61769; | 100 | ||||
| Crystal structure of HLA-A*03:01 in complex with a mutant PIK3CA peptide |
Heteromer P04439; P42336; P61769; | 100 | 5×GOL; 3×FMT; | |||
| HLA Class I antigen |
Heteromer P04439; P40967; P61769; | 100 | 1×EDO; 2×GOL; | |||
| 1E6 TCR in complex with HLA-A02 carrying RQFGPDWIVA |
Heteromer A0A0B4J271; A0A0B4J2E0; A0A5B9; P01848; P04439; P61769; | 100 | 15×EDO; 2×PG4; 4×SO4; 1×GOL; | |||
| KIR3DL1 in complex with HLA-B*57:03 presenting the peptide LSSPVTKSF |
Heteromer I3ZN84; P43629; P61769; | 100 | 3×NAG; | |||
| A peptide complexed with HLA-B*3901 |
Heteromer O00571; P01889; P61769; | 100 | ||||
| KRAS-G12D specific TCR9a in complex with C*05-GADGVGKSL |
Heteromer A2BF26; P61769; | 100 | 2×MG; 2×GOL; 2×SO4; | |||
| Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 142-5 |
Heteromer K9N5Q8; P01902; P61769; | 100 | ||||
| HLA-B*57:01 complexed to pep-V and Abacavir |
Heteromer P01889; P61769; | 100 | 1×1KX; 1×CL; | |||
| The Immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled by its MHC-bound Conformation |
Heteromer P01889; P03206; P61769; | 100 | 2×ACY; | |||
| Human Class I MHC HLA-A2 in complex with the WT-1 (126-134) peptide |
Heteromer P04439; P19544; P61769; | 100 | 3×GOL; | |||
| Crystal structure of FcRn bound to UCB-303 |
Heteromer P55899; P61769; | 100 | 1×EQY; 1×NAG; 5×GOL; | |||
| Crystal structure of FcRn at pH3 |
Heteromer P55899; P61769; | 100 | 3×GOL; | |||
| Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-… |
Heteromer P01889; P61769; Q98Y46; | 100 | ||||
| Xenoreactive complex AHIII 12.2 TCR bound to p1049/HLA-A2.1 |
Heteromer P01849; P04213; P04439; P61769; Q9NPA0; | 100 | ||||
| Crystal Structure of HLA-A*0201 in complex with NA231, an influenza epitope |
Heteromer P04439; P61769; Q9Q0U7; | 100 | ||||
| Structures of Three HIV-1 HLA-B5703-Peptide Complexes and Identification of Related HLAs Potentiall… |
Heteromer P01889; P61769; Q70A61; | 100 | ||||
| Crystal Structure of HLA A*0101 in complex with NP44-S7N, an 9-mer influenza epitope |
Heteromer P04439; P61769; Q07FI1; | 100 | ||||
| The structure of HLA-A*3003/RT313 |
Heteromer A0A173ADK6; P04585; P61769; | 100 | ||||
| HLA-A24 in complex with HIV-1 Nef126-10(8T10F) |
Heteromer P04439; P61769; Q77378; | 100 | ||||
| Newly identified epitope V60 from HBV core protein complexed with HLA-A*0201 |
Heteromer P04439; P61769; Q9QAC5; | 100 | ||||
| Structure of chicken CD1-2 with bound fatty acid |
Heteromer P61769; Q5GL29; | 100 | 3×NAG; 1×PLM; | |||
| Crystal structure of RQA_V phosphopeptide bound to HLA-A2 |
Heteromer P04439; P33241; P61769; | 100 | 3×EDO; 1×NA; | |||
| MHC I A02 Allele presenting YLQLRTFLL |
Heteromer A0A140T913; P0DTC2; P61769; | 100 | 12×IOD; 1×PEG; | |||
| HIV RT derived peptide complexed to HLA-A*0301 |
Heteromer P04439; P61769; Q9YV12; | 100 | ||||
| Human Class I MHC HLA-A2(A150P) in complex with the Tel1p peptide |
Heteromer P04439; P38110; P61769; | 100 | 2×GOL; | |||
| Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance |
Heteromer P04439; P61769; Q9YYH6; | 100 | ||||
| The crystal structure of a self-peptide complexed to Abacavir and HLA-B*57:01 |
Heteromer O00267; P01889; P61769; | 100 | 1×1KX; | |||
| HLA-A2.1 KVAELVHFL |
Heteromer E0YFW1; P04439; P61769; | 100 | ||||
| The structure of HLA-B*35:01 in complex with the peptide (RPQVPLRPMTY) |
Heteromer P01889; P61769; Q9YYU8; | 100 | ||||
| THREE DIMENSIONAL STRUCTURE OF A PEPTIDE EXTENDING OUT ONE END OF A CLASS I MHC BINDING SITE |
Heteromer P04439; P27797; P61769; | 100 | ||||
| KIR3DL1*005 in complex with HLA-A*24:02 presenting the RYPLTFGW peptide |
Heteromer A0A5H2UYS3; P04601; P43629; P61769; | 100 | 4×NAG; | |||
| KIR3DL1 in complex with HLA-B*57:01-TW10 |
Heteromer P01889; P03366; P43629; P61769; | 100 | 3×NAG; | |||
| Crystal structure of HLA-A*11:01 in complex with SVLNDIFSRL, an 10-mer epitope from SARS-CoV-2 Spik… |
Heteromer P0DTC2; P61769; Q5S3G3; | 100 | 17×EDO; 3×NA; 1×PEG; 3×CL; 1×MG; | |||
| CD1a-phosphatidylglycerol binary structure |
Heteromer P06126; P61769; | 100 | 1×NAG; 1×MW9; 2×EDO; 1×MES; 2×PEG; | |||
| Crystal structure of HLA-B*0801.N80I.R82L.G83R |
Heteromer P01889; P61769; | 100 | ||||
| Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 2009 H1N1 swine origin… |
Heteromer P01889; P61769; | 100 | ||||
| HLA-B*15:01 complexed with a synthetic peptide |
Heteromer F4NBQ1; P61769; | 100 | 1×EDO; 2×NA; 1×ACT; | |||
| Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide |
Heteromer P04439; P61769; | 100 | 2×GOL; 1×MES; | |||
| Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1918 strain |
Heteromer P01889; P61769; | 100 | ||||
| Crystal Structure of the TK3 TCR in complex with HLA-B*3501/HPVG |
Heteromer P01889; P03211; P61769; | 100 | 1×SO4; | |||
| Crystal structure of HLA-B*08:01 in complex with ELRSRYWAI viral peptide |
Heteromer P61769; Q9Q0U8; | 100 | 4×EDO; 1×PEG; | |||
| Crystal Structure of HLA B*4403 in complex with EEYLQAFTY a self peptide from the ABCD3 protein |
Heteromer P61769; Q2L6G2; | 100 | ||||
| Structure of HLA-A2 P130 |
Heteromer P04439; P61769; | 100 | 3×PEG; | |||
| HLA-B*58:01 presenting LTVQVARVW |
Heteromer P01889; P61769; | 100 | ||||
| MHC CLASS I MOLECULE B*3501 COMPLEXED WITH PEPTIDE VPLRPMTY FROM THE NEF PROTEIN (75-82) OF HIV1 |
Heteromer P01889; P61769; | 100 | ||||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer P04439; P61769; | 100 | ||||
| Structure of human MR1-Ac-6-FP in complex with human MAIT M33.64 TCR |
Heteromer P61769; Q95460; | 100 | 1×PRO; 1×30W; 7×GOL; | |||
| Phosphorylation of MHC I peptide |
Heteromer O78189; P18583; P61769; | 100 | ||||
| KIR3DL1*114 in complex with HLA-B*57:03 presenting the AW10 peptide |
Heteromer A0A5J6VN80; I3ZN84; P35221; P61769; | 100 | 4×NAG; | |||
| Crystal structure of HLA-B*5801 complex with HIV-1 gag derived peptide TW10 |
Heteromer P01889; P03366; P61769; | 100 | ||||
| Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation |
Heteromer C1K0Y1; P01111; P61769; | 100 | 2×SO4; 6×GOL; 2×MG; | |||
| Human Class I Major Histocompatibility Complex, A02 allele, presenting IIGWMWIPV |
Heteromer A0A140T913; P61769; | 100 | 5×EDO; 1×GOL; 3×SO4; 1×NA; 1×P4G; | |||
| HLA Class I antigen |
Heteromer A0A0B4J279; A0A592; A0A5B9; P01848; P04439; P40967; P61769; | 100 | 10×EDO; 3×GOL; 8×SO4; | |||
| CD1a-42:2 SM binary complex |
Heteromer P06126; P61769; | 100 | 1×FO4; 1×MES; | |||
| 1E6 TCR in complex with HLA-A02 carrying RQFGPDFPTI |
Heteromer A0A0B4J271; A0A0B4J2E0; A0A5B9; P01848; P04439; P61769; | 100 | 30×EDO; 3×GOL; 5×SO4; | |||
| Crystal Structure of HLA-A*0201 in complex with M1-F5L |
Heteromer P04439; P61769; | 100 | ||||
| Crystal structure of HLA-A*03:01 in complex with a mutant PIK3CA peptide analogue (Trp-6 Bta) |
Heteromer P04439; P42336; P61769; | 100 | 1×GOL; | |||
| Crystal structure of HLA-A*03:01 in complex with a wild-type PIK3CA peptide |
Heteromer P04439; P42336; P61769; | 100 | 2×GOL; | |||
| Crystal structure of engineered TCR (796) complexed to HLA-A*02:01 presenting MAGE-A10 9-mer peptide |
Heteromer P43363; P61769; Q861F7; | 100 | 3×GOL; 1×CL; | |||
| HLA-B*57:01 presenting LSDSTARDVTW |
Heteromer P01889; P61769; | 100 | ||||
| STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH DOT1L(998-1006) PEPTIDE |
Heteromer P01889; P61769; Q8TEK3; | 100 | 1×GLC; 1×NA; | |||
| Crystal structure of HTLV-1 TAX peptide Bound to Human Class I MHC HLA-A2 with the K66A mutation in… |
Heteromer P04439; P14079; P61769; | 100 | 14×GOL; | |||
| SARS-CoV-2 Spike-derived peptide S269-277 (YLQPRTFLL) presented by HLA-A*02:01 |
Heteromer P0DTC2; P61769; Q53Z42; | 100 | ||||
| Structure of S2-198 TCR in complex with HLA-A*03:01 bound to ELFSYLIEK peptide |
Heteromer P04439; P61769; | 100 | 1×TOE; 2×EDO; 1×PO4; | |||
| ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYKL-INDEX… |
Heteromer P01889; P61769; | 100 | ||||
| HLA-E*01:03 in complex with Mtb14 |
Heteromer P13747; P61769; P9WQE5; | 100 | 4×GOL; 8×SO4; | |||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P01889; P03407; P61769; | 100 | 2×GOL; 6×EDO; 2×SO4; | |||
| The crystal structure of class I Major histocompatibility complex, H-2Kd at 2.0 A resolution |
Heteromer P01902; P61769; | 100 | ||||
| SARS-CoV-2 YLQ peptide binds to HLA-A2 |
Heteromer A0A140T913; P0DTC2; P61769; | 100 | 1×PG4; | |||
| HLA*A2402 complexed with HIV nef138 Y2F mutant 10mer epitope |
Heteromer P04439; P04601; P61769; | 100 | ||||
| Structure of chimeric HLA-A*11:01-A*02:01 bound to HIV-1 RT peptide |
Heteromer P04585; P61769; | 100 | ||||
| Crystal Structure of HLA A*1101 in complex with KTNGNAFIGK, an 10-mer epitope from Influenza B |
Heteromer P04666; P61769; U5YJK1; | 100 | ||||
| HLA-B*15:01 complexed with a synthetic peptide |
Heteromer D9J307; P61769; | 100 | 1×GOL; 4×EDO; 2×ACT; 1×NA; | |||
| Human Class I MHC HLA-A2 in complex with sorting nexin 24 (127-135) peptide KLSHQPVLL |
Heteromer A0A140T913; P61769; Q9Y343; | 100 | 1×NO3; | |||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P01889; P03407; P61769; | 100 | 3×GOL; 3×EDO; 1×SO4; | |||
| 6218 TCR in complex with H2-Db PA224-233 with a cysteine mutant |
Heteromer A0A075B6C4; A0A0G2LB96; K7N5M4; K7N5N2; O89752; P01899; P61769; | 100 | 4×NA; | |||
| Crystal structure of HLA-B*5701 complex with an HIV-1 Gag-derived epitope QW9 |
Heteromer P04585; P61769; U6BR87; | 100 | 1×MES; 1×IPA; | |||
| Crystal structure of C25-NLV-HLA-A2 complex |
Heteromer P04439; P18139; P61769; | 100 | 1×IMD; | |||
| Peptide modification of MHC class I molecules |
Heteromer O78189; P18583; P61769; | 100 | ||||
| Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-… |
Heteromer P01889; P03466; P61769; | 100 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide G4M-V… |
Heteromer P04439; P61769; Q03463; | 100 | ||||
| Crystal structure of HLA-B*4402 in complex with the R5A mutant of a self-peptide derived from DPA*0… |
Heteromer P01889; P61769; Q95HB9; | 100 | 2×ACT; 5×GOL; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with Melan-A MART1 decapeptide variant |
Heteromer P04439; P61769; Q16655; | 100 | ||||
| Crystal structure of HLA-B*2705 complexed with the double citrullinated vasoactive intestinal pepti… |
Heteromer A3F718; P32241; P61769; | 100 | ||||
| HLA-B*27:05 presenting an HIV-1 11mer peptide |
Heteromer O78189; P04585; P61769; | 100 | 1×GOL; | |||
| STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PHOSPHOPEPTIDE, CUBIC CRYSTAL FORM |
Heteromer P01889; P61769; Q03164; | 100 | 1×12P; 1×PE8; 2×PGE; 1×PEG; 1×PG4; 1×ACT; 1×1PE; | |||
| Crystal Structure of B*4405 presenting a 10mer EBV epitope |
Heteromer P01889; P03204; P61769; | 100 | 2×GOL; | |||
| Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with Ebola virus-der… |
Heteromer A0A125R585; O72142; P61769; | 100 | ||||
| Crystal structure of MHC CLass I HLA-A2.1 bound to HIV-1 Peptide RT468-476 |
Heteromer P03366; P04439; P61769; | 100 | 3×MES; 5×GOL; | |||
| HLA-E*01:03 in complex with Mtb44 |
Heteromer P13747; P61769; P9WGR1; | 100 | 4×SO4; | |||
| CD1a binary complex with lysophosphatidylcholine |
Heteromer P06126; P61769; | 100 | 1×MLT; 1×42H; | |||
| KIR3DL1 in complex with HLA-B*57:01 presenting TSNLQEQIGW |
Heteromer P01889; P03366; P43629; P61769; | 100 | 3×NAG; | |||
| MHC Class I A02 Allele presenting LLLGIGILVL, in complex with Mel5 TCR |
Heteromer A0A140T913; P61769; Q10589; | 100 | 4×GOL; | |||
| Crystal structure of HLA-A0201 in complex with an azobenzene- containing peptide |
Heteromer P04439; P61769; | 100 | 4×IPA; | |||
| HLA-B*15:02 complexed with a synthetic peptide |
Heteromer F4NBQ8; P61769; | 100 | 2×ACT; 3×GOL; 2×EDO; 1×NA; | |||
| Crystal Structure of HLA-A*0201 in complex with M1-L3W |
Heteromer P04439; P61769; | 100 | ||||
| ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYQL-7Q MU… |
Heteromer P01889; P61769; | 100 | ||||
| Structure determination of an enhanced affinity TCR, a24b17, in complex with HLA-A*02:01 presenting… |
Heteromer A0A5B8RNS7; P61769; Q16655; | 100 | 5×GOL; 7×EDO; 5×SO4; 3×TAM; | |||
| PF6-M1-HLA-A2 |
Heteromer P03485; P04439; P61769; | 100 | ||||
| Structure of HLA-A2:01 with peptide G13E |
Heteromer P04439; P61769; | 100 | ||||
| Crystal Structure of the TK3-Gln55His TCR in complex with HLA-B*3501/HPVG |
Heteromer P01889; P03211; P61769; | 100 | 1×SO4; | |||
| Crystal structure of the binary complex between HLA-A2 and HCMV NLV-T8V peptide variant |
Heteromer P04439; P61769; | 100 | ||||
| Directed Evolution of Human T-cell Receptor CDR2 residues by phage display dramatically enhances af… |
Heteromer P01848; P04439; P61769; P78358; | 98.99 | 1×NA; 4×GOL; | |||
| THE THREE-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 ANGSTROMS RESOLUTION SUGGESTS A GENERAL MECHANISM… |
Heteromer P01889; P61769; | 100 | ||||
| Human Class I MHC HLA-A2(A150P) in complex with the Tax peptide |
Heteromer P04439; P61769; | 100 | 1×GOL; | |||
| HLA-B*2705 bound to nona-peptide m9 |
Heteromer P01889; P61769; | 100 | ||||
| KIR3DL1*001 in complex with HLA-B*57:03 presenting the AW10 peptide |
Heteromer I3ZN84; P35221; P43629; P61769; | 100 | 3×NAG; | |||
| Crystal structure of a HLA-B*35:01-NP10 with D1 TCR |
Heteromer O19626; P61769; | 98.99 | 1×EDO; 1×NA; 5×PO4; | |||
| N17.1.2 recognition of NRAS neoantigens |
Heteromer F6IQR9; P61769; | 100 | 8×GOL; 2×EDO; | |||
| Crystal structure of PKD2 phosphopeptide bound to HLA-A2 |
Heteromer P04439; P61769; Q9BZL6; | 100 | 4×CD; 1×GOL; | |||
| Human Leukocyte Antigen Class I A02 Carrying LLWNGPMQV |
Heteromer P03314; P04439; P61769; | 100 | 1×EDO; 1×GOL; 2×PEG; | |||
| Crystal Structure Of HLA-B*2709 Complexed With the self-Peptide TIS from EGF-response factor 1 |
Heteromer P01889; P47974; P61769; | 100 | 2×GOL; | |||
| Complex Structure of HLA-A*2402 with the Peptide from HCoV(CoV-HKU1) spike protein |
Heteromer A0A5H2UYS3; P61769; Q5MQD0; | 100 | ||||
| A2 HLA complex with E1A heteroclitic variant of Melanoma peptide |
Heteromer P04439; P61769; | 100 | 6×GOL; 1×SO4; | |||
| 1E6 TCR in complex with HLA-A02 carrying YQFGPDFPIA |
Heteromer A0A0B4J271; A0A0B4J2E0; A0A5B9; P01848; P04439; P61769; | 100 | 3×SO4; 3×EDO; | |||
| Engineered scFv 10LH bound to PHOX2B/HLA-A24:02 |
Heteromer F6IR24; P61769; Q99453; | 100 | 2×GOL; 2×NO3; | |||
| HLA Class I antigen |
Heteromer P04439; P40967; P61769; | 100 | 1×GOL; 4×EDO; 5×SO4; | |||
| Crystal structure of human 0606T1-2 TCR bound to HLA-A*03:01 in complex with a mutant PIK3CA peptide |
Heteromer P04439; P42336; P61769; | 100 | 13×GOL; | |||
| Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5S peptide variant |
Heteromer P04439; P61769; | 100 | ||||
| Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection |
Heteromer P01889; P04591; P61769; | 100 | ||||
| Porcine (Sus scrofa) Major Histocompatibility Complex, class I, with human beta2 micro globulin, pr… |
Heteromer B1PJV3; P61769; Q9Q0U8; | 100 | 2×EDO; | |||
| Crystal Structure of CD1a in Complex with a Sulfatide |
Heteromer P06126; P61769; | 100 | 2×NAG; 1×NAG; 1×FUC; 1×SLF; | |||
| Crystal structure of HLA-B*57:01.I80N.L82R.R83G |
Heteromer P01834; P01889; P61769; | 100 | ||||
| Crystal Structure of ILNAMIAKI peptide bound to HLA-A2 |
Heteromer P04439; P61769; Q68CZ6; | 100 | 2×GOL; | |||
| HLA-B*15:02 complexed with a synthetic peptide |
Heteromer F4NBQ8; P61769; | 100 | 2×GOL; 1×ACT; | |||
| Crystal structure of HLA-A2*0201 in complex with a nonameric altered peptide ligand (ALGIGILTV) fro… |
Heteromer P04439; P61769; | 100 | ||||
| Crystal structure of HLA-A1:MAGE-A1 in complex with Fab-Hyb3 |
Heteromer P04439; P43355; P61769; | 100 | 2×GOL; | |||
| Structure of human MR1-DA-6-FP in complex with human MAIT A-F7 TCR |
Heteromer P61769; Q95460; | 100 | 1×7WP; 4×GOL; 2×NA; | |||
| Crystal structure of DMF5 TCR bound to HLA-A2 presenting synthetic peptide MMWDRGLGMM |
Heteromer P04439; P61769; | 100 | ||||
| HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P2-Gln. |
Heteromer P13747; P61769; P9WGR1; | 100 | 2×SO4; | |||
| Crystal Structure of HLA A*2402 in complex with TYQWVLKNL, an 9-mer epitope from Influenza B virus |
Heteromer A0A5H2UYS3; P61769; Q9QLL6; | 100 | ||||
| Crystal Structure of HLA A*02:03 Bound to HBV Core 18-27 |
Heteromer P0C6H2; P61769; Q2LC95; | 100 | ||||
| SARS-CoV-2 Spike-derived peptide S1215-1224 (YIWLGFIAGL) presented by HLA-A*02:01 |
Heteromer P0DTC2; P61769; Q53Z42; | 100 | ||||
| Crystal structure of InhA:01 TCR in complex with HLA-E (Y84C) bound to InhA (53-61 GCG) |
Heteromer P13747; P61769; P9WGR1; | 100 | 8×EDO; | |||
| Crystal structure of TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK) |
Heteromer A0A583ZB34; P01116; P01849; P61769; Q5R1I3; | 100 | ||||
| Crystal structure of the 'restriction triad' mutant of HLA B*3508, beta-2-microglobulin and EBV pep… |
Heteromer P01889; P03206; P61769; | 100 | 7×ACY; 1×GOL; 8×PEG; | |||
| The structure of HLA-A/Pep16 |
Heteromer A0A0G2JPD3; P0DTC2; P61769; | 100 | ||||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer P04439; P61769; | 100 | ||||
| Crystal structure of a H5-specific CTL epitope variant derived from H5N1 influenza virus in complex… |
Heteromer P04439; P61769; Q1WDM0; | 100 | ||||
| HLA*A2402 complex with HIV nef138 Y2F-8mer mutant epitope |
Heteromer P04439; P04601; P61769; | 100 | ||||
| Crystal structure of HLA-A*11:01 in complex with KRAS peptide (VVGAGGVGK) |
Heteromer P01116; P61769; U5YJJ6; | 100 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with Melan-A MART1 decapeptide variant |
Heteromer P04439; P61769; Q16655; | 100 | ||||
| Nonstandard peptide binding of HLA-B*5101 complexed with HIV immunodominant epitope KM1(LPPVVAKEI) |
Heteromer P01889; P24740; P61769; | 100 | ||||
| Crystal structure of HLA-B*2709 complexed with the vasoactive intestinal peptide type 1 receptor (V… |
Heteromer P01889; P32241; P61769; | 100 | 3×GOL; 1×MN; | |||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer O11822; P04439; P61769; | 100 | ||||
| Crystal Structure Analysis of NY-ESO-1 epitope, SLLMWITQC, in complex with HLA-A2 |
Heteromer P04439; P61769; P78358; | 100 | 1×SO4; | |||
| Crystal Structure of the human cytomegalovirus protein US2 bound to the MHC class I molecule HLA-A2… |
Heteromer P04439; P09713; P14079; P61769; | 100 | ||||
| HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) COMPLEX WITH A NONAMERIC PEPTIDE FROM MELANOM… |
Heteromer P04439; P43357; P61769; | 100 | ||||
| Crystal Structure of HLA-A*03:01 in complex with VVRPSVASK, an 9-mer epitope from Influenza B virus |
Heteromer P04439; P13884; P61769; | 100 | 3×SO4; | |||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer O11818; P04439; P61769; | 100 | ||||
| CD1a-lipid binary complex |
Heteromer P06126; P61769; | 100 | 1×FOF; 3×EDO; | |||
| ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKRYKL-5R MU… |
Heteromer P01889; P61769; | 100 | ||||
| CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1058 |
Heteromer P04439; P61769; | 100 | ||||
| Human MHC Class I, A24 Allele presenting QLPRLFPLL, Complex with 4C6 TCR |
Heteromer A0A5H2UYS3; P61769; | 100 | 1×BTB; 1×SO4; 1×EDO; | |||
| ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGRKKYKL-3R MU… |
Heteromer P01889; P61769; | 100 | ||||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer P04439; P61769; | 100 | ||||
| TCR-antigen complex AS8.4-YEIH-HLA*B27 |
Heteromer A3F718; P61769; P62723; | 100 | 1×GOL; | |||
| Structure of human MR1-HMB in complex with human MAIT A-F7 TCR |
Heteromer P61769; Q95460; | 100 | 1×PRO; 1×7WQ; 1×GOL; | |||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer P04439; P61769; | 100 | ||||
| CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VA… |
Heteromer P04439; P61769; | 100 | ||||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer P04439; P61769; | 100 | ||||
| Crystal structures of high affinity human T-cell receptors bound to pMHC reveal native diagonal bin… |
Heteromer P01848; P04439; P61769; P78358; | 98.99 | 6×SO4; 11×GOL; 1×CA; 1×MG; 1×EPE; | |||
| Uncommon structural features of rabbit MHC class I (RLA-A1) complexed with rabbit haemorrhagic dise… |
Heteromer P06140; P27410; P61769; | 100 | ||||
| HLA B7:02 with RPIIRPATL |
Heteromer P01889; P04666; P61769; | 100 | 7×EDO; | |||
| Newly identified epitope Mn2 from SARS-CoV M protein complexed withHLA-A*0201 |
Heteromer P04439; P59596; P61769; | 100 | ||||
| Structure of UL18, a Peptide-Binding Viral MHC Mimic, Bound to a Host Inhibitory Receptor |
Heteromer P08560; P60709; P61769; Q8NHL6; | 100 | 7×NAG; 1×MAN; 1×BMA; 1×FUC; | |||
| STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANT NONAMER AND DECAMER HIV-1 EPITOPES CLEARLY … |
Heteromer P04439; P04602; P61769; | 100 | ||||
| HLA-B*15:02 complexed with a synthetic peptide |
Heteromer F4NBQ8; P61769; | 100 | 1×EDO; 1×ACT; 1×GOL; | |||
| Human Leukocyte Antigen Class I A02 Carrying LLWNGPIAV |
Heteromer P03314; P04439; P61769; | 100 | 3×GOL; 1×EDO; 6×SO4; 1×PEG; | |||
| Crystal structure of MHC-I H2-KD complexed with peptides of Mycobacterial tuberculosis (YQSGLSIVM) |
Heteromer P01902; P61769; P9WQP1; | 100 | 3×GOL; 8×EDO; | |||
| HHAT L75F Neoantigen Peptide KQWLVWLFL Presented by HLA-A206 |
Heteromer P61769; Q5VTY9; U5YJP1; | 100 | ||||
| HLA-B*27:05 presenting an HIV-1 6mer peptide |
Heteromer O78189; P04585; P61769; | 100 | 1×ARG; | |||
| Crystal structure of the vaccinia derived peptide A11R in complex with the murine MHC CLASS I H-2 KB |
Heteromer P01901; P61769; Q49PI7; | 100 | ||||
| CD1a-36:2 SM binary complex |
Heteromer P06126; P61769; | 100 | 1×WU7; 4×EDO; 1×NAG; | |||
| Crystal Structure Determination Of HLA A2 Complexed to Peptide GP2 with the substitution (I2L/V5L/L… |
Heteromer P04439; P61769; | 100 | ||||
| Crystal Structure of the cross-restricted T18A TCR and HLAB8101 bound to HIV-1 Gag TL9 peptide |
Heteromer I3ZN85; P04585; P61769; | 100 | ||||
| Human Major Histocompatibility Complex A24 Allele presenting QLPRLFPLL |
Heteromer A0A5H2UYS3; P61769; | 100 | 4×EDO; 4×PEG; 4×SO4; | |||
| TCR in complex with HLA-E*01:03 bound to HBV envelope 371-379 index peptide |
Heteromer A0A075B6T6; A0A0K0K1A5; P0DTU3; P0DTU4; P13747; P61769; Q67953; | 100 | ||||
| HLA-B*27:05 presenting an HIV-1 14mer peptide |
Heteromer O78189; P04585; P61769; | 100 | 2×GOL; | |||
| CD1b in complex with Phophatidylinositol |
Heteromer P29016; P61769; | 100 | 1×PII; 3×NO3; 1×D12; 1×TWT; | |||
| Crystal structure of InhA:01 TCR in complex with HLA-E bound to InhA (53-61) |
Heteromer P13747; P61769; P9WGR1; | 100 | ||||
| N17.1.2 recognition of NRAS neoantigens |
Heteromer F6IQR9; P61769; | 100 | ||||
| Crystal Structure Of HLA-B*2705 Complexed With the self-Peptide TIS from EGF-response factor 1 |
Heteromer P01889; P47974; P61769; | 100 | 2×GOL; | |||
| Human Leukocyte Antigen A02 presenting ILAKFLHTL |
Heteromer O14746; P04439; P61769; | 100 | 1×SO4; 1×EDO; | |||
| AS4.3-PRPF3-HLA*B27 |
Heteromer A3F718; O43395; P61769; | 100 | 5×NAG; 1×ASP; 3×SO4; 1×EDO; | |||
| Uncommon structural features of rabbit MHC class I (RLA-A1) complexed with rabbit haemorrhagic dise… |
Heteromer P06140; P27410; P61769; | 100 | ||||
| Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25… |
Heteromer A0A0X9JHC1; P04439; P61769; | 100 | ||||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the modified TAX (Y5F) peptide |
Heteromer P04439; P61769; | 100 | 11×GOL; | |||
| Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25… |
Heteromer A0A0X9JHC1; P04439; P61769; | 100 | ||||
| HLA-A24 in complex with HIV-1 Nef134-8(2F) |
Heteromer P04439; P04601; P61769; | 100 | ||||
| Crystal structure of a H5-specific CTL epitope derived from H5N1 influenza virus in complex with HL… |
Heteromer P04439; P61769; Q2F4V2; | 100 | ||||
| SARS-CoV-2 Spike-derived peptide S489-497 (YFPLQSYGF) presented by HLA-A*29:02 |
Heteromer B0UXQ0; P0DTC2; P61769; | 100 | 3×SO4; 2×MG; 1×NA; | |||
| Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-… |
Heteromer P01889; P03204; P61769; | 100 | ||||
| Crystal Structures of HLA-B*1501 in Complex with Peptides from Human UbcH6 and Epstein-Barr Virus E… |
Heteromer P01889; P12977; P61769; | 100 | 1×PG4; 1×URE; 2×GOL; | |||
| Human leukocyte antigen B*07:02 in complex with SARS-CoV2 epitope SPRWYFYYL |
Heteromer P01889; P59595; P61769; | 100 | 1×P6G; | |||
| Crystal Structure of CA5 TCR-HLA B*3505-LPEP complex |
Heteromer C5MK56; P01848; P01850; P61769; Q3KSS8; | 100 | 3×NA; 8×IOD; | |||
| Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 mutant (Met52 Asp53 Leu54 delet… |
Heteromer A0A125R585; O55778; P61769; | 100 | ||||
| Crystal structure of MHC CLass I HLA-A2.1 bound to HIV-1 envelope peptide env120-128 |
Heteromer P04439; P04583; P61769; | 100 | 3×MES; 5×GOL; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS4b-1807-1816 decapeptide |
Heteromer P04439; P61769; Q9DIT6; | 100 | ||||
| Crystal structure of MHC CLass I HLA-A2.1 bound to Cytomegalovirus (CMV) pp65 epitope |
Heteromer P04439; P06725; P61769; | 100 | 7×GOL; | |||
| Crystal structure of MHC CLass I HLA-A2.1 bound to a Peiodate- cleavable peptide |
Heteromer P04439; P06725; P61769; | 100 | 2×GOL; 1×MES; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with EBV bmlf1-280-288 nonapeptide T4P v… |
Heteromer P04439; P61769; Q3KSU1; | 100 | ||||
| Crystal structure of LMP2 peptide from EBV in complex with HLA-A*11:01 |
Heteromer P04439; P13285; P61769; | 100 | 5×GOL; | |||
| Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with H17N10 influenz… |
Heteromer A0A125R585; H6QM94; P61769; | 100 | ||||
| Human leukocyte antigen A*0201 in complex with SARS-CoV2 epitope KLWAQCVQL |
Heteromer A0A140T913; P0DTD1; P61769; | 100 | 2×GOL; | |||
| Crystal structure of MHC-I H2-KD complexed with peptides of Mycobacterial tuberculosis (YYQSGLSIV) |
Heteromer P01902; P61769; P9WQP1; | 100 | 2×GOL; 1×EDO; | |||
| Crystal structure of non-phosphorylated form of RTF PHOSPHOPEPTIDE BOUND TO HLA-A2 in complex with … |
Heteromer O15061; P04439; P61769; Q8NHL6; | 100 | ||||
| KIR3DL1*005 in complex with HLA-B*57:01 |
Heteromer P01834; P01889; P43629; P61769; | 100 | 3×NAG; | |||
| THE THREE-DIMENSIONAL STRUCTURE OF A CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE MISSING THE … |
Heteromer P04439; P61769; | 100 | ||||
| Crystal Structures of High Affinity Human T-Cell Receptors Bound to pMHC RevealNative Diagonal Bind… |
Heteromer P01848; P04439; P61769; P78358; | 98.99 | 9×SO4; 3×PGE; 1×7PE; 11×GOL; | |||
| The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its V… |
Heteromer P03485; P04439; P61769; | 100 | ||||
| HLA-C*06:02 presenting VRSRR(ABA)LRL |
Heteromer P10321; P61769; | 100 | 6×EDO; | |||
| crystal structure of HLA B*3508 LPEP-P10Ala, peptide mutant P10-ala |
Heteromer P01889; P61769; | 100 | ||||
| Crystal Structure Analysis of NY-ESO-1 epitope analogue, SLLMWITQS, in complex with HLA-A2 |
Heteromer P04439; P61769; | 100 | 1×SO4; | |||
| Structure of HLA-A2:01 with peptide G11N |
Heteromer P04439; P61769; | 100 | 2×GOL; | |||
| Crystal Structure Determination of HLA-A2.1 Complexed to GP2 Peptide Variant(I2L/V5L) |
Heteromer P04439; P61769; | 100 | ||||
| Crystal Structure of HLA B*4403 in complex with EEYLKAWTF, a mimotope |
Heteromer P01889; P61769; | 100 | ||||
| Crystal structure of InhA:01 TCR in complex with HLA-E (F116C) bound to InhA (53-61 H4C) |
Heteromer P13747; P61769; P9WGR1; | 100 | 4×EDO; | |||
| Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide |
Heteromer P04439; P61769; | 100 | 2×GOL; 2×MES; | |||
| MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE TPYDINQML FROM GAG PROTEIN OF HIV2 |
Heteromer P01889; P61769; | 100 | ||||
| ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYRL-7R MU… |
Heteromer P01889; P61769; | 100 | ||||
| The complex between TCR DMF5 and human Class I MHC HLA-A2 with the bound MART-1(27-35) nonameric pe… |
Heteromer P01848; P04439; P61769; | 100 | ||||
| AS4.2-YEIH-HLA*B27 |
Heteromer A3F718; P61769; P62723; | 100 | 2×GOL; 3×NAG; | |||
| MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE LS6 (KPIVQYDNF) FROM THE MALARIA PARASITE P. FAL… |
Heteromer P01889; P61769; | 100 | ||||
| HLA peptide complex |
Heteromer A0A140T913; P0DTC2; P61769; | 100 | 4×EDO; | |||
| NYBR1-A2-SLSKILDTV |
Heteromer A0A0B4J277; A0A584; K7N5M3; K7N5M4; P04439; P61769; Q9BXX3; | 100 | 1×PEG; 2×EDO; 3×GOL; 8×SO4; 1×EPE; | |||
| SARS-CoV-2 RLQ peptide-specific TCR pRLQ3 binds to RLQ-HLA-A2 |
Heteromer A0A140T913; P0DTC2; P61769; | 100 | ||||
| Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP8 epitope from 2005 H1N1 influenza strain |
Heteromer F4NBT2; P61769; | 100 | ||||
| Weak TCR binding to an unstable insulin epitope drives type 1 diabetes |
Heteromer P01308; P01902; P61769; | 100 | 3×EDO; 2×GOL; 4×SO4; | |||
| HLA2.1 KVAELVWFL |
Heteromer E0YFW1; P04439; P61769; | 100 | ||||
| Weak TCR binding to an unstable insulin epitope drives type 1 diabetes |
Heteromer P01308; P01902; P61769; | 100 | 1×EDO; 3×SO4; | |||
| Crystal structure of HLA-B*4001 in complex with SARS-CoV derived peptide N216-225 GETALALLLL |
Heteromer A0A499S0B6; P59595; P61769; | 100 | ||||
| The structure of HLA-A/L1-2 |
Heteromer A0A0G2JPD3; P03101; P61769; | 100 | ||||
| Crystal Structure of HLA-C*0501 in complex with SAE |
Heteromer P10321; P61769; | 100 | ||||
| Crystal structure of high affinity TCR in complex with pHLA harbouring bacterial peptide |
Heteromer P13747; P61769; P9WGR1; | 100 | ||||
| 1E6 TCR in Complex with HLA-A0e carrying RQWGPDPAAV |
Heteromer A0A0B4J271; A0A0B4J2E0; A0A5B9; P01848; P04439; P61769; | 100 | 12×EDO; 3×GOL; 4×SO4; | |||
| Crystal structure of MHC CLass I HLA-A2.1 bound to residual fragments of a photocleavable peptide t… |
Heteromer P04439; P61769; | 100 | 3×GOL; | |||
| A2-MHC Complex carrying FLTGIGIITV |
Heteromer P04439; P61769; | 100 | 7×EDO; 1×SO4; 1×GOL; | |||
| The complex between high-affinity TCR DMF5(alpha-D26Y,beta-L98W) and human Class I MHC HLA-A2 with … |
Heteromer K7N5M3; K7N5M4; P04439; P61769; Q16655; | 100 | ||||
| HLA-B*15:02 complexed with a synthetic peptide |
Heteromer F4NBQ8; P61769; | 100 | 1×GOL; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with Melan-A MART1 decapeptide variant |
Heteromer P04439; P61769; Q16655; | 100 | ||||
| Crystal Structure of HLA-A*02:01 in complex with KLNDLCFTNV, an 10-mer epitope from SARS-CoV-2 Spik… |
Heteromer A0A140T913; P0DTC2; P61769; | 100 | 1×GOL; | |||
| Single chain trimer HLA-A*02:01 (Y108C, A163C) with Wilms tumor protein peptide RMFPNAPYL |
Heteromer A0A6S7XV52; P16213; P19544; | 100.0 | ||||
| TCR in complex with HLA-E*01:03 bound to HBV envelope 371-379 S3N peptide |
Heteromer A0A075B6T6; A0A0K0K1A5; P0DTU3; P0DTU4; P13747; P61769; Q67953; | 100 | ||||
| Crystal structure of affinity enhanced TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (… |
Heteromer A0A583ZB34; P01116; P01849; P61769; Q5R1I3; | 100 | ||||
| Crystal structure of H-2Dd with C84-C139 disulfide in complex with gp120 derived peptide P18-I10 |
Heteromer P01900; P04578; P61769; | 100 | ||||
| Complex of HLA-A2, a class I MHC, with a p53 peptide |
Heteromer A0A140T913; P04637; P61769; | 100 | ||||
| AS3.1-PRPF3-HLA*B27 |
Heteromer A3F718; O43395; P61769; | 100 | 1×GOL; 1×NAG; | |||
| Conflicting selective forces affect CD8 T-cell receptor contact sites in an HLA-A2 immunodominant H… |
Heteromer O11822; P04439; P61769; | 100 | ||||
| Crystal structure of SYNT001, a human FcRn blocking monoclonal antibody |
Heteromer P55899; P61769; | 100 | 3×NHE; | |||
| HIV Nef derived peptide Nef73 complexed to HLA-A*0301 |
Heteromer P04439; P04601; P61769; | 100 | ||||
| Crystal Structure of HLA A*0101 in complex with NP44, an 9-mer influenza epitope |
Heteromer P03466; P04439; P61769; | 100 | ||||
| Crystal structure of HLA-A2 in complex with LILRB1 |
Heteromer P04439; P04585; P61769; Q8NHL6; | 100 | ||||
| Recognition of peptide-MHC by a V-delta/V-beta TCR |
Heteromer P04439; P61769; Q9YYU8; | 100 | ||||
| HLA*A2402 complexed with HIV nef138 10mer epitope |
Heteromer P04439; P04601; P61769; | 100 | ||||
| SARS-CoV-2 YLQ peptide-specific TCR pYLQ7 binds to YLQ-HLA-A2 |
Heteromer A0A140T913; P0DTC2; P61769; | 100 | ||||
| Crystal structure of DMF5 TCR bound to HLA-A2 presenting synthetic peptide SMLGIGIVPV |
Heteromer P04439; P61769; | 100 | ||||
| HLA-B*15:01 complexed with a synthetic peptide |
Heteromer D9J307; P61769; | 100 | 2×ACT; 1×EDO; 1×GOL; | |||
| Structure of HLA-A68 complexed with an HIV derived peptide |
Heteromer P04439; P61769; Q9YXY3; | 100 | ||||
| MAGE-A3 Reactive TCR in complex with Titin Epitope in HLA-A1 |
Heteromer A0A0B4J279; A0A578; A0A5B9; P01848; P04439; P61769; Q8WZ42; | 100 | 1×GOL; 11×SO4; | |||
| HLA*A2402 complexed with HIV nef138 8mer epitope |
Heteromer P04439; P04601; P61769; | 100 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide N3S v… |
Heteromer P04439; P61769; Q03463; | 100 | ||||
| Crystal structure of TK3 TCR-HLA-B*35:08-HPVG complex |
Heteromer C5MK56; P01848; P01850; P03211; P61769; | 100 | 2×CL; 3×NA; | |||
| Crystal structure of HLA, B*4403, and peptide EEPTVIKKY |
Heteromer P01889; P61769; Q9Y5X3; | 100 | ||||
| Structures of HLA-A*1101 in complex with immunodominant nonamer and decamer HIV-1 epitopes clearly … |
Heteromer P04439; P12499; P61769; | 100 | ||||
| Crystal structure of HLA-B*4402 in complex with the F3A/R5A double mutant of a self-peptide derived… |
Heteromer P01889; P61769; Q95HB9; | 100 | 1×ACT; | |||
| Human leukocyte antigen A*0201 in complex with SARS-CoV2 epitope ALWEIQQVV |
Heteromer A0A140T913; P0DTD1; P61769; | 100 | 3×GOL; 2×PGE; | |||
| Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 37-1 |
Heteromer K9N5Q8; P01902; P61769; | 100 | ||||
| Newly identified epitope N1 derived from SARS-CoV N protein complexed with HLA-A*2402 |
Heteromer P04439; P59595; P61769; | 100 | ||||
| Crystal structure of a high affinity Human Serum Albumin variant bound to the Neonatal Fc Receptor |
Heteromer P02768; P55899; P61769; | 100 | 11×SO4; | |||
| HLA-A24 in complex with HIV-1 Nef134-8(wt) |
Heteromer P04439; P04601; P61769; | 100 | ||||
| Crystal Structure of HLA-A*2402 Complexed with a Newly Identified Peptide from 2009 H1N1 PA (649-65… |
Heteromer P04439; P61769; Q9YXL3; | 100 | ||||
| CD1a-42:1 SM binary complex |
Heteromer P06126; P61769; | 100 | 1×WUA; 2×EDO; | |||
| Crystal structure of human CD8aa-MR1-Ac-6-FP complex |
Heteromer P01732; P61769; Q95460; | 100 | 1×30W; 1×PO4; 1×CL; | |||
| Human CD1d presenting alpha-Galactosylceramide in complex with VHH nanobody 1D5 |
Heteromer P15813; P61769; | 100 | 1×NAG; 1×NAG; 2×NAG; 5×SO4; 1×AGH; 5×CL; | |||
| Crystal Structure of C12C TCR-HA B2705-KK10 |
Heteromer P01889; P03366; P61769; | 100 | ||||
| Large CDR3a loop alteration as a function of MHC mutation |
Heteromer P04213; P04439; P61769; Q9NPA0; | 100 | ||||
| Crystal structure of HLA-G presenting KGPPAALTL peptide |
Heteromer P17693; P61769; | 100 | 1×CO; 2×CL; | |||
| Structure of HLA-A2:01 with peptide Y16R |
Heteromer P04439; P61769; | 100 | 2×GOL; 1×NA; | |||
| Defining the structural basis for human alloantibody binding to human leukocyte antigen allele HLA-… |
Heteromer F6IQY1; P61769; | 100 | 3×GOL; 2×PEG; | |||
| The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its V… |
Heteromer P04439; P61769; | 100 | ||||
| Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphi… |
Heteromer P01889; P61769; Q70XD7; | 100 | ||||
| The complex between H27-14 TCR and HLA-A24 bound to HIV-1 Nef134-10(wt) peptide |
Heteromer P04439; P61769; Q9YYU8; | 100 | ||||
| KIR3DL1*001 in complex with HLA-A*24:02 presenting the RYPLTFGW peptide |
Heteromer A0A5H2UYS3; P04601; P43629; P61769; | 100 | 1×FMT; 1×ACT; 3×NAG; | |||
| HLA B7:02 with HPNGYKSLSTL |
Heteromer P01889; P12601; P61769; | 100 | 3×EDO; 1×PEG; | |||
| Next generation monomeric IgG4 Fc |
Heteromer P01861; P55899; P61769; | 100 | 1×NAG; | |||
| Crystal structure of HLA-A*03:01 in complex with a mutant PIK3CA peptide |
Heteromer P04439; P42336; P61769; | 100 | 4×FMT; 1×GOL; | |||
| Crystal structure of a HLA-B*35:01-NP7 with D1 TCR |
Heteromer F4NBT2; P61769; | 100 | 4×PO4; | |||
| Crystal Structure of HLA-A*1101 in complex with H1-22, an influenza A(H1N1) virus epitope |
Heteromer P04439; P61769; P68043; | 100 | ||||
| Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with Ebola virus-der… |
Heteromer A0A125R585; O72142; P61769; | 100 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide C6V v… |
Heteromer P04439; P61769; Q03463; | 100 | ||||
| SILv44 T cell receptor bound to HLA-A2 presenting gp100T2M peptide (IMDQVPFSV) |
Heteromer A0A140T913; P40967; P61769; | 100 | 1×FLC; | |||
| SILv44 T cell receptor bound to HLA-A2 presenting gp100 peptide (ITDQVPFSV) |
Heteromer A0A140T913; P40967; P61769; | 100 | 3×GOL; | |||
| Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a mela… |
Heteromer P01848; P01850; P04439; P61769; Q16655; | 100 | 2×EPE; 7×SO4; | |||
| Crystal structure of HLA-A1101 in complex with an azobenzene- containing peptide |
Heteromer P04439; P61769; | 100 | ||||
| Ternary complex of FcRn ectodomain, FcRn binding optimised human serum albumin and the albumin-bini… |
Heteromer P02768; P55899; P61769; | 100 | 1×MES; 1×JG5; 1×BME; 1×CYS; | |||
| MHC A02 Allele presenting MTSAIGILVP |
Heteromer P04439; P61769; | 100 | ||||
| 1E6 TCR in complex with HLA-A02 carrying MVW peptide |
Heteromer A0A0B4J271; A0A0B4J2E0; A0A5B9; P01848; P04439; P61769; | 100 | 5×EDO; 5×SO4; 1×GOL; | |||
| T cell receptor-p53-HLA-A2 complex |
Heteromer A0A140T913; P04637; P61769; | 100 | ||||
| Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a mela… |
Heteromer P01848; P01850; P04439; P61769; | 100 | 1×TAM; 11×SO4; | |||
| Crystal structure of LS10-TCR/M1-HLA-A*02 complex |
Heteromer P03485; P04439; P61769; | 100 | 1×EDT; | |||
| Crystal structure of HLA-A*11:01 in complex with KRAS peptide (VVVGAGGVGK) |
Heteromer A0A583ZB34; P01111; P61769; | 100 | ||||
| HLA class I histocompatibility antigen |
Heteromer A0A0B4J271; A0A0B4J2E0; A0A5B9; P01848; P04439; P61769; | 100 | 4×SO4; | |||
| HLA-A24 in complex with modified 9mer WT1 peptide |
Heteromer D9UAY1; P19544; P61769; | 100 | 1×NAG; 5×GOL; | |||
| Human MHC Class I, A24 Allele presenting LWM, Complex with 4C6 TCR |
Heteromer A0A5H2UYS3; P01308; P61769; | 100 | 3×SO4; 1×EPE; 3×EDO; | |||
| Next generation monomeric IgG4 Fc bound to neonatal Fc receptor |
Heteromer P01861; P55899; P61769; | 100 | 1×NAG; | |||
| Crystal structure of HLA-B*27:09 complexed with the self-peptide pVIPR and Copper |
Heteromer P01889; P32241; P61769; | 100 | 3×CU; | |||
| Structure of S8-9F3 TCR in complex with HLA-A*11:01 bound to ELFSYLIEK peptide |
Heteromer A0A583ZB34; P61769; | 100 | ||||
| Single chain trimer HLA-A*02:01 (H98L, Y108C) with HPV.16 E7 peptide YMLDLQPETTDL |
Heteromer A0A6S7XV52; P03129; P16213; | 100 | ||||
| Human Class I MHC HLA-A2 in complex with synthetic peptide MMWDRGLGMM |
Heteromer P04439; P61769; | 100 | ||||
| The crystal structure of LC13 TcR in complex with HLAB8-EBV peptide complex |
Heteromer P01848; P01850; P01889; P61769; Q3KST2; | 100 | ||||
| THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEP… |
Heteromer P03485; P04439; P61769; | 100 | ||||
| THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEP… |
Heteromer P04439; P14079; P61769; | 100 | ||||
| Human Leukocyte Antigen Class I A02 Carrying LLWAGPMAV |
Heteromer P03314; P04439; P61769; | 100 | 1×NA; 2×EDO; 5×SO4; 2×GOL; | |||
| HLA-A24 in complex with HIV-1 Nef134-10(6L) |
Heteromer P04439; P61769; Q9WPU2; | 100 | ||||
| CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A2.1)/BETA 2-MICROGLOBULIN/PEPTIDE P1049 COMPLEX |
Heteromer P04439; P61769; Q9NPA0; | 100 | ||||
| Crystal structure of TK3 TCR-HLA-B*35:01-HPVG-Q5 complex |
Heteromer C5MK56; P01848; P01850; P03211; P61769; | 100 | 3×SO4; | |||
| Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 142-2 |
Heteromer K9N5Q8; P01902; P61769; | 100 | ||||
| Crystal Structure of HLA-B*5701, presenting the self peptide, LSSPVTKSF |
Heteromer P01834; P01889; P61769; | 100 | 4×GOL; | |||
| The human non-classical major histocompatibility complex molecule HLA-E |
Heteromer P13747; P17693; P61769; | 100 | ||||
| Crystal Structure of SB27 TCR in complex with HLA-B*3508-13mer peptide |
Heteromer P01848; P01850; P01889; P03206; P61769; | 100 | 7×IOD; | |||
| MHC Class I A02 Allele presenting NLSALGIFST |
Heteromer A0A140T913; P61769; Q9Y6M1; | 100 | 3×PEG; 2×SO4; 1×EDO; | |||
| THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEP… |
Heteromer P04439; P04588; P61769; | 100 | ||||
| Crystal structure of Fab fragment of antibody DX-2507 bound to FcRn-B2M |
Heteromer P55899; P61769; Q6NS95; S6BAN1; | 100 | 2×EDO; 2×NHE; | |||
| COMPLEX BETWEEN HUMAN T-CELL RECEPTOR B7, VIRAL PEPTIDE (TAX) AND MHC CLASS I MOLECULE HLA-A 0201 |
Heteromer A0A0K0K1A5; A0A5B9; P01848; P04437; P04439; P14079; P61769; | 100 | ||||
| Crystal Structure of LILRB2(LIR2/ILT4/CD85d) complexed with HLA-G |
Heteromer P16104; P17693; P61769; Q8N423; | 100 | ||||
| Crystal Structure of T10 |
Heteromer P61769; Q31206; | 100 | ||||
| Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with MERS-CoV-derive… |
Heteromer A0A125R585; K9N5Q8; P61769; | 100 | ||||
| Crystal structure of killer cell immunoglobulin-like receptor KIR2DS2 in complex with HLA-A |
Heteromer P04439; P43631; P61769; Q76ZQ3; | 100 | ||||
| Engineered Human HLA_A2 MHC Class I molecule in complex with TCR and SV9 peptide |
Heteromer A0A0B4J279; A0A0K0K1A5; K7N5M4; K7N5N2; P04439; P61769; | 100 | 1×GOL; 1×ACT; | |||
| Structure of human MR1-ethylvanillin in complex with human MAIT A-F7 TCR |
Heteromer P61769; Q95460; | 100 | 1×PRO; 1×N36; 6×GOL; | |||
| AH3 recognition of mutant HLA-A2 W167A |
Heteromer P01849; P04439; P61769; Q9NPA0; | 100 | ||||
| The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its V… |
Heteromer P04439; P61769; | 100 | ||||
| DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF TH… |
Heteromer P01889; P61769; | 100 | ||||
| The complex between C1-28 TCR and HLA-A24 bound to HIV-1 Nef134-10(2F) peptide |
Heteromer P04439; P61769; Q9YYU3; | 100 | 3×CO; | |||
| Structure of the H2DB-TCR ternary complex with HSF2 melanoma neoantigen |
Heteromer P01899; P38533; P61769; | 100 | 13×GOL; 4×SO4; | |||
| Crystal structure of 1406 TCR bound to HLA-A2 with HCV 1406-1415 antigen peptide |
Heteromer P04439; P27958; P61769; | 100.0 | ||||
| Crystal Structure Analysis of NY-ESO-1 epitope analogue, SLLMWITQA, in complex with HLA-A2 |
Heteromer P04439; P61769; | 100 | 1×SO4; | |||
| Crystal structure of the T-cell receptor NYE_S1 bound to HLA A2*01-SLLMWITQV |
Heteromer P04439; P61769; P78358; | 100 | ||||
| AS4.3-RNASEH2b-HLA*B27 |
Heteromer A0A2R8Y7R8; A3F718; P61769; | 100 | 6×GOL; 4×NAG; 1×SO4; | |||
| Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP7 epitope from 2002 H3N2 influenza strain |
Heteromer F4NBT2; P61769; | 100 | ||||
| Killer cell immunoglobulin-like receptor 2DL3 in complex with HLA-C*07:02 |
Heteromer P10321; P43628; P61769; P68431; | 100 | ||||
| Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection |
Heteromer P01889; P04585; P61769; | 100 | ||||
| Crystal structure of HLA molecule with an KIR receptor |
Heteromer F6IQA6; P27958; P43631; P61769; | 100 | ||||
| Single chain trimer HLA-A*02:01 (Y108C) with HPV.16 E7 peptide YMLDLQPETTDL |
Heteromer A0A6S7XV52; P03129; P16213; | 100.0 | ||||
| Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr… |
Heteromer P01848; P01850; P61769; Q3KSU1; Q8WLS4; | 98.99 | 11×GOL; 7×SO4; 1×MES; | |||
| Single chain trimer HLA-A*02:01 (H98L, Y108C) with HPV.16 E7 peptide YMLDLQPET |
Heteromer A0A6S7XV52; P03129; P16213; | 100.0 | 1×PO4; | |||
| HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P9-Phe. |
Heteromer P13747; P61769; P9WGR1; | 100 | 1×SO4; | |||
| TCR mimic antibody (Fab fragment) in complex with AFP/HLA-A*02 |
Heteromer A0A140T913; P02771; P61769; | 100 | 1×1PE; 1×FMT; 4×GOL; 2×PG4; 1×PGE; 1×EPE; | |||
| The crystal structure of H-2Db complexed with a partial peptide epitope suggests an MHC Class I ass… |
Heteromer P01899; P26590; P61769; | 100 | 2×GOL; | |||
| HHAT Wild Type Peptide KQWLVWLLL Presented by HLA-A206 |
Heteromer P61769; Q5VTY9; U5YJP1; | 100 | ||||
| High resolution crystal structure of HLA-B*1402 in complex with the latent membrane protein 2 pepti… |
Heteromer P13285; P61769; Q56H30; | 100 | ||||
| Crystal structure of MHC CLass I HLA-A2.1 bound to a peptide representing the epitope of the H5N1 (… |
Heteromer P04439; P61769; Q33CG5; | 100 | 1×GOL; 1×MES; | |||
| MHC Class I A02 Allele presenting NLSALGIFST, in complex with Mel5 TCR |
Heteromer A0A140T913; P61769; Q9Y6M1; | 100 | 2×EDO; | |||
| Gag:02 TCR in complex with HLA-E. |
Heteromer A0A075B6U7; A0A0B4J268; A0A0J9YX06; B6S6I4; K7N5M4; P04435; P0DSE1; P13747; P61769; | 100 | ||||
| The complex between high affinity TCR DMF5(alpha-D26Y,beta-L98W) and human Class I MHC HLA-A2 with … |
Heteromer P04439; P61769; Q16655; | 100 | ||||
| Crystal structure of the T-cell receptor NYE_S2 bound to HLA A2*01-SLLMWITQV |
Heteromer P04439; P61769; P78358; | 100 | ||||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5K-4-[3-Indo… |
Heteromer P01848; P01850; P04439; P61769; | 100 | 5×SO4; 13×GOL; 1×3IB; | |||
| Crystal structure of a human Valpha24(-) NKT TCR in complex with CD1d/alpha-galactosylceramide |
Heteromer K7N5M3; K7N5M4; P15813; P61769; | 100 | 5×NAG; 1×AGH; 1×FUC; 2×GOL; | |||
| Crystal Structure of HLA-A*1101 in complex with H7-22, an influenza A(H7N9) virus epitope |
Heteromer P04439; P61769; Q9Q0U8; | 100 | ||||
| HLA-B*27:05 presenting an HIV-1 7mer peptide |
Heteromer O78189; P04585; P61769; | 100 | 1×ARG; 1×GOL; | |||
| Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVVGAGGVGK) |
Heteromer A0A583ZB34; P01111; P61769; | 100 | 3×SO4; | |||
| Uncommon structural features of rabbit MHC class I (RLA-A1) complexed with rabbit haemorrhagic dise… |
Heteromer P06140; P27410; P61769; | 100 | ||||
| The complex between TCR DMF4 and human Class I MHC HLA-A2 with the bound MART-1(27-35) nonameric pe… |
Heteromer P01848; P04439; P61769; Q16655; | 100 | ||||
| Single chain trimer HLA-A*02:01 (H98L, Y108C) with HPV.16 E7 peptide YMLDLQPETTDLYC |
Heteromer A0A6S7XV52; P03129; P16213; | 100.0 | ||||
| Crystal structure of an anaplastic lymphoma kinase-derived neuroblastoma tumor antigen bound to the… |
Heteromer P01889; P61769; Q9UM73; | 100 | 7×GOL; 5×SO4; | |||
| THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEP… |
Heteromer P04439; P04582; P61769; | 100 | ||||
| HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2.1 |
Heteromer P04439; P61769; | 100 | ||||
| SPECIFICITY POCKETS FOR THE SIDE CHAINS OF PEPTIDE ANTIGENS IN HLA-AW68 |
Heteromer P04439; P61769; | 100 | ||||
| Crystal structure of HLA-C*07:02 in complex with RYR peptide |
Heteromer P10321; P61769; P68431; | 100 | 3×ZN; | |||
| Structure of HLA-A*0201 complexed with peptide Md3-C9 derived from a clustering region of restricte… |
Heteromer P59596; P61769; Q53Z42; | 100 | ||||
| HFE (HUMAN) HEMOCHROMATOSIS PROTEIN |
Heteromer P61769; Q30201; | 100 | ||||
| Crystal structure of HLA-B*4402 in complex with the R5A/F7A double mutant of a self-peptide derived… |
Heteromer P01889; P61769; Q95HB9; | 100 | 1×GOL; | |||
| Crystal structure of the KFJ37 TCR-NY-ESO-1-HLA-B*07:02 complex |
Heteromer A0A0B4J1U6; A0A0B4J268; P01889; P61769; P78358; | 100 | ||||
| Structure of the HLA-E-VMAPRTLIL/KK50.4 TCR complex |
Heteromer P01848; P01850; P13747; P16780; P61769; | 100 | 5×IOD; | |||
| COMPLEX BETWEEN HUMAN T-CELL RECEPTOR, VIRAL PEPTIDE (TAX), AND HLA-A 0201 |
Heteromer A0A075B6T6; A0A0K0K1A5; A0A5B9; P01848; P04439; P14079; P61769; | 97.98 | 2×EMC; | |||
| Crystal Structure of the LC13 TCR in complex with HLA B*4405 bound to EEYLKAWTF a mimotope |
Heteromer P01848; P01850; P01889; P61769; | 100 | ||||
| 1E6-A*0201-ALWGPDPAAA Complex, Triclinic |
Heteromer P01308; P04439; P61769; | 100 | ||||
| Crystal structure of human FcRn with a monomeric peptide inhibitor |
Heteromer P55899; P61769; | 100 | ||||
| YLQ-SG3 TCR in complex with SARS-CoV-2 Spike-derived peptide S269-277 (YLQPRTFLL) presented by HLA-… |
Heteromer P0DTC2; P61769; Q53Z42; | 100 | 4×NA; | |||
| TCR-antigen complex AS4.2-PRPF3-HLA*B27 |
Heteromer A3F718; O43395; P61769; | 100 | 4×GOL; 3×NAG; 1×SO4; | |||
| SARS-CoV-2 specific private TCR RLQ7 in complex with RLQ-T1006I-HLA-A2 |
Heteromer A0A140T913; P0DTC2; P61769; | 100 | 1×PG4; | |||
| The complex between T36-5 TCR and HLA-A24 bound to HIV-1 Nef134-10(2F) peptide in space group P2121… |
Heteromer P04439; P61769; Q9YYU3; | 100 | ||||
| TCR in complex with HLA-E*01:03 bound to HBV envelope 371-379 L6I peptide |
Heteromer A0A075B6T6; A0A0K0K1A5; P0DTU3; P0DTU4; P13747; P61769; Q67953; | 100 | ||||
| HLA-A24 in complex with HIV-1 Nef134-10(2F) |
Heteromer P04439; P61769; Q9YYU3; | 100 | ||||
| T cell receptor-p53-HLA-A2 complex |
Heteromer A0A140T913; P04637; P61769; | 100 | ||||
| MAGE-A3 reactive TCR in complex with MAGE-A3 in HLA-A1 |
Heteromer A0A0B4J279; A0A578; A0A5B9; P01848; P04439; P43357; P61769; | 100 | 7×SO4; | |||
| HLA-E*01:03 in complex with the HIV epitope, RL9HIV |
Heteromer P04585; P13747; P61769; | 100 | 2×SO4; | |||
| Crystal Structure of the cross-restricted T18A TCR and HLAB4201 bound to HIV-1 Gag TL9 peptide |
Heteromer P04585; P61769; V6E0U6; | 100 | ||||
| Human Class I MHC HLA-A2 in complex with sorting nexin 24 (127-135) neoantigen KLSHQLVLL |
Heteromer P61769; Q53Z42; Q9Y343; | 100 | 1×PEG; 2×GOL; | |||
| Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS G12D peptide (VVVGADGVGK) |
Heteromer A0A583ZB34; P01111; P61769; | 100 | 2×SO4; | |||
| Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant |
Heteromer P04439; P61769; | 98.99 | 3×CL; 1×GOL; | |||
| CRYSTAL STRUCTURE OF HLA-A2-WT1-RMF AND FAB 11D06 |
Heteromer A0A140T913; P19544; P61769; | 100 | 5×NA; | |||
| MHC CLASS I H-2DB COMPLEXED WITH GLYCOPEPTIDE K3G |
Heteromer P01899; P04857; P61769; | 100 | 2×GOL; 1×SO4; 1×NAG; | |||
| Crystal structure of InhA:01 TCR in complex with HLA-E (S147C) bound to InhA (53-61 H3C) |
Heteromer P13747; P61769; P9WGR1; | 100 | ||||
| Crystal structure of a HLA-B*35:01-NP6 with D1 TCR |
Heteromer O19626; P61769; | 100 | ||||
| Human Class I Major Histocompatibility Complex, A02 allele, presenting LLS (t-butyl)Y FGTPT |
Heteromer A0A140T913; P61769; | 100 | 2×SO4; | |||
| Crystal structure of peptide-HLA-A24 bound to S19-2 V-delta/V-beta TCR |
Heteromer P03407; P04439; P61769; | 100 | ||||
| The complex between TCR DMF5 and human Class I MHC HLA-A2 with the bound MART-1(26-35)(A27L) peptide |
Heteromer P01848; P04439; P61769; | 100 | ||||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the bound HuD peptide |
Heteromer P01848; P04439; P61769; | 100 | 7×GOL; 1×SO4; | |||
| Human Leukocyte Antigen Class I A02 Carrying LLWNGPMHV |
Heteromer P03314; P04439; P61769; | 100 | 2×PEG; 3×SO4; 1×GOL; | |||
| Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances af… |
Heteromer P01848; P01850; P04439; P61769; P78358; | 97.98 | ||||
| COMPLEX RECOGNITION OF THE SUPERTYPIC BW6-DETERMINANT ON HLA-B AND-C MOLECULES BY THE MONOCLONAL AN… |
Heteromer P01889; P03204; P61769; | 100 | ||||
| Rhesus macaque MHC class I molecule Mamu-B*17-HW8 |
Heteromer P61769; Q89490; Q9GJ77; | 100 | ||||
| Human Class I Major Histocompatibility Complex, A02 allele, presenting LLGWVFAQV |
Heteromer A0A140T913; P13726; P61769; | 100 | ||||
| Crystal structure of ELS4 TCR bound to HLA-B*3501 presenting EBV peptide EPLPQGQLTAY at 1.7A |
Heteromer P01848; P01850; P01889; P03206; P61769; | 100 | ||||
| Complex of T cell Receptor with HHAT Neoantigen Peptide KQWLVWLFL Presented by HLA-A206 |
Heteromer P61769; Q5VTY9; U5YJP1; | 100 | ||||
| Crystal structure of HLA-A*11:01 in complex with SVLNDILARL, an 10-mer epitope from SARS-CoV-2 Spik… |
Heteromer P0DTC2; P61769; Q5S3G3; | 100 | 1×PEG; 8×EDO; 2×CL; 2×SO4; 2×NA; | |||
| Structure of a MHC I-Tapasin-ERp57 complex |
Heteromer O15533; P01899; P30101; P61769; | 100 | 1×NAG; | |||
| Crystal structure of non-phosphorylated form of RQA_V phosphopeptide bound to HLA-A2 in complex wit… |
Heteromer P04439; P33241; P61769; Q8NHL6; | 100 | 1×EDO; | |||
| CRYSTAL STRUCTURE OF THE HUMAN MHC-RELATED FC RECEPTOR |
Heteromer P55899; P61769; | 100 | 1×BME; | |||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the bound Tel1p peptide |
Heteromer P04439; P38110; P61769; | 100 | 6×GOL; | |||
| First insight into marsupial MHC I peptide presentation: immune features of lower mammals parallele… |
Heteromer P61769; Q95IT0; | 100 | ||||
| Structure of HLA-A2:01 with peptide Y10L |
Heteromer P04439; P61769; | 100 | 1×GOL; | |||
| Crystal Structure of the LC13 TCR in complex with HLA B*4405 bound to EEYLQAFTY a self peptide from… |
Heteromer P01848; P01850; P01889; P61769; | 100 | ||||
| Murine MHC class I H-2Db in complex with human b2-microglobulin and LCMV-derived immunodminant pept… |
Heteromer P01899; P61769; | 100 | ||||
| an affinity enhanced T cell receptor in complex with HLA-A0201 restricted HCV NS3 peptide KLVALGINAV |
Heteromer P04439; P27958; P61769; | 97.98 | ||||
| The complex between T36-5 TCR and HLA-A24 bound to HIV-1 Nef134-10(2F) peptide |
Heteromer P04439; P61769; Q9YYU3; | 100 | ||||
| CRYSTAL STRUCTURE OF HLA-CW4, A LIGAND FOR THE KIR2D NATURAL KILLER CELL INHIBITORY RECEPTOR |
Heteromer P10321; P61769; | 97.98 | ||||
| Crystal Structure of the TK3-Gln55Ala TCR in complex with HLA-B*3501/HPVG |
Heteromer P01889; P03211; P61769; | 100 | 1×SO4; | |||
| Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a mela… |
Heteromer P01848; P01850; P04439; P61769; | 100 | 4×SO4; 2×GOL; | |||
| AS4.3-YEIH-HLA*B27 |
Heteromer A3F718; P61769; P62723; | 100 | 3×NAG; 1×SO4; | |||
| Consequences of HLA single chain trimer mutations on peptide presentation and binding affinity |
Heteromer A0A678ZGP6; P16213; | 100 | ||||
| Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP4 epitope from 1972 influenza strain |
Heteromer F4NBT2; P61769; Q08041; | 100 | ||||
| Human Leukocyte Antigen A02 presenting ILGKFLHWL |
Heteromer O14746; P04439; P61769; | 100 | 6×EDO; 1×SO4; | |||
| 1E6-A*0201-ALWGPDPAAA Complex, Monoclinic |
Heteromer P01308; P04439; P61769; | 100 | 2×SO4; | |||
| Structure of chimeric HLA-A*02:01 bound to CMV peptide |
Heteromer D2KZ37; P61769; | 100 | ||||
| Single chain trimer HLA-A*02:01 (Y108A) with HPV.16 E7 peptide YMLDLQPETTDLYC |
Heteromer A0A678ZGP6; P03129; P16213; | 100.0 | ||||
| HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P2-Phe. |
Heteromer P13747; P61769; P9WGR1; | 100 | 3×ZN; 3×SO4; | |||
| The complex between the high affinity version of A6 TCR (A6c134) and human Class I MHC HLA-A2 with … |
Heteromer P04439; P0C213; P61769; | 100 | 10×GOL; | |||
| TCR-peptide specificity overrides affinity enhancing TCR-MHC interactions |
Heteromer H2RG00; K7N5N2; O14746; P01850; P04439; P61769; | 100 | 1×GOL; 2×EDO; | |||
| Crystal Structure of HLA-A*2402 in complex with IYFSPIRVTF, an 10-mer epitope from Influenza B virus |
Heteromer A0A5H2UYS3; C0RVT5; P61769; | 100 | 1×MG; | |||
| 868 TCR in complex with HLA A02 presenting SLYFNTIAVL |
Heteromer P04439; P04591; P61769; | 100 | 13×EDO; 3×GOL; 2×SO4; | |||
| T4H2 T cell receptor bound to HLA-A2 presenting gp100 peptide (ITDQVPFSV) |
Heteromer A0A140T913; P40967; P61769; | 100 | ||||
| A2-MHC Complex carrying FATGIGIITV |
Heteromer P04439; P61769; | 100 | 4×SO4; | |||
| Consequences of HLA single chain trimer mutations on peptide presentation and binding affinity |
Heteromer A0A678ZGP6; P03129; P16213; | 100.0 | ||||
| SARS-CoV-2 specific private TCR RLQ7 in complex with RLQ-HLA-A2 |
Heteromer A0A140T913; P0DTC2; P61769; | 100 | 1×PG4; | |||
| Crystal structure of pHLA-B35 in complex with TU55 T cell receptor |
Heteromer P01889; P04585; P61769; | 100 | 3×GOL; | |||
| Crystal Structure of HLA-A*2402 in complex with 2009 pandemic influenza A(H1N1) virus and avian inf… |
Heteromer A0A0X9JHC1; P04439; P61769; | 100 | ||||
| Plasticity of human CD8 binding to peptide-HLA-A*2402 |
Heteromer P01732; P04439; P61769; Q9YYU8; | 100 | ||||
| Structure of HLA-A68 complexed with an HIV Env derived peptide |
Heteromer P04439; P61769; Q70626; | 100 | ||||
| HLA-C*06:02 presenting ARFNDLRFV |
Heteromer P10321; P61769; Q13761; | 100 | ||||
| CD1b in complex with GM2 ganglioside |
Heteromer P29016; P61769; | 100 | 1×GM2; 1×D12; 1×TWT; | |||
| Crystal Structure of SB47 TCR-HLA B*3505-LPEP complex |
Heteromer C5MK56; P01848; P01850; P61769; Q3KSS8; | 100 | 1×NA; 2×MG; | |||
| HEMOCHROMATOSIS PROTEIN HFE COMPLEXED WITH TRANSFERRIN RECEPTOR |
Heteromer P02786; P61769; Q30201; | 100 | 2×NAG; 2×CA; | |||
| Crystal structure of human CD1d-lysophosphatidylcholine |
Heteromer P15813; P61769; | 100 | 1×NAG; 1×LSC; 1×HEX; 3×SO4; 4×GOL; 1×UND; | |||
| Crystal Structure of a Human Major Histocompatibilty complex |
Heteromer P13747; P61769; Q0QI92; | 100 | ||||
| Crystal Structure of HLA-A*2402 Complexed with a telomerase peptide |
Heteromer O14746; P04439; P61769; | 100 | 5×SO4; 2×GOL; | |||
| Newly identified epitope from SARS-CoV membrane protein complexed with HLA-A*0201 |
Heteromer P04439; P59596; P61769; | 100 | ||||
| The complex between TCR DMF4 and human Class I MHC HLA-A2 with the bound MART-1(26-35)(A27L) decame… |
Heteromer P01848; P04439; P61769; Q16655; | 100 | ||||
| The human non-classical major histocompatibility complex molecule HLA-E |
Heteromer P13747; P61769; | 100 | 1×SO4; | |||
| Crystal Structure of CF34 TCR in complex with HLA-B8/FLR |
Heteromer P01850; P01889; P61769; | 100 | 5×CD; 6×CL; 6×NA; | |||
| Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1 bound to its MHC lig… |
Heteromer P10321; P43626; P61769; | 100 | ||||
| Crystal structure of the first class MHC mamu and Tat-Tl8 complex |
Heteromer P61769; | 100 | ||||
| Crystal structure of human class i mhc (hla-a2.1) complexed with beta 2-microglobulin and hiv-rt va… |
Heteromer P04439; P61769; | 100 | ||||
| CRYSTAL STRUCTURE OF HUMAN A6 TCR COMPLEXED WITH HLA-A2 BOUND TO ALTERED HTLV-1 TAX PEPTIDE P6A |
Heteromer P01848; P04439; P61769; | 100 | ||||
| Crystal structure of the public RA14 TCR in complex with the HCMV dominant NLV/HLA-A2 epitope |
Heteromer P01848; P04439; P61769; | 100 | 1×SO4; 1×CL; | |||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5(3,4-difluo… |
Heteromer P01850; P04439; P61769; | 100 | 6×GOL; | |||
| CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-5V |
Heteromer P04439; P61769; | 100 | ||||
| Complex structure of HLA0201 with recognizing SARS-CoV-2 epitope S1 |
Heteromer A0A5H2UU57; P0DTC2; P61769; | 100 | ||||
| GY9-Mamu-A*02-hb2m |
Heteromer P19505; P61769; Q30597; | 100 | ||||
| SARS-CoV-2 RLQ peptide binds to HLA-A2 |
Heteromer A0A140T913; P0DTC2; P61769; | 100 | ||||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5(4-fluoroPh… |
Heteromer P01848; P01850; P04439; P61769; | 100 | 4×GOL; | |||
| HLA class I histocompatibility antigen |
Heteromer P04439; P61769; | 100 | 2×EPE; 4×SO4; 2×EDO; | |||
| Human Leukocyte Antigen A02 presenting ILAKFLHWL, in complex with cognate T-Cell Receptor |
Heteromer A0A0B4J277; A0A0K0K1A5; K7N5M3; K7N5M4; O14746; P04439; P61769; | 100 | 5×EDO; 1×GOL; 5×SO4; | |||
| Class I MHC (HLA-A*02) presenting alpha fetoprotein peptide (AFP) |
Heteromer A0A140T913; P02771; P61769; | 100 | 3×PGE; 5×PEG; 1×1PE; | |||
| Crystal Structure of HLA-A*11:01-GTS3 |
Heteromer P04439; P61769; Q6YMS4; | 100 | 1×K; | |||
| T4H2 T cell receptor bound to HLA-A2 presenting gp100T2L peptide (ILDQVPFSV) |
Heteromer A0A140T913; P40967; P61769; | 100 | 1×GOL; | |||
| THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E |
Heteromer P13747; P61769; | 100 | 1×SO4; | |||
| Apo FcRn Structure at pH 4.5 |
Heteromer P55899; P61769; | 100 | ||||
| Complex structure of HLA2402 with recognizing SARS-CoV-2 epitope QYIKWPWYI |
Heteromer F6IR24; P0DTC2; P61769; | 100 | ||||
| Crystal Structure of 9C2 TCR bound to CD1d |
Heteromer P0CF51; P15813; P61769; Q6PJ56; | 100 | 2×NAG; 1×NAG; 1×NAG; 1×BMA; 1×MG; 1×JLS; 1×CL; | |||
| Human Class I MHC HLA-A2 bound to sorting nexin 24 (127-135) neoantigen KLSHQLVLL |
Heteromer A0A140T913; P61769; Q9Y343; | 100 | 1×PEG; | |||
| Crystal structure of HLA-B*5701 complex with HIV-1 gag derived peptide TW10 |
Heteromer P01889; P03366; P61769; | 100 | ||||
| Large CDR3a loop alteration as a function of MHC mutation. |
Heteromer P01849; P04213; P04439; P61769; Q9NPA0; | 100 | ||||
| The complex between TCR JKF6 and human Class I MHC HLA-A2 presenting the MART-1(27-35)(A27L) peptide |
Heteromer P04439; P61769; Q16655; | 100 | ||||
| HLA-B*07:02 in complex with SARS-CoV-2 nucleocapsid peptide N105-113 |
Heteromer P01889; P0DTC9; P61769; | 100 | 3×CL; | |||
| Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection |
Heteromer P01889; P04591; P61769; | 100 | ||||
| 868 TCR in complex with HLA A02 presenting SLYNTIATL |
Heteromer P04439; P04591; P61769; | 100 | 5×EDO; 2×GOL; 8×SO4; | |||
| MHC CLASS I H-2DB COMPLEXED WITH A SENDAI VIRUS NUCLEOPROTEIN PEPTIDE |
Heteromer P01899; P04858; P61769; | 100 | 1×SO4; | |||
| Crystal Structure of HLA A*2402 in complex with TYQWIIRNW, an 9-mer influenza epitope |
Heteromer A0A5H2UYS3; P03428; P61769; | 100 | 1×CA; 2×NA; 1×NI; | |||
| Structure of HLA-A*02:01 in complex with NY-ESO-1 peptide and PA2.1 Fab |
Heteromer A0A140T9X5; P61769; | 100 | ||||
| T4H2 T cell receptor bound to HLA-A2 presenting gp100T2M peptide (IMDQVPFSV) |
Heteromer A0A140T913; P40967; P61769; | 100 | ||||
| Crystal Structure of HLA B*0801 in complex with HSKKKCDEL and DD31 TCR |
Heteromer P01889; P61769; X2G898; | 100 | 3×IOD; 1×NA; | |||
| Structure of human D462-E4 TCR in complex with human MR1-5-OP-RU |
Heteromer P61769; Q95460; | 100 | 1×2LJ; 2×GOL; 1×BR; 1×NA; 2×CL; | |||
| Crystal structure of C3 TCR complex with QW9-bound HLA-B*5301 |
Heteromer P04585; P61769; S6BVK3; | 100 | ||||
| Rational development of high-affinity T-cell receptor-like antibodies |
Heteromer P04439; P61769; P78358; | 100 | ||||
| Human FcRn extra-cellular domain complexed with Fab fragment of Rozanolixizumab |
Heteromer P55899; P61769; | 100 | 2×CL; 2×NA; | |||
| CRYSTAL STRUCTURE OF HLA-A*0201 COMPLEXED WITH A PEPTIDE WITH THE CARBOXYL-TERMINAL GROUP SUBSTITUT… |
Heteromer P04439; P61769; | 100 | ||||
| MHC A02 Allele presenting MTSAIGILPV |
Heteromer P04439; P61769; | 100 | ||||
| Complex structure of HLA2402 with recognizing SARS-CoV-2 epitope pep4 |
Heteromer D9UAY1; P0DTC2; P61769; | 100 | ||||
| Gag:02 TCR in complex with HLA-E featuring a non-natural amino acid |
Heteromer A0A075B6U7; A0A0B4J268; A0A0J9YX06; K7N5M4; P04435; P0DSE1; P13747; P61769; | 100 | ||||
| HLA-B*73:01 bound to a 10mer peptide in complex with KIR2DL2 |
Heteromer A0A583ZBV1; P43627; P61769; | 100 | 4×GOL; 1×PEG; 2×NAG; | |||
| Valpha3S1 Vbeta13S1 HLA C 0602 VRSRRCLRL |
Heteromer F6IQM2; P61769; | 100 | ||||
| MHC with 9-mer peptide |
Heteromer J9UGS3; P61769; | 100 | ||||
| 868 TCR in complex with HLA A02 presenting SLYNTVATL |
Heteromer P04439; P04591; P61769; | 100 | 4×EDO; 3×SO4; | |||
| Crystal Structure of HLA A*1101 in complex with SALEWIKNK, an 9-mer epitope from Influenza B |
Heteromer P06816; P61769; U5YJK1; | 100 | 1×MG; 1×SO4; | |||
| Crystal Structure of the JM22 TCR in complex with HLA-A*0201 in complex with M1-G4E |
Heteromer A0A075B6N1; A0A087WT01; A0A5B9; P01848; P04439; P61769; | 100 | ||||
| D30 TCR in complex with HLA-A*11:01-GTS1 |
Heteromer A0A087WSZ9; K7N5N2; P04439; P17763; P61769; | 100 | ||||
| The complex between TCR a7b2 and human Class I MHC HLA-A0201-WT1 with the bound RMFPNAPYL peptide. |
Heteromer P04439; P19544; P61769; | 100 | 2×EDO; | |||
| Crystal structure of an anaplastic lymphoma kinase-derived neuroblastoma tumor antigen bound to the… |
Heteromer P04439; P61769; Q9UM73; | 100 | ||||
| Human MHC Class I, A24 Allele presenting QLPRLFPLL, Complex with 4C6 TCR, monoclinic form |
Heteromer A0A5H2UYS3; P61769; | 100 | 1×MES; 1×EDO; 2×SO4; | |||
| T cell response to a HIV reverse transcriptase epitope presented by the protective allele HLA-B*51:… |
Heteromer K7N5M3; P01850; P01889; P61769; R4WL38; | 100 | ||||
| UL40:01 TCR in complex with HLA-E with a non-natural amino acid |
Heteromer A0A087WT03; A0A087X096; A0A0B4J200; A0A5B0; A0A5B9; P01848; P13747; P61769; | 100 | ||||
| Nonstandard peptide binding of HLA-B*5101 complexed with HIV immunodominant epitope KM2(TAFTIPSI) |
Heteromer P01889; P12499; P61769; | 100 | ||||
| The crystal structure of human CD1d with and without alpha-Galactosylceramide |
Heteromer P15813; P61769; | 100 | 1×AGH; | |||
| STRUCTURE OF A COMPLEX BETWEEN THE HUMAN NATURAL KILLER CELL RECEPTOR KIR2DL2 AND A CLASS I MHC LIG… |
Heteromer P10321; P43627; P52292; P61769; | 100 | ||||
| Germline-governed recognition of a cancer epitope by an immunodominant human T cell receptor |
Heteromer P01848; P01850; P61769; Q16655; Q8WLS4; | 100 | 2×GOL; 2×SO4; | |||
| THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEP… |
Heteromer P04439; P12901; P61769; | 100 | ||||
| Structure of Cowpox CPXV203 in complex with MHCI (H-2Kb) |
Heteromer P01012; P01901; P61769; Q8QMP2; | 100 | ||||
| Crystal Structure of the Murine MHC Class Ib Molecule M10.5 |
Heteromer P61769; Q860W6; | 100 | 1×NAG; | |||
| Structural basis for ineffective T-cell responses to MHC anchor residue improved heteroclitic pepti… |
Heteromer P04439; P61769; Q16655; | 100 | 4×EDO; | |||
| T cell receptor-p53-HLA-A2 complex |
Heteromer A0A140T913; P04637; P61769; | 100 | ||||
| Crystal structure of the T-cell receptor GVY01 bound to HLA A2*01-GVYDGREHTV |
Heteromer P43358; P61769; Q53Z42; | 100 | ||||
| Emergence of immune escape at dominant SARS-CoV-2 killer T-cell epitope |
Heteromer A0A140T913; P0DTC2; P61769; | 100 | 1×PEG; 3×SO4; | |||
| Crystal Structure of EM2 TCR in complex with HLA-B*37:01-NP338 |
Heteromer P01889; P61769; | 100 | ||||
| HLA-B*27:05 in complex with the pan-HLA-Ia monoclonal antibody W6/32 |
Heteromer A3F718; P61769; | 100 | ||||
| Crystal Structure of HLA B*3501-IPS in complex with a Delta-Beta TCR, clone 12 TCR |
Heteromer P01889; P18139; P61769; | 100 | ||||
| Structure of HLA-A*24:02 in complex with peptide, LYLPVRVLI |
Heteromer A0A5H2UYS3; P61769; Q2TAZ0; | 100 | ||||
| KIR3DL1*086 in complex with HLA-A*24:02 presenting the NEF peptide |
Heteromer A0A411J078; I6LEK9; P61769; | 100 | 2×NAG; | |||
| Human FcRn complexed with human serum albumin |
Heteromer P02768; P55899; P61769; | 100 | ||||
| Crystal structure of B17.R2 TCR in complex with H2D-b-NP366 |
Heteromer P01899; P61769; Q9Q0U8; | 100 | 1×EDO; | |||
| Structure of ESK1 in complex with HLA-A*0201/WT1 |
Heteromer P04439; P19544; P61769; | 100 | ||||
| Alpha-beta TCR Binding to Neoantigen KQWLVWLFL Presented by HLA-A206 |
Heteromer P61769; Q53Z42; Q5VTY9; | 100 | 2×GOL; | |||
| 1E6 TCR in Complex with HLA-A02 carrying AQWGPDPAAA |
Heteromer A0A0B4J271; A0A0B4J2E0; A0A5B9; P01308; P01848; P04439; P61769; | 100 | ||||
| Structure of wtMHC class I with NY-ESO1 double mutant |
Heteromer P04439; P61769; | 100 | 2×CL; 1×GOL; | |||
| Crystal structure of HLA-B*5201 in complexed with HIV immunodominant epitope (TAFTIPSI) |
Heteromer P01889; P12499; P61769; | 100 | ||||
| The Crystal Structure of Human CD1b with a Bound Bacterial Glycolipid |
Heteromer P29016; P61769; | 100 | 1×GMM; | |||
| Crystal structure of human TCR Alpha Chain-TRAV12-3, Beta Chain-TRBV6-5, Antigen-presenting molecul… |
Heteromer A0A0B4J271; A0A0K0K1A5; A0A5B9; P01848; P15813; P61769; | 100 | 2×NAG; 1×JLS; | |||
| CRYSTAL STRUCTURE ANALYSIS OF THE GAMMA/DELTA T CELL LIGAND T22 |
Heteromer P61769; Q31615; | 100 | ||||
| Crystal Structure of SB27 TCR in complex with the 'restriction triad' mutant HLA-B*3508-13mer |
Heteromer A0A5B9; P01848; P01889; P03206; P61769; | 100 | 7×IOD; | |||
| Crystal structure of human FcRn with a dimeric peptide inhibitor |
Heteromer P55899; P61769; | 100 | ||||
| Crystal structure of the RL42 TCR in complex with HLA-B8-FLR |
Heteromer P01848; P01889; P61769; Q3KST2; | 100 | ||||
| Structure of HD14 TCR in complex with HLA-B7 presenting an EBV epitope |
Heteromer P01889; P12977; P61769; | 100 | 1×PEG; 3×EDO; | |||
| The human non-classical major histocompatibility complex molecule HLA-E |
Heteromer P13747; P61769; | 100 | 1×SO4; | |||
| Structure of the HLA-E-VMAPRTLVL/GF4 TCR complex |
Heteromer P04439; P13747; P61769; | 100 | ||||
| Crystal structure of human 21LT2-2 TCR bound to HLA-A*03:01 in complex with a mutant PIK3CA peptide |
Heteromer P04439; P42336; P61769; | 100 | 1×ACT; 1×GOL; | |||
| Crystal structure of the T-cell receptor NYE_S3 bound to HLA A2*01-SLLMWITQV |
Heteromer P04439; P61769; P78358; | 100 | ||||
| Complex of T cell Receptor with HHAT Wild Type Peptide KQWLVWLLL Presented by HLA-A206 |
Heteromer P61769; Q5VTY9; U5YJP1; | 100 | ||||
| Noncanonical binding of single-chain A6 TCR variant S3-4 in complex with Tax/HLA-A2 |
Heteromer A0A140T913; P14079; P61769; | 100 | 1×MES; | |||
| Structural and functional basis for HLA-G isoform recognition of immune checkpoint receptor LILRBs |
Heteromer P17693; P61769; Q8NHL6; Q9BTM1; | 100 | 4×IOD; | |||
| Crystal Structure of HLA-A*11:01 with GTS1 peptide |
Heteromer P04439; P17763; P61769; | 100 | 1×CL; | |||
| HLA class I histocompatibility antigen |
Heteromer P04439; P61769; | 100 | 4×SO4; | |||
| SARS-CoV-2 specific T cell receptor |
Heteromer P0DTC9; P61769; U5YKE0; | 100 | ||||
| human 199.54-16 TCR in complex with Melan-A/MART-1 (26-35) peptide and HLA-A2 |
Heteromer A0A075B6T6; A0A0C4ZKA8; A0A5B3; K7N5N2; P04439; P61769; Q16655; | 100 | 1×SCN; 2×K; 1×CL; | |||
| Crystal structure of non-phosphorylated form of RLS PHOSPHOPEPTIDE BOUND TO HLA-A2 in complex with … |
Heteromer P04439; P61769; Q8NC44; Q8NHL6; | 100 | ||||
| Crystal structure of disulfide-linked HLA-G dimer |
Heteromer P16104; P17693; P61769; | 100 | ||||
| D30 TCR in complex with HLA-A*11:01-GTS3 |
Heteromer A0A087WSZ9; K7N5N2; P04439; P61769; Q6YMS4; | 100 | ||||
| Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation |
Heteromer C1K0Y1; P01111; P61769; | 100 | ||||
| The complex between public TCR TD08 and HLA-A24 bound to HIV-1 Nef138-8 peptide |
Heteromer F6IQZ4; P04601; P61769; | 100 | ||||
| The complex of TCR NYN-I and HLA-A24 bound to SARS-CoV-2 Spike448-456 peptide NYNYLYRLF |
Heteromer P0DTC2; P61769; Q6IVJ7; | 100 | ||||
| TCR peptide HLA-A2 complex |
Heteromer A0A140T913; P0DTC2; P61769; | 100 | ||||
| DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF TH… |
Heteromer P01889; P61769; | 100 | ||||
| Crystal structure of CD1d-lipid-antigen complexed with Beta-2-Microglobulin, NKT15 Alpha-Chain and … |
Heteromer P01848; P15813; P61769; | 100 | 1×NAG; 2×NAG; 1×AGH; | |||
| Crystal structure of human FcRn with a peptide inhibitor at multiple sites |
Heteromer P55899; P61769; | 100 | ||||
| MHC Class I A02 Allele presenting EAAGIGILTV, in complex with Mel8 TCR |
Heteromer A0A140T913; P61769; Q16655; | 100 | 2×EDO; | |||
| human 199.16 TCR in complex with Melan-A/MART-1 (26-35) peptide and HLA-A2 |
Heteromer A0A075B6N1; P01848; P04439; P61769; Q16655; | 100 | 1×NA; | |||
| Crystal structure of the TAPBPR-MHC I peptide editing complex |
Heteromer P01899; P61769; Q53GH5; | 100 | ||||
| Human leukocyte antigen F (HLA-F) presents peptides and regulates immunity through interactions wit… |
Heteromer P30511; P61769; Q8NHL6; | 100 | 1×NAG; | |||
| The complex between H25-11 TCR and HLA-A24 bound to HIV-1 Nef138-8 peptide |
Heteromer F6IQZ4; P04601; P61769; | 100 | ||||
| Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK) |
Heteromer P01116; P61769; U5YJJ6; | 100 | ||||
| HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein |
Heteromer P04439; P61769; Q3KSS7; | 100 | ||||
| Crystal structure of FcRn and beta-2-microglobulin in complex with IgG1-Fc-MST-HN (efgartigimod) |
Heteromer P01857; P55899; P61769; | 100 | 1×NAG; 1×NAG; | |||
| Crystal structure of the four Ig-like domains of LILRB1 complexed with HLA-G |
Heteromer P04908; P17693; P61769; Q8NHL6; | 100 | ||||
| Structure of the HLA-E-VMAPRTLIL/GF4 TCR complex |
Heteromer P13747; P16780; P61769; | 100 | ||||
| Crystal structure of HLA-A*11:01 in complex with SVLNDILSRL, an 10-mer epitope from SARS-CoV-2 Spik… |
Heteromer P0DTC2; P61769; Q5S3G3; | 100 | 1×PEG; 1×EDO; | |||
| Neoantigen p53R175H-specific TCR 6-11 binds to p53R175H-HLA-A2 |
Heteromer P04439; P04637; P61769; | 100 | ||||
| Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK) |
Heteromer P01116; P61769; U5YJJ6; | 100 | ||||
| The complex between public TCR TD08 and HLA-A24 bound to HIV-1 Nef138-8 (2F) peptide |
Heteromer F6IQZ4; P04601; P61769; | 100 | ||||
| Human CD94/NKG2A in complex with HLA-E |
Heteromer P13747; P17693; P26715; P61769; Q13241; | 100 | ||||
| Crystal Structure of HLA-A2 Bound to LIR-1, a Host and Viral MHC Receptor |
Heteromer P04439; P12499; P61769; Q8NHL6; | 100.0 | ||||
| Immune receptor |
Heteromer P06334; P61769; Q9BCZ1; | 100 | 2×NAG; 2×NAG; 1×NAG; | |||
| Crystal Structure of the DM1 TCR in complex with HLA-B*4405 and decamer EBV antigen |
Heteromer P01848; P01889; P03204; P61769; | 100 | ||||
| Crystal structure of TCR C7 in complex with HCMV NLV epitope presented by HLA-A2 |
Heteromer P04439; P18139; P61769; | 100 | ||||
| Crystal structure of human CD1d presenting alpha-Galactosylceramide in complex with NKT12 TCR and V… |
Heteromer A0A0B4J240; K7N5M3; K7N5M4; P15813; P61769; | 100.0 | 1×NAG; 1×AGH; | |||
| Structure of the antibody fragment H2 in complex with HLA-A*02:01/p53R175H |
Heteromer A0A140T913; P04637; P61769; | 100 | ||||
| Ternary complex between Neonatal Fc receptor, serum albumin and Fc |
Heteromer P01857; P02768; P55899; P61769; | 100 | 2×NAG; | |||
| Structure of NKG2A/CD94 bound to HLA-E |
Heteromer P13747; P17693; P26715; P61769; Q13241; | 100 | ||||
| HLA-A*01:01 complex with NRAS Q61K peptide by NMR |
Heteromer P01111; P04439; P61769; | 100 | ||||
| Cryo-EM structure of echovirus 11 complexed with its uncoating receptor FcRn at pH 5.5 |
Heteromer A0A0R5YS56; A0A346I7K2; E0WN77; P55899; P61769; Q2LJ73; | 100 | ||||
| Structure of the human MHC I peptide-loading complex editing module |
Heteromer O15533; P04439; P27797; P30101; P61769; | 100 | 1×NAG; 1×NAG; | |||
| E30 F-particle in complex with FcRn |
Heteromer A0A0F6T703; A8BJF8; P55899; P61769; Q8QWB2; | 100 | 1×MYR; | |||
| Structure of a fully assembled T-cell receptor engaging a tumor-associated peptide-MHC I |
Heteromer P04234; P04439; P07766; P09693; P20963; P40967; P61769; | 100 | 6×NAG; | |||
| Cryo-EM structure of Echovirus 6 complexed with its uncoating receptor FcRn at PH 7.4 |
Heteromer P55899; P61769; | 100 | 1×SPH; 1×K; 1×NA; | |||
| CryoEM structure of HLA-A2 MAGEA4 (230-239) in complex with REGN6972 Fab |
Heteromer P43358; P61769; Q861F7; | 100 | ||||
| CryoEM structure of HLA-A2 MAGEA4 (286-294) in complex with H2aM31345N Fab |
Heteromer P43361; P61769; Q861F7; | 100 | ||||
| CryoEM structure of PN45428 TCR-CD3 in complex with HLA-A2 MAGEA4 |
Heteromer P04234; P07766; P09693; P20963; P43358; P61769; Q861F7; | 100 | 1×NAG; 2×NAG; 6×NAG; 1×Y01; | |||
| CryoEM structure of HLA-A2 bound to MAGEA4 (230-239) peptide |
Heteromer P61769; Q53Z42; | 100 | ||||
| Structure of a synthetic antibody in complex with a class I MHC presenting a hapten-peptide conjuga… |
Heteromer A0A3G8GE10; P01116; P61769; | 100 | 1×MOV; | |||
| Structure of the P1B7 antibody bound to the Sotorasib-modified KRas G12C peptide presented by the A… |
Heteromer P01116; P04439; P61769; | 100 | 1×MOV; | |||
| Structure of a synthetic antibody in complex with a class I MHC presenting a hapten-peptide conjuga… |
Heteromer P01116; P04439; P61769; | 100 | 1×MOV; | |||
| Cryo-EM structure of HLA-B*73:01 bound to a 9mer peptide and two Fabs |
Heteromer A0A858LJX3; P61769; | 100 | ||||
| Cryo-EM structure of echovirus 11 complexed with its uncoating receptor FcRn at pH 7.4 |
Heteromer A0A0R5YS56; A0A346I7K2; E0WN77; P55899; P61769; Q2LJ73; | 100 | ||||
| Structure of a synthetic antibody in complex with a class I MHC presenting a hapten-peptide conjuga… |
Heteromer P01116; P04439; P61769; | 100 | 1×MOV; | |||
| CryoEM structure of PN45545 TCR-CD3 in complex with HLA-A2 MAGEA4 (230-239) |
Heteromer P04234; P07766; P09693; P20963; P43358; P61769; Q861F7; | 100 | 1×NAG; 5×NAG; 1×Y01; 5×NAG; | |||
| Structure of the human PLC editing module |
Heteromer O15533; P04439; P27797; P30101; P61769; | 100 | 1×NAG; 1×MAN; | |||
| Crystal structure of HA-1 minor histocompatibility antigen bound to human class I MHC HLA-A2 |
Heteromer P04439; P61769; Q92619; | 100 | ||||
| Crystal structure of HLA A2*01-AVYDGREHTV |
Heteromer P43358; P61769; Q53Z42; | 100 | 3×EDO; | |||
| Crystal Structure of Human CD1b in Complex with PG |
Heteromer P29016; P61769; | 100 | 1×NAG; 1×NAG; 1×NAG; 1×CUY; 1×IOD; 1×CL; 2×NA; 3×EDO; 1×D3D; | |||
| Crystal Structure of HLA-A*0201 in complex with SARS-CoV-2 N316-324 |
Heteromer P0DTC9; P61769; Q861F7; | 100 | 1×ACT; 2×CD; 4×NA; | |||
| Crystal Structure of HLA B*0801 in complex with ELK_IYM, ELKRKMIYM |
Heteromer P01889; P61769; Q9YRL3; | 100 | 2×ACT; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with AFP137 nonapeptide |
Heteromer P02771; P04439; P61769; | 100 | ||||
| Structure of HLA-B*40:02 in complex with the phosphorylated endogenous peptide REF(p)SKEPEL |
Heteromer P01889; P61769; Q9NQS7; | 100 | 1×EDO; | |||
| Structure of DbNA(10) peptides bound to H-2Db MHC-I |
Heteromer P01899; P03468; P61769; | 100 | 2×EDO; 2×PEG; 1×PO4; | |||
| Crystal Structure of HLA-A*0201in complex with SARS-CoV-2 N159-167 |
Heteromer P0DTC9; P61769; Q861F7; | 100 | ||||
| Crystal Structure of Human CD1b in Complex with Phosphatidylethanolamine C34:1 |
Heteromer P29016; P61769; | 100 | 1×NAG; 1×NAG; 1×L9Q; 1×NI; 1×CUY; 4×CL; 2×IOD; 4×EDO; | |||
| HLA-A*02:01 bound to Neuroblastoma Derived IGFBPL1 peptide |
Heteromer A0A140T913; P61769; Q8WX77; | 100 | 1×GOL; | |||
| Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presenta… |
Heteromer P04439; P35222; P61769; | 100 | 6×CD; 2×MG; 2×GOL; | |||
| Crystal Structure of HLA-B*15:01 in complex with spike derived peptide NQKLIANAF from OC43 virus |
Heteromer P61769; | 100 | 3×ACT; | |||
| Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presenta… |
Heteromer P04439; P35222; P61769; | 100 | 3×GOL; 2×MG; 6×CD; | |||
| Crystal structure of HLA-C05 in complex with a tumor mut10m peptide |
Heteromer P01116; P10321; P61769; | 100 | ||||
| Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presenta… |
Heteromer P04439; P61769; Q9Y4H2; | 100 | 5×CD; 2×MG; 2×GOL; | |||
| Crystal Structure of Human CD1b in Complex with POPC |
Heteromer P29016; P61769; | 100 | 1×NAG; 1×NAG; 1×NAG; 1×POV; 1×CUY; 7×CL; 3×EDO; 1×NA; 2×IOD; | |||
| Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presenta… |
Heteromer P04439; P30305; P61769; | 100 | 6×CD; 1×MG; 6×GOL; | |||
| Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presenta… |
Heteromer P04439; P30305; P61769; | 100 | 4×GOL; 6×CD; 1×MG; | |||
| Crystal Structure of Human CD1b in Complex with Endogenous PC C40:5 |
Heteromer P29016; P61769; | 100 | 1×NAG; 1×NAG; 3×IOD; 1×3IV; 1×3IY; 4×EDO; 1×NA; | |||
| HLA-C*0801 Crystal Structure |
Heteromer D9J353; P10321; P61769; | 100 | ||||
| Crystal Structure of Human CD1b in Complex with Lysosulfatide |
Heteromer P29016; P61769; | 100 | 1×NAG; 1×NAG; 1×SGF; 1×CUY; 1×IOD; 4×EDO; 3×CL; | |||
| Antigen presenting molecule |
Heteromer P06126; P61769; | 100 | 1×6F8; | |||
| Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation |
Heteromer C1K0Y1; P01111; P61769; | 100 | ||||
| Crystal structure of HLA-C08 in complex with a tumor mut9m peptide |
Heteromer C1K0Y1; P01116; P61769; | 100 | ||||
| Crystal structure of HLA-C08 in complex with a tumor mut10m peptide |
Heteromer C1K0Y1; P01116; P61769; | 100 | ||||
| Crystal structure of human CD1b presenting Phosphatidylinositol C34:1 |
Heteromer P29016; P61769; | 100 | 1×NAG; 1×NAG; 6×EDO; 6×CL; 2×NA; 1×6UL; 2×IOD; 1×PIE; | |||
| Crystal structure of HLA B*13:01 in complex with SVLNDILARL, an 10-mer epitope from SARS-CoV-2 Spik… |
Heteromer C5IYE8; P0DTC2; P61769; | 100 | 3×PEG; 4×EDO; 2×NA; | |||
| CD1a binary complex with sphingomyelin |
Heteromer P06126; P61769; | 100 | 1×3XU; | |||
| Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presenta… |
Heteromer P04439; P61769; Q9Y4H2; | 100 | 5×CD; 1×CO; | |||
| Structure of human MR1-Ac-6-FP in complex with human MAIT B-B10 TCR |
Heteromer P61769; Q95460; | 100 | 2×CL; 6×GOL; 3×ACT; 1×30W; 1×NA; | |||
| HLA-B*07:02 in complex with 229E-derived coronavirus nucleocapsid peptide N75-83 |
Heteromer P01889; P15130; P61769; | 100 | 7×ZN; 1×NA; 8×CL; 8×K; 1×BR; | |||
| Crystal Structure of Human CD1b in Complex with Sphingomyelin C34:2 |
Heteromer P29016; P61769; | 100 | 1×NAG; 1×NAG; 2×EDO; 1×3LY; 1×6UL; 4×CL; 2×IOD; 1×NI; | |||
| KIR3DL1 in complex with HLA-B*57:01.I80T |
Heteromer P01834; P01889; P43629; P61769; | 100 | 3×NAG; | |||
| Structure of human MR1-Ac-6-FP in complex with human MAIT B-G8 TCR |
Heteromer P61769; Q95460; | 100 | 2×GOL; 1×30W; 3×NA; | |||
| Structure of human MR1-Ac-6-FP in complex with human MAIT TRBV6-1 TCR |
Heteromer P61769; Q95460; | 100 | 1×30W; | |||
| KIR3DL1*001 in complex with HLA-A*24:02 presenting the TW9 peptide |
Heteromer A0A411J078; P43629; P61769; Q809Q3; | 100.0 | 2×NAG; | |||
| Structure of E8 TCR in complex with human MR1 bound to 6FP |
Heteromer P61769; Q95460; | 100 | 1×JSO; | |||
| Crystal structure of LS01-TCR/M1-HLA-A*02 complex |
Heteromer P03485; P04439; P61769; | 100 | 3×GOL; | |||
| Structure of E8 TCR in complex in human MR1 bound to 3FSA |
Heteromer P61769; Q95460; | 100 | 1×7ZS; | |||
| Crystal structure of non-phosphorylated form of AMPD2 phosphopeptide bound to HLA-A2 |
Heteromer P04439; P61769; Q01433; | 100 | 3×EDO; 1×NA; | |||
| Crystal Structure of HLA-A*0201in complex with SARS-CoV-2 N351-359 |
Heteromer P0DTC9; P61769; Q861F7; | 100 | 3×3NI; 3×CL; 1×CD; | |||
| HLA-B*15:02 complexed with a synthetic peptide |
Heteromer F4NBQ8; P61769; | 100 | 2×ACT; 1×GOL; 3×EDO; 1×NA; | |||
| Crystal Structure of KMD Phosphopeptide Bound to Human Class I MHC HLA-A2 |
Heteromer P04439; P61769; Q86UW6; | 100 | 1×EDO; | |||
| Structure of human MR1-5-OP-RU in complex with human MAIT M33.64 TCR |
Heteromer P61769; Q95460; | 100 | 1×2LJ; | |||
| Structure of human MR1-Ac-6-FP in complex with human MAIT C-A11 TCR |
Heteromer P61769; Q95460; | 100 | 1×30W; 1×CL; 4×GOL; 1×B3P; | |||
| Structure of E8 TCR in complex in human MR1 bound to 3FBA |
Heteromer P61769; Q95460; | 100 | 1×OVV; 1×EDO; 1×MPO; | |||
| MA2-MART1-HLAA0201 |
Heteromer A0A140T9X5; P61769; Q16655; | 100 | 3×GOL; | |||
| Crystal Structure of HLA-A*02:01/NY-ESO-1 (SLLMWITQV) and a target specific TRACeR-I |
Heteromer A0A5B8RNS7; P61769; P78358; | 100 | 3×SO4; | |||
| Human CD1d presenting sphingomyelin C24:1 in complex with VHH nanobody 1D17 |
Heteromer P15813; P61769; | 100 | 2×FO4; 4×NAG; | |||
| HLA-B*15:02 complexed with a synthetic peptide |
Heteromer F4NBQ8; P61769; | 100 | 2×ACT; 1×EDO; | |||
| HLA-B*15:02 complexed with a synthetic peptide |
Heteromer F4NBQ8; P61769; | 100 | 2×ACT; 1×EDO; | |||
| Structure of S2 TCR in complex with HLA-A*03:01 bound to ELFSYLIEK peptide |
Heteromer P04439; P61769; | 100 | ||||
| Human CD1c with ligands in A' and F' channel |
Heteromer P29016; P29017; P61769; | 100 | 2×DAO; 1×STE; 4×GOL; 2×PO4; | |||
| Crystal structure of the BC8B TCR-CD1b-PI complex |
Heteromer P29016; P61769; | 100 | 1×NAG; 1×NAG; 2×EDO; 2×GOL; 1×MAN; 1×NAG; 1×CUY; 1×CL; 3×NA; | |||
| Structure of human MR1-Ac-6-FP in complex with human MAIT B-F3-C1 TCR |
Heteromer P61769; Q95460; | 100 | 1×30W; | |||
| Structure of E8 TCR in complex in human MR1 K43A |
Heteromer P61769; Q95460; | 100.0 | ||||
| Structure of human MR1-Ac-6-FP in complex with human MAIT B-C10 TCR |
Heteromer P61769; Q95460; | 100 | 1×30W; 2×GOL; | |||
| KIR3DL1*015 in complex with HLA-B*57:01 |
Heteromer P01834; P01889; P43629; P61769; | 100 | 3×NAG; | |||
| Structure of human MR1-Ac-6-FP in complex with human MAIT C-C10 TCR |
Heteromer P61769; Q95460; | 100 | 1×30W; 1×GOL; 1×NA; | |||
| The molecular bases of Delta/Alpha beta T cell-mediated antigen recognition. |
Heteromer P15813; P61769; | 100 | 1×NAG; 1×NAG; 1×NAG; 1×JLS; | |||
| Single chain trimer HLA-A*24:02 (Y108C, A163C) with 8mer peptide YPPVPETF |
Heteromer F6IR24; P16213; Q6NSI4; | 100.0 | ||||
| Crystal Structure of CD1d-lipid complexed with Beta-2-Microglobulin, TCR Alpha-Chain and TCR Beta-C… |
Heteromer P15813; P61769; | 100 | 1×NAG; 1×NAG; 1×NAG; 1×GOL; 1×A1AHF; 2×SO4; | |||
| RD-1 Mart-1 High bound to Mart-1 decameric peptide (ELA) in complex with HLA-A2 |
Heteromer A0A075B6T6; A0A0K0K1A5; P04439; P61769; Q16655; | 100 | ||||
| Structure of HLA-A2:01 with peptide Y9L |
Heteromer P04439; P61769; | 100 | 3×GOL; | |||
| The complex between TIL 1383i TCR and human Class I MHC HLA-A2 with the bound Tyrosinase(369-377)(N… |
Heteromer P04439; P14679; P61769; | 100.0 | ||||
| KIR3DL1*114 in complex with HLA-A*24:02 presenting the NEF peptide |
Heteromer A0A411J078; A0A5J6VN80; P61769; | 100 | 2×NAG; | |||
| COMPLEX OF THE HUMAN MHC CLASS I GLYCOPROTEIN HLA-A2 AND THE T CELL CORECEPTOR CD8 |
Heteromer P01732; P04439; P61769; | 100 | ||||
| CD1a-sulfatide-gdTCR complex |
Heteromer A0A0C4DH28; A0A1B0GX56; P01848; P01850; P06126; P61769; | 100 | 1×CIS; 6×EDO; 1×NAG; 1×PEG; 2×SO4; | |||
| Human CD1d presenting alpha-Galactosylceramide in complex with VHH nanobody 1D22 |
Heteromer P15813; P61769; | 100 | 1×NAG; 1×NAG; 1×NAG; 1×AGH; 2×PEG; 1×CL; 1×SO4; 1×BGC; | |||
| Crystal structure of CD1a in complex with a synthetic mycobactin lipopeptide |
Heteromer P06126; P61769; | 100 | 1×NAG; 1×JH0; | |||
| CD1a ternary complex with lysophosphatidylcholine and BK6 TCR |
Heteromer P01848; P01850; P06126; P61769; | 100 | 2×NAG; 1×42H; | |||
| Crystal Structure of CD1d-lipid complexed with Beta-2-Microglobulin, TCR Alpha-Chain and TCR Beta-C… |
Heteromer P15813; P61769; | 100 | 1×NAG; 2×NAG; 1×FO4; 1×NA; | |||
| Crystal Structure of HLA A*2402 in complex with TYQWIIRNWET, an 11-mer epitope from Influenza |
Heteromer A0A5H2UYS3; P03428; P61769; | 100 | ||||
| Ternary crystal structure of the 3C8 TCR-CD1c-monoacylglycerol complex |
Heteromer P29017; P61769; | 100 | 1×NAG; 1×EKG; 2×D10; 3×K; 3×EDO; 1×PEG; | |||
| The complex among DMF5(alpha-D26Y, alpha-Y50A,beta-L98W) TCR, human Class I MHC HLA-A2 and MART-1(2… |
Heteromer A0A075B6T6; A0A1B0GXE1; K7N5M4; P01848; P04439; P61769; Q16655; | 100 | ||||
| CD1a-dideoxymycobactin-gdTCR complex |
Heteromer A0A0C4DH28; A0A1B0GX56; P01848; P01850; P06126; P61769; | 100 | 2×EDO; 1×WGR; 1×SO4; | |||
| Killer cell immunoglobulin-like receptor 2DL2 in complex with HLA-C*07:02 |
Heteromer P10321; P43627; P61769; P68431; | 100 | ||||
| Inhibitory immune receptor protein complex |
Heteromer P61769; Q95460; | 100.0 | 1×30W; | |||
| Stimulatory immune receptor protein complex |
Heteromer A0A0C4DH27; A0JD37; P61769; Q95460; | 100 | 1×2LJ; | |||
| CD1a-endo-gdTCR complex |
Heteromer A0A0C4DH28; A0A1B0GX56; P01848; P01850; P06126; P61769; | 100 | 1×PEG; 1×SO4; | |||
| Crystal structure of GEM42 TCR-CD1b-GMM complex |
Heteromer P29016; P61769; | 100 | 3×NAG; 5×SO4; 4×CL; 2×NA; 1×6UL; 1×CS; 1×70E; | |||
| CD1c in complex with phosphatidylcholine |
Heteromer P29017; P61769; | 100.0 | 3×NAG; 1×D12; 1×6PL; 1×NA; 1×SO4; 1×BME; 1×EDO; 1×MES; | |||
| TCR589 in complex with HIV(Pol448-456)/HLA-B35 |
Heteromer K7N5M4; P01889; P04585; P61769; Q6IRV4; | 100 | 1×NAG; 3×ZN; 1×NAG; | |||
| Crystal structure of JDI TCR in complex with HLA-A*11:01 bound to KRAS G12D peptide (VVVGADGVGK) |
Heteromer A0A583ZB34; P01111; P61769; | 100 | ||||
| Crystal Structure of TAPBPR and H2-Dd complex |
Heteromer P01900; P61769; Q9BX59; | 100 | 1×EDO; 1×GOL; | |||
| G12V-TCR complex with HLA-A3 |
Heteromer P01116; P04439; P61769; | 100 | ||||
| Crystal structure of TCR PF8 in complex with flu MP(58-66) epitope presented by HLA-A2 |
Heteromer K7N5M3; P03485; P04439; P61769; | 100.0 | ||||
| TCR - CD3 complex bound to HLA |
Heteromer H9BNV4; P01848; P04234; P07766; P09693; P0DTU4; P20963; P61769; P78358; | 100.0 | 1×NAG; 8×NAG; 2×CLR; | |||
| Crystal Structure of HLA-A*0201 in complex with FLNDK, a 15 mer self-peptide |
Heteromer P04439; P61769; | 100 | 2×PEG; 1×CL; | |||
| Structure of DbNA(11) peptides bound to H-2Db MHC-I |
Heteromer P01899; P03468; P61769; | 100 | 1×SO4; | |||
| Crystal Structure of human CD1b in complex with C36-GMM |
Heteromer P29016; P61769; | 100 | 1×NAG; 1×6UL; 1×NAG; 2×ACT; 2×CL; 1×70E; 1×NA; | |||
| Structure of human MAIT A-F7 TCR in complex with human MR1-2`OH-Ethyl-5-OP-U |
Heteromer P61769; Q95460; | 100 | 1×GOL; 1×OZD; 1×NA; | |||
| HLA-B*57:01 presenting LTVQVARVW |
Heteromer P01889; P61769; | 100 | ||||
| HLA-B*58:03 presenting LTVQVARVY |
Heteromer P01889; P61769; | 100 | ||||
| Structure of human MAIT A-F7 TCR in complex with human MR1-5'OH-Pentyl-5-OP-U |
Heteromer P61769; Q95460; | 100 | 1×OYD; | |||
| Structure of human MAIT A-F7 TCR in complex with human MR1 3'D-5-OP-RU |
Heteromer P61769; Q95460; | 100 | 4×GOL; 1×Q81; 2×NA; | |||
| Structure of human MAIT A-F7 TCR in complex with human MR1-5-OP-RU |
Heteromer P61769; Q95460; | 100 | 1×Q87; 1×GOL; 1×CL; 1×NA; | |||
| Structure of human MAIT A-F7 TCR in complex with human MR1-Ribityl-less |
Heteromer P61769; Q95460; | 100 | 1×OYG; 1×NA; | |||
| Structure of human MAIT A-F7 TCR in complex with patient MR1-R9H-Ac-6-FP |
Heteromer P61769; Q95460; | 100 | 1×TKG; 2×GOL; 1×CL; | |||
| Crystal Structure of HLA-A*68:01 in complex with NP145-156, a 12 mer influenza peptide |
Heteromer P04439; P61769; Q9Q0U8; | 100 | 1×IOD; 3×MG; 2×SO4; | |||
| HLA-B*57:01 presenting LTVQVARVY |
Heteromer P01889; P61769; | 100 | ||||
| Structure of human MR1-3-F-SA in complex with human MAIT A-F7 TCR |
Heteromer P61769; Q95460; | 100 | 1×7ZS; 1×GOL; 1×ACT; | |||
| Structure of human MAIT A-F7 TCR in complex with human MR1-3`OH-Propyl-5-OP-U |
Heteromer P61769; Q95460; | 100 | 1×GOL; 1×CL; 1×Q7S; 1×NA; | |||
| Structure of human MAIT A-F7 TCR in complex with patient MR1-R9H without ligand |
Heteromer P61769; Q95460; | 100 | 2×ACT; 2×GOL; | |||
| Structure of human MAIT A-F7 TCR in complex with human MR1-4'OH-Butyl-5-OP-U |
Heteromer P61769; Q95460; | 100 | 1×Q7P; 1×GOL; 2×NA; | |||
| Structure of human MAIT A-F7 TCR in complex with human MR1-2'D-5-OP-RU |
Heteromer P61769; Q95460; | 100 | 2×GOL; 1×Q84; 3×NA; | |||
| Structure of human MAIT A-F7 TCR in complex with human MR1-DB28 |
Heteromer P61769; Q95460; | 100 | 1×GOL; 1×P1J; 1×ACT; | |||
| Structure of S2 TCR in complex with HLA-A*11:01 bound to ELFSYLIEK peptide |
Heteromer A0A583ZB34; P61769; | 100 | ||||
| Structure of human MR1-5-OP-RU in complex with human MAIT M33.64(Y95alphaF) TCR |
Heteromer P61769; Q95460; | 100 | 1×GOL; 1×2LJ; | |||
| HLA-B*57:01 presenting LSSPVTKSW |
Heteromer P01889; P61769; | 100 | ||||
| HLA-B*57:03 presenting LSSPVTKSW |
Heteromer I3ZN84; P61769; | 100 | ||||
| Structure of human MR1-5-OP-RU in complex with human MAIT TRAJ20 TCR |
Heteromer P61769; Q95460; | 100 | 1×2LJ; 2×GOL; 1×NA; | |||
| Structure of human MAIT A-F7 TCR in complex with human MR1-Pyridoxal-5'-phosphate |
Heteromer P61769; Q6P4G7; Q95460; | 100 | 2×GOL; 1×ACY; 1×NA; | |||
| Crystal structure of the KFJ5 TCR-NY-ESO-1-HLA-B*07:02 complex |
Heteromer A0A0B4J268; A0A5B6; P01889; P61769; P78358; | 100.0 | ||||
| Crystal Structure of Human CD1b in Complex with PA |
Heteromer P29016; P61769; | 100 | 1×NAG; 1×NAG; 1×NAG; 1×D21; 1×CUY; 1×PEG; 4×CL; 1×EDO; 3×IOD; 1×NA; | |||
| Structure of human MAIT A-F7 TCR in complex with human MR1-JYM72 |
Heteromer P61769; Q95460; | 100 | 1×GOL; 1×OYV; 2×NA; | |||
| Crystal Structure of Human CD1b in Complex with Mycobacterial C85-GMM |
Heteromer P29016; P61769; | 100 | 1×NAG; 1×ZR2; 1×NAG; 1×CL; 3×IOD; | |||
| Structure of E8 TCR in complex in human MR1 bound to 4FBA |
Heteromer P61769; Q95460; | 100 | 1×4MA; 6×EDO; | |||
| Structure of human MAIT A-F7 TCR in complex with human MR1-NV18.1 |
Heteromer P61769; Q95460; | 100 | 1×N18; 2×GOL; 1×ACT; | |||
| Crystal structure of TCR-MR1 ternary complex and non-covalently bound 5-(2-oxopropylideneamino)-6-D… |
Heteromer P01850; P61769; Q6P4G7; Q95460; | 100 | 2×Q87; 1×GOL; | |||
| Complex of HLA-A2, a class I MHC, with a p53 peptide |
Heteromer A0A140T913; P04637; P61769; | 100 | ||||
| Crystal structure of BC8B TCR-CD1b-PC complex |
Heteromer P29016; P61769; | 100 | 1×NAG; 1×CUY; 1×POV; 1×CL; | |||
| Structure of E8 TCR in complex with human MR1 bound to 5-OP-RU |
Heteromer P61769; Q95460; | 100 | 1×2LJ; 2×EDO; | |||
| Structure of human MAIT A-F7 TCR in complex with human MR1-Pyridoxal |
Heteromer P61769; Q95460; | 100 | 1×PXL; 3×GOL; 2×ACY; 1×CL; 1×CA; | |||
| KIR3DL1*114 in complex with HLA-A*24:02 presenting the TW9 peptide |
Heteromer A0A411J078; A0A5J6VN80; P61769; Q809Q3; | 100 | 2×NAG; | |||
| The human non-classical major histocompatibility complex molecule HLA-E |
Heteromer P10321; P13747; P61769; | 100 | ||||
| Crystal structure of TK3 TCR-HLA-B*35:08-HPVG-D5 complex |
Heteromer C5MK56; P01848; P01850; P61769; Q3KSS4; | 98.84 | ||||
| Crystal Structure of the JM22 TCR in complex with HLA-A*0201 in complex with M1-F5L |
Heteromer A0A075B6N1; A0A087WT01; A0A5B9; P01848; P04439; P61769; | 100 | ||||
| Crystal structure of human CD1d-alpha-Galactosylceramide in complex with semi-invariant NKT cell re… |
Heteromer P15813; P61769; | 100 | 1×NAG; 1×NAG; 1×AGH; 1×MG; | |||
| Structure of human MR1-5OH-DCF in complex with human MAIT A-F7 TCR |
Heteromer P61769; Q95460; | 100 | 2×ACT; 1×GOL; | |||
| Crystal structure of TCR-MR1 ternary complex and covalently bound 5-(2-oxopropylideneamino)-6-D-rib… |
Heteromer P01850; P61769; Q6P4G7; Q95460; | 100 | 2×2LJ; 1×NA; | |||
| Crystal structure of a MHC class I-peptide complex |
Heteromer P04439; P60201; P61769; | 100 | ||||
| Complex structure of HLA2402 with recognizing SARS-CoV-2 Y453F epitope NYNYLFRLF |
Heteromer A0A7T3RIT5; P0DTC2; P61769; | 100 | 2×EDO; | |||
| Crystal structure of a complex between the Human adenovirus type 4 E3-19K protein and MHC class mol… |
Heteromer P04439; P14079; P61769; Q8BEL5; | 100.0 | ||||
| Structure of human MR1-diclofenac in complex with human MAIT A-F7 TCR |
Heteromer P61769; Q95460; | 100 | 2×NA; 1×ACT; 2×GOL; 1×DIF; | |||
| Crystal structure of PG90 TCR-CD1b-PG complex |
Heteromer A0A087WT03; P29016; P61769; Q6P4G7; | 100 | 1×NAG; 1×CUY; 1×NAG; 12×EDO; 2×NA; 1×D3D; 2×ACT; 1×CL; | |||
| Ternary crystal structure of the human NKT TCR-CD1d-C20:2 complex |
Heteromer P15813; P61769; | 100 | 2×NAG; 1×DB3; 1×MG; | |||
| Crystal structure of human autoreactive-Valpha24 NKT TCR in complex with CD1d-beta-galactosylcerami… |
Heteromer P01848; P15813; P61769; | 100 | 1×GCY; | |||
| Structure of MHC-class I related molecule MR1 |
Heteromer P61769; Q95460; | 100 | 1×6FP; 1×CL; 1×PO4; | |||
| Structure of human MR1-5-OP-RU in complex with human MAIT TRBV20 TCR |
Heteromer P61769; Q95460; | 100 | 1×2LJ; 1×NA; | |||
| Recognition of MHC-like molecule |
Heteromer P61769; Q95460; | 100 | 1×2LJ; 1×NAG; | |||
| Structure of human MR1-5-OP-RU in complex with human MAV36 TCR |
Heteromer P61769; Q95460; | 100 | 1×2LJ; | |||
| Crystal structure of ternary complex of human MR1, ligand #4, and MAIT-TCR A-F7 |
Heteromer P01848; P0DTU4; P61769; Q95460; | 100 | 1×A1LXU; | |||
| STRUCTURE OF THE HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN, HLA-A2 |
Heteromer P04439; P61769; | 100 | ||||
| Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation |
Heteromer C1K0Y1; P01111; P61769; | 100 | ||||
| HLA-B*15:02 complexed with a synthetic peptide |
Heteromer F4NBQ8; P61769; Q9BYJ1; | 100 | 1×NA; 2×GOL; 2×ACT; 5×EDO; | |||
| Crystal Structure of HLA-B*37:01 in complex with NP338-L7S influenza peptide |
Heteromer P01889; P61769; | 100 | ||||
| TCR55 in complex with Pep20/HLA-B35 |
Heteromer K7N5M4; P01889; P61769; Q6IRV4; | 100 | 27×GOL; 4×PO4; | |||
| Structure of human MAIT A-F7 TCR in complex with human MR1-4'D-5-OP-RU |
Heteromer P61769; Q95460; | 100 | 1×GOL; 1×Q7J; 1×NA; | |||
| Structure of human MAIT A-F7 TCR in complex with human MR1-5'D-5-OP-RU |
Heteromer P61769; Q95460; | 100 | 1×2LJ; 3×GOL; 1×NA; | |||
| Structure of human MR1-2-OH-1-NA in complex with human MAIT A-F7 TCR |
Heteromer P61769; Q95460; | 100 | 1×7WO; 2×GOL; 2×CL; 1×NA; | |||
| Structure of human MAIT TCR in complex with human MR1-6-FP |
Heteromer P01850; P61769; Q95460; | 100 | 1×6FP; | |||
| Crystal structure of TCR-MR1 ternary complex bound to 5-(2-oxoethylideneamino)-6-D-ribitylaminourac… |
Heteromer P01850; P61769; Q6P4G7; Q95460; | 100 | 1×2L4; | |||
| The structure of human MAIT TCR in complex with MR1-K43A-RL-6-Me-7OH |
Heteromer P01850; P61769; Q6P4G7; Q95460; | 100 | 1×GOL; 1×1VY; | |||
| Crystal structure of human TCR Alpha Chain-TRAV21-TRAJ8, Beta Chain-TRBV7-8, Antigen-presenting gly… |
Heteromer A0A0B4J279; A0A5B9; P01848; P15813; P61769; | 100 | 2×NAG; 1×JLS; | |||
| Structure of human MR1-5-OP-RU in complex with human MAIT TRBV6-4 TCR |
Heteromer P61769; Q95460; | 100 | 1×2LJ; | |||
| Structure of human MR1-5-OP-RU in complex with human MAIT C-A11 TCR |
Heteromer P61769; Q95460; | 100 | 1×2LJ; 1×B3P; | |||
| Structure of human MR1-5-OP-RU in complex with human MAIT B-B10 TCR |
Heteromer P61769; Q95460; | 100 | 1×2LJ; 1×GOL; | |||
| Structure of human MR1-5-OP-RU in complex with human MAIT C-C10 TCR |
Heteromer P61769; Q95460; | 100 | 1×2LJ; 1×GOL; | |||
| Structure of human MR1-5-OP-RU in complex with human MAIT B-F3-C1 TCR |
Heteromer P61769; Q95460; | 100 | 1×2LJ; 2×GOL; | |||
| Ternary crystal structure of the human NKT TCR-CD1d-4'deoxy-alpha-galactosylceramide complex |
Heteromer P15813; P61769; | 100 | 2×NAG; 1×4GH; 1×MG; | |||
| Crystal structure of an iNKT TCR in complex with CD1d-lysophosphatidylcholine |
Heteromer P15813; P61769; | 100.0 | 1×NAG; 1×LSC; 1×HEX; 1×D12; 1×GOL; | |||
| Crystal structure of Tapasin in complex with HLA-B*44:05 (T73C) |
Heteromer D5H3J5; O15533; P61769; | 100.0 | ||||
| Structure of an early native-like intermediate of beta2-microglobulin amyloidosis |
Heteromer P61769; | 98.95 | 4×SO4; 1×GOL; | |||
| CD1a ternary complex with endogenous lipids and BK6 TCR |
Heteromer P01848; P01850; P06126; P61769; | 100.0 | 1×NAG; 1×OLA; | |||
| Structure of the Beta2_microglobulin involved in amyloidogenesis |
Heteromer A2KD59; P61769; | 100 | ||||
| Structure of echovirus 18 in complex with neonatal Fc receptor |
Heteromer P55899; P61769; Q8V635; | 100.0 | 1×PLM; 1×GUN; | |||
| Heterogeneous dodecamer formed from macrocycles containing a sequence from beta-2-microglobulin(63-… |
Heteromer P61769; | 85.71 | 13×SO4; 9×CL; | |||
| beta-2-microglobulin V27M amyloid fibril form 4PF | homo-12-mer | 98.44 | ||||
| Two protofilament beta-2-microglobulin amyloid fibril | homo-8-mer | 100 | ||||
| Crystal structure of Beta 2 Microglobulin amyloidogenic segment LSFSKD | homo-8-mer | 100 | ||||
| A regulatable switch mediates self-association in an immunoglobulin fold | homo-6-mer | 98.98 | 6×CU; 1×TLA; | |||
| beta-2-microglobulin DeltaN6 amyloid fibril form 2PFa | homo-6-mer | 100 | ||||
| beta-2-microglobulin DeltaN6 amyloid fibril form 2PFb | homo-6-mer | 100 | ||||
| beta-2-microglobulin D76N amyloid fibril form 2PFa | homo-6-mer | 98.82 | ||||
| Hexamer formed by a macrocycle containing a sequence from beta-2-microglobulin (63-69). | homo-6-mer | 71.43 | 6×CL; 6×SO4; 6×NA; | |||
| Crystal Structure of the tetrameric Beta-2 microglobulin DIMC20 mutant | homo-4-mer | 98.99 | 10×CD; 2×NA; | |||
| Crystal structure of the beta-2 microglobulin DIMC50 disulphide-linked homodimer mutant | homo-4-mer | 98.98 | 3×PEG; 3×PO4; | |||
| A Native to Amyloidogenic Transition Regulated by a Backbone Trigger | homo-4-mer | 98.94 | ||||
| Crystal structure of tetrameric beta-2-microglobulin deltaN6 S52C stabilized by a covalent ligand | homo-4-mer | 98.89 | 2×TRS; 4×SJK; | |||
| 3D Structure of amyloid protofilaments of beta2-microglobulin fragment probed by solid-state NMR | homo-4-mer | 100 | ||||
| A new V27M variant of beta 2 microglobulin induced amyloidosis in a patient with long-term hemodial… | homo-2-mer | 98.99 | 4×GOL; 2×MG; 2×CA; 2×PO4; | |||
| Crystal structure of dimeric S33C beta-2 microglobulin mutant at 1.9 Angstrom resolution | homo-2-mer | 98.99 | ||||
| Crystal structure of Beta 2 Microglobulin domain-swapped dimer | homo-2-mer | 100 | 3×GOL; | |||
| Crystal structure of dimeric S33C beta-2 microglobulin mutant in complex with Thioflavin (ThT) at 2… | homo-2-mer | 98.99 | 3×TFX; | |||
| Crystal structure of dimeric S33C beta-2 microglobulin mutant at 1.4 Angstrom resolution | homo-2-mer | 98.98 | ||||
| FYLLYYT segment from human Beta 2 Microglobulin (62-68) displayed on 54-membered macrocycle scaffold | homo-2-mer | 87.5 | 1×MPD; | |||
| Crystal Structure of the amyloid-fibril forming peptide KDWSFY derived from human Beta 2 Microglobu… | homo-2-mer | 100 | 1×PE4; 1×NA; | |||
| HLA-A*0201 single chain trimer with HPV.16 E7 peptide LLMGTLGIV | monomer | 97.98 | ||||
| Crystal structure of beta-2-microglobulin D76G mutant | monomer | 98.99 | ||||
| Crystal structure of beta-2-microglobulin D76A mutant | monomer | 98.99 | ||||
| Crystal structure of beta-2-microglobulin D76E mutant | monomer | 98.99 | 2×GOL; 1×PGE; | |||
| Crystal structure of the D98N Beta-2 Microglobulin mutant | monomer | 98.99 | 1×PGE; 1×PEG; 1×ACT; | |||
| Crystal structure of beta-2-microglobulin D76Y mutant | monomer | 98.99 | ||||
| The double mutant of Beta-2 microglobulin K58P-W60G | monomer | 97.98 | 1×PE4; | |||
| Crystal structure of the D76A Beta-2 Microglobulin mutant | monomer | 98.99 | 1×PGE; 1×ACT; | |||
| Crystal structure of the D76E Beta-2 Microglobulin mutant | monomer | 98.99 | 1×PGE; | |||
| Crystal structure of the D76N Beta-2 Microglobulin mutant | monomer | 98.99 | 1×NA; 1×ACT; 1×PEG; | |||
| Crystal structure of the D59N Beta-2 Microglobulin mutant | monomer | 98.99 | 1×PEG; | |||
| Crystal structure of the D76H Beta-2 Microglobulin mutant | monomer | 98.99 | 1×ACT; 1×PGE; | |||
| The crystal structure of beta2-microglobulin R97Q mutant | monomer | 98.99 | 1×ACT; | |||
| Crystal structure of beta-2-microglobulin D76Q mutant | monomer | 98.99 | ||||
| Crystal structure of the D38N Beta-2 Microglobulin mutant | monomer | 98.99 | 1×PEG; 1×ACT; | |||
| Crystal structure of W95L beta-2 microglobulin | monomer | 98.99 | 1×PGE; | |||
| Crystal structure of the D53N Beta-2 Microglobulin mutant | monomer | 98.99 | 1×PEG; 1×ACT; | |||
| Human beta-2 microglobulin double mutant W60G-N83V | monomer | 97.98 | 2×GOL; 2×ACT; 1×PEG; | |||
| Crystal Structure of a single chain trimer composed of HLA-B*39:06 Y84C variant, beta-2microglobuli… | monomer | 100.0 | 1×EDO; 1×GOL; 1×CL; | |||
| Crystal Structure of a single chain trimer composed of HLA-B*39:01 Y84C variant, beta-2microglobuli… | monomer | 100.0 | 1×P4G; 1×EDO; | |||
| Crystal Structure of a single chain trimer composed of HLA-B*39:06 Y84C variant, beta-2microglobuli… | monomer | 100.0 | 7×SO4; 8×EDO; 2×PEG; | |||
| The crystal structure of beta2-microglobulin D76N mutant at room temperature | monomer | 98.99 | ||||
| Human beta-2 microglobulin mutant V85E | monomer | 98.99 | 1×ACT; | |||
| structure of W60V beta-2 microglobulin mutant | monomer | 98.99 | ||||
| Beta 2 microglobulin mutant D59P | monomer | 98.99 | ||||
| Crystal structure of the human beta-2 microglobulin mutant W60G | monomer | 98.99 | ||||
| X-ray crystal structure of the N-terminal region from HCMV US11 binding to HLA-A*02:01 | monomer | 100.0 | 2×GOL; | |||
| Crystal structure of Human double mutant beta2-microglobulin Q8H-L65T | monomer | 97.98 | ||||
| Beta 2 microglobulin mutant W60C | monomer | 98.99 | ||||
| The crystal structure of wt beta2-microglobulin at room temperature | monomer | 100 | ||||
| CD1c in complex with MPM (mannosyl-beta1-phosphomycoketide) | monomer | 100 | 1×NAG; 1×D12; 1×MK0; | |||
| Protein-induced photophysical changes to the amyloid indicator dye, thioflavin T | monomer | 98.99 | 1×CU; | |||
| CD1c in complex with PM (phosphomycoketide) | monomer | 100 | 1×NAG; 1×PMK; 6×CL; 3×MLI; | |||
| Structure of MHC-class I related molecule MR1 with bound M3Ade | monomer | 100.0 | 1×R8F; | |||
| Structure of human CD1e | monomer | 100 | 1×NAG; 1×GOL; | |||
| NMR solution structure of the human beta2-microglobulin | monomer | 100 | ||||
| Prion-like conversion during amyloid formation at atomic resolution | monomer | 100 | ||||
| Solution structure of W60G mutant of human beta2-microglobulin | monomer | 98.99 | ||||
| The high resolution crystal structure of beta2-microglobulin under physiological conditions | monomer | 100 | ||||
| Crystal structure of beta-2-microglobulin D76K mutant | monomer | 98.98 | ||||
| human beta-2 microglobulin double mutant W60G-Y63W | monomer | 97.96 | ||||
| Crystal structure of beta-2-microglobulin D76S mutant | monomer | 98.97 | 3×GOL; | |||
| Protein induced photophysical changes to the amyloid indicator dye, thioflavin T | monomer | 98.96 | 1×HG; 2×TFX; 1×TLA; 2×ACT; | |||
| The Crystal Structure of human beta2-microglobulin | monomer | 100 | 1×NA; | |||
| D53P beta-2 microglobulin mutant | monomer | 98.97 | 1×PE4; | |||
| Beta2 microglobulin mutant H31Y displays hints for amyloid formations | monomer | 98.97 | ||||
| Crystal Structure of monomeric human beta-2-microglobulin | monomer | 100 | 1×NA; | |||
| The Crystal Structure of human beta2-microglobulin, L39W W60F W95F Mutant | monomer | 96.84 | 1×NA; | |||
| Prion-like conversion during amyloid formation at atomic resolution | monomer | 100 | ||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6uj8.1.B | monomer | 0.84 | 100.00 | |||